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Introduction	
On	 a	 daily	 basis,	 a	 whole	 range	 of	 totally	 diverse	 patients	 present	 themselves	 to	 health	 care	
professionals.	 Health	 care	 practitioners	 endeavour	 to	 treat	 them	 all	 as	 adequately	 as	 possible.	
Although	the	majority	of	the	patients	can	be	treated	by	regular	care,	often	including	conventional,	
licensed	medicinal	products,	regrettably	not	all	patients	can	be	sufficiently	treated	with	the	licensed	
medicinal	 products	 currently	 available[1].	 Medicinal	 products	 developed	 and	 manufactured	 in	
academic	 institutions,	 including	 tailor-made	 pharmaceutical	 products,	 can	 help	 fill	 the	 needs	 of	
special	 (small)	 patient	 cohorts	 that,	 at	 present,	 have	 no	 available	 licensed	 treatments.	 Reaching	
these	 specific	 patients	 with	 academic	medicinal	 products	 does	most	 frequently	 not	 occur	 via	 the	







	 are	 a	 relatively	 new	 group	 of	medicinal	 products,	 where	 the	 preclinical	 and	 early	 clinical	
development	 most	 frequently	 originate	 in	 academic	 institutions[2].	 ATMPs	 are	 considered	 as	
innovative	 and	 complex	 medicinal	 products	 that	 differ	 from	 conventional	 products	 in	 their	
characteristics	and	manufacturing.	Since	the	special	Regulation	(EC)	No.	1394/2007	came	into	force	
in	 2009,	 a	 centralized	 regulatory	 framework	 for	 obtaining	 marketing	 authorization	 for	 these	
innovative	 products	 was	 established[3,4].	 The	 Committee	 for	 Medicinal	 Products	 for	 Human	 Use	
(CHMP)	 is	 responsible	 for	 the	 evaluation	 of	 quality,	 safety	 and	 efficacy	 of	 all	 medicinal	 products	
within	 the	centralized	procedures[5].	However,	due	 to	 its	 complexity,	a	new	group	of	experts,	 the	
Committee	 for	 Advanced	 Therapies	 (CAT),	 has	 been	 installed	 by	 the	 European	Medicines	 Agency	
(EMA)	to	support	 the	CHMP[4].	After	 the	scientific	assessment	evaluation	of	an	ATMP	by	the	CAT,	
the	CHMP	provides	a	recommendation	for	marketing	authorization,	 followed	by	a	 final	decision	of	
the	 European	 Commission	 (EC)[3].	 Increasing	 numbers	 of	 clinical	 trials	 with	 ATMPs	 have	 been	
performed	globally	and	more	and	with	 increasing	 involvement	of	commercial	companies	 in	clinical	
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GTMPs	 are	 products	 that	 include	 genes	 for	 diagnostic,	 prophylactic	 or	 therapeutic	 purposes.	
Classification	of	 a	GTMP	 is	based	on	 two	 requirements:	 (1)	 the	active	 ingredient	 should	exist	of	 a	
biological	originated	recombinant	nucleic	acid	and	(2)	the	nucleic	acid	should	directly	be	responsible	
for	 the	 main	 mode	 of	 action,	 hence	 incorporating	 in	 a	 genetic	 sequence	 for	 the	 regulation,	
replacement,	reparation,	deletion	or	addition	purposes.	These	nucleic	acids	are	administered,	after	






is	 elaborated	 in	 this	 thesis,	 is	 the	 Chimeric	 Antigen	 Receptor	 T-cell	 (CAR	 T-cell).	 In	 this	 type	 of	
product,	a	receptor	for	antigen	recognition	is	 introduced	in	T-cells,	by	which	T-cells	specifically	can	





to	 the	 patient	 for	 diagnosis,	 prevention,	 or	 as	 a	 treatment,	 for	 example,	 Zalmoxis®.	 Substantial	
manipulation,	such	as	cell	culturing	or	differentiation	with	growth	factors,	is	defined	by	the	EMA	as	
“during	 the	 manufacturing	 process	 the	 cells	 or	 tissue(s)	 have	 been	 manipulated	 so	 that	 their	
biological	 characteristics,	 physiological	 functions	 or	 structural	 properties	 have	 been	 modified	 to	
achieve	 their	 intended	 function”[8],	 see	 table	 2	 for	 a	 list	 of	 non-substantial	manipulations[8].	 Cell	










non-homologous	 function,	with	 the	main	purpose	 to	 regenerate,	 repair,	or	 replace	 tissue,	 such	as	
skin,	for	example	Holoclar®[8,9].	A	simple	illustration	of	a	TEP	is	shown	in	figure	4.	
Finally,	 apart	 from	 these	 three	 subtypes	 of	 ATMPs,	 we	 can	 distinguish	 a	 group	 of	 so-called	




Figure	 4.	 Illustration	 of	 tissue	 engineered	 product	 (TEP).	 Cells	 can	 be	 extracted	 from	 either	 the	 patient	
(autologous)	or	from	a	donor	(allogeneic).	
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are	 dealing	 with	 a	 novel	 and	 complex	 type	 of	 medicinal	 products.	 In	 clinical	 studies,	 this	 should	 be	
balanced	with	the	fact	that	these	products	 include	personalized	aspects	and	that	they	can	be	used	for	
treatment	of	 serious	medical	 conditions,	 left	untreated	until	now	 [11].	Authorities	also	 recognise	 that	
performing	a	proper	benefit/risk	assessment	can	be	challenging	for	these	products[3].	The	production	of	
ATMPs	differs	 from	 conventional	 products	 and	 faces	 less	 precise	 controls.	Non-clinical	 animal	models	




is	 not	 always	 possible	 to	 follow	 the	 standard	 and	 required	 set	 of	 rules	 for	 clinical	 development.	 For	
example,	due	to	use	of	autologous	cells,	 it	 is	not	possible	to	use	healthy	volunteers	 in	the	exploratory	
phase	I	clinical	trial[6].	But	also	the	pivotal	trial	design,	for	retrieving	comprehensive	data	for	marketing	






















products	 have	 obtained	 marketing	 approval	 in	 the	 EU	 until	 now[2,12].	 It	 is	 important	 to	 determine	
whether	 this	 is	caused	by	the	products	being	relatively	new	and	thus	 in	need	of	 time,	or	whether	 the	
current	 system	 is	 not	 suitable	 for	 these	 ATMPs,	 leading	 to	 hurdles	 in	 the	 development	 procedure.	
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Unlicensed	 pharmaceutical	 preparations,	 the	 second	 group	 of	 medicinal	 products	 discussed	 in	 this	
thesis,	 produced	 in	 (hospital)	 pharmacies	 are	 already	 used	 in	 regular	 patient	 care,	 in	 contrast	 to	 the	
innovative	 ATMPs[13].	 As	 mentioned	 before,	 not	 all	 existing	 diseases	 can	 be	 treated	 by	 means	 of	
licensed	medicinal	products.	For	 these	patients,	often	suffering	 from	orphan	diseases	 (<5	patients	per	
10.000	 people)[12],	 pharmaceutical	 preparations	 can	 be	 the	 solution.	 However,	 since	 these	
pharmaceutical	 preparations	 are	 unlicensed	 no	 formal	 independent	 product	 approval	 is	 in	 place.	 It	 is	
therefore	 important	 to	discuss	how	patient	 safety	 can	be	 guaranteed.	Although	academic	 institutions	
are	 often	 involved	 in	 development,	 they	 are	 not	 involved	 in	 obtaining	 marketing	 approval	 for	 these	
products.	Whenever	marketing	approval	is	granted,	commercial	parties	are	involved	and	drug	prices	are	
very	 high.	 These	 high	 costs	 conflict	with	 the	 relatively	 low	prices	 of	 pharmaceutical	 preparations	 and	
may	therefore	lead	to	continued	non-treatment	of	patients.	Understanding	pharmaceutical	preparations	
including	 the	 safety	 requirements	 and	 proper	 documentation	 can	 facilitate	 these	 pharmaceutical	
preparations	to	the	special	patient	cohorts	in	need.	
An	 example	 of	 a	 pharmaceutical	 preparation	 used	 in	 regular	 clinical	 care	 is	 3,4-diaminopyridine	 (3,4-
DAP)	 for	 the	 treatment	 of	 the	 orphan	 autoimmune	 disease	 Lambert-Eaton	 Myasthenic	 Syndrome	
(LEMS).	As	there	is	no	current	curative	treatment	for	LEMS,	other	therapy	goals	are	pursued.	3,4-DAP	is	
globally	 the	 most	 frequently	 used	 symptomatic	 treatment.	 It	 is	 an	 inhibitor	 of	 the	 voltage-gated	













The	 ultimate	 goal	 of	 academic	medicinal	 products	 is	 to	 provide	 treatment	 for	 all	 patients,	 also	 those	
whose	medical	needs	have,	thus	far,	not	been	met.	These	types	of	patients	would	strongly	benefit	from	
academic	medicinal	 products	 whether	 these	 are	 licensed	 or	 not.	 The	 general	 aim	 of	 this	 thesis	 is	 to	
investigate	how	these	academic	medicinal	products	could	eventually	reach	regular	patient	care.	This	will	
be	 explored	 by	 investigating	 the	 ATMP	 development	 field	 from	 hurdles	 experienced	 in	 early	 clinical	
development	 towards	 the	decision-making	by	 regulatory	 authorities	 of	 these	products	 (Part	 I)	 and	by	
describing	how	unlicensed	pharmaceutical	preparations	should	remain	available	 in	regular	clinical	care	
with	guaranteed	safety	at	an	affordable	price	(Part	II).	
In	 the	 first	 part	 of	 this	 thesis,	 the	 focus	 is	 on	 the	 new	 innovative	 group	 of	 ATMPs.	 In	 Chapter	 2	 a	
summary	 of	 the	 strengths	 of	 academic	 institutions	 during	 the	 development	 trajectory	 of	 ATMPs	 is	




differ	 for	 clinical	 trials	 progress	 to	 a	 subsequent	 phase	 or	 not,	 as	 a	 proxy	 for	 success	 in	 clinical	
development.	 Finally,	 in	 Chapter	 6	 the	 decision-making	 of	 (non-)approved	 ATMPs	 in	 the	 EU	 is	
investigated.	Variables	and	the	interpretation	of	these	variables	by	the	regulatory	authorities	which	led	
to	(non-)approval	of	an	ATMP	are	compared	among	the	different	approval	decisions.		
The	 second	 part	 of	 this	 thesis	 begins	 with	 an	 overview	 of	 the	 different	 types	 of	 pharmaceutical	
preparations	in	Chapter	7.	 It	 is	discussed	how	safe	use	of	these	products	should	be	ensured,	based	on	
pharmaceutical	 quality	 assurance	 and	 benefit/risk-assessment.	 In	 Chapter	 8	 a	 case-study	 of	 an	
unlicensed	 pharmaceutical	 preparation,	 3,4-DAP,	 is	 described.	 Here,	 available	 data	 of	 the	 unlicensed	
3,4-DAP	 is	 compared	 with	 data	 available	 for	 marketing	 authorization	 approval	 of	 the	 licensed	
formulation,	 Firdapse®,	 to	 investigate	whether	 the	 increased	costs	of	 the	 licensed	 formulation	 can	be	
justified.		
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toward	approval	 for	 regular	patient	care	 is	disappointingly	 low.	 In	 this	paper,	we	define	strengths	and	
hurdles	 applying	 to	 the	 development	 of	 cell	 therapy	 medicinal	 products	 in	 academic	 institutes,	 and	






Increasing	pathophysiological	 knowledge	 and	 technological	 advances	 should	permit	development	of	 a	
variety	of	safe	and	effective	innovative	drugs.	In	particular,	the	field	of	cell	and	tissue	therapies	has	been	
boosted	 by	 improved	 insights	 into	 immunology	 and	 disease	 biology,	 especially	 for	 regenerative	 and	
cancer	 medicines[1].	 These	 therapies,	 particularly	 autologous	 ones,	 are	 technically	 challenging	 when	
compared	with	the	manufacture	of	conventional	pharmaceutical	products	but	are	akin	to	cell	and	organ	
transplant	 products	 making	 their	 development	 fit	 better	 with	 academic	 institutes	 than	 conventional	
manufacturers[2,3].	 This	 explains	 why	most	 cell	 therapy	 strategies	 originate	 from	 academic	 research	
groups	across	the	EU	and	the	USA.	The	development	of	these	promising	novel	therapies	results	in	high-
impact	 scientific	 publication	 of	 preclinical	 and	 clinical	 data,	 but	 only	 very	 few	 cell	 therapies	 have	
obtained	a	marketing	authorization	(MA)	(for	regulatory	background	see	Box	1)[4].	
Box	1.	Regulatory	framework	for	cell	therapies	in	the	USA	and	Europe		
In	 Europe	 cell	 therapies	 belong	 to	 the	 advanced	 therapy	 medicinal	 products	 (ATMPs),	 which	 are	 defined	 in	 EU	 regulation	









under	 the	Tissue	and	Cells	Directive	 (2004/23/EC)	 in	 the	EU	and	 the	HCT/Ps	 in	 the	USA.	Cells	which	have	been	 subjected	 to	
substantial
a
	 manipulation	 and/or	 cells	 	 which	 are	 used	 in	 a	 non-homologous	 fashion
a






Many	 cell	 therapies	 are	 in	 development	 for	 (ultra-)orphan	 indications[5,6];	 possibly	 because	 of	 the	
disease-specific	 mode	 of	 action,	 and	 because	most	 cell	 therapies	 are	 ‘tailored’	 for	 each	 patient.	 Cell	
therapies	have	been	thought	 to	be	of	 limited	commercial	value	owing	to	 the	challenging	 logistics	 that	
are	associated	with	personalized	manufacturing.	In	addition,	commercial	developers	are	more	cautious	
in	 committing	 to	 high	 risk	 products	 in	 early	 development[7].	 Only	 in	 recent	 years,	 a	 series	 of	
breakthrough	results	have	persuaded	companies	to	invest	in	academic	cell	therapies	toward	commercial	
development	(Box	2).	
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followed	 up	 by	 well-designed	 (controlled)	 Phase	 II/	 III	 trials[5].	 Thus,	 although	 academic	 product	
development	receives	medical	ethical	clinical	trial	approval,	the	collected	data	are	not	sufficient	to	build	
a	dossier	for	MA.	A	possible	explanation	could	be	that	academic	drug	developers	are	driven	by	novelty	
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Abbreviations:	CTL=	Cytot xic	T-Lymphocyte;	CAR-T	=	Chimeric	Antigen	Receptor	T-Cell;	CLL	=	Chronic	 Lymphoblastic	 Leukemia;	ADA-
SCID	=	Adenosine	Deaminase	Def iency	–	Sever 	Combined	I munodeficiency;	GSK	=	GlaxoSmithKline.	
http://ir.kitepharma.com/rele detail.cfm?rel aseid=901985;	http://www.pharmaworldmagaz ne.com/italy-leader-in-the-


















Many	of	the	academic	cell	therapies	have	been	tested	in	multiple	early-phase	ex l 	 li i l	trials,	
resulting	in	peer-reviewed	publications[8].	However,	in	Europe	98%	of	clinical	cell	therapy	trials	have	not	
contributed	to	development	of	licensed	products	yet[5].	Even	successful	early	clinical	trials	were	rarely	
followed	 up	 by	 well-designed	 (controlled)	 Phase	 II/	 III	 trials[5].	 Thus,	 although	 academic	 product	
development	receives	medical	ethical	clinical	trial	approval,	the	collected	data	are	not	sufficient	to	build	
a	dossier	for	MA.	A	possible	explanation	could	be	that	academic	drug	developers	are	driven	by	novelty	





development	 and	 even	 fewer	 have	 become	 standard	 patient	 care.	 Subsequently,	 we	 aim	 to	 provide	
recommendations	 to	 public	 stakeholders	 involved	 in	 development	 of	 cell	 therapies,	 to	 exploit	 their	















cell	 and	 tissue	 samples[4].	 Biobanking	 of	 patient	 samples	 has	 become	 well	 organized	 and	 for	 many	
indications	 these	 collections	 are	 shared	 among	 academic	 centres	 at	 national	 and	 international	 levels.	
High-quality	collections	of	patient	samples	are	essential	to	start	proper	pathophysiological	research,	and	




Even	 larger	 amounts	 of	 human	 cells	 or	 tissues	 are	 required	 to	 start	 translation	 toward	 clinical	
development.	 In	most	 academic	 institutes,	 core	 facilities	 are	 operational	 for	 procurement,	 processing	
and	 storage	 of	 human	 cells	 and	 tissues	 to	 facilitate	 transplantation	 of	 hematopoietic	 stem	 cells	 and	
tissues[15].	 These	 facilities	 are	 often	 suitable	 to	 supply	 the	 local	 cell	 therapy	manufacturing	 facilities	
directly	 and	 to	 support	 the	 transport	 of	 human	 material	 to	 other	 academic	 institutes.	 Driven	 by	
promising	 preclinical	 data,	 many	 academic	 institutes	 have	 constructed	 cell	 therapy	 manufacturing	
facilities	that	are	compliant	with	GMP	guidelines	over	the	past	15	years[3].	
For	autologous	and	allogeneic	cell	therapies,	patient	or	(un)matched	donor	material	procurement	up	to	
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product	 release	 and	 treatment	 can	 therefore	 be	 rapidly	 and	 efficiently	 organized	 within	 a	 single	
institute.	By	contrast,	pharmaceutical	companies	frequently	rely	on	centralized	manufacturing	facilities,	
often	 limited	 to	 only	 a	 few	 sites	 or	 even	 one	 site	 globally,	 which	 means	 shipment	 of	 the	 starting	




Because	 patients	 already	 receive	 medical	 treatment	 at	 academic	 institutes,	 efficient	 clinical	 trial	
recruitment,	 enrolment	 and	 compliance	 are	 well	 supported	 by	 dedicated	 research	 teams	 at	 clinical	
departments.	 For	 (ultra)-orphan	 diseases,	 relatively	 large	 patient	 cohorts	 are	 concentrated	 in	 specific	
academic	 institutes,	 which	 can	 efficiently	 be	 connected	 to	 other	 cohorts	 through	 existing	 regional	 or	
international	collaborations,	consortia	and	patient	registries[17].	For	clinical	trials	investigating	safety,	it	
is	 crucial	 to	 have	 an	 intensive	 and	 long-term	 patient	 follow-up.	 As	 (modified)	 living	 cells	 are	
administered,	clinical	and	mechanistic	monitoring	of	direct	and	long-term	effects	is	needed	and	provides	






To	 improve	 understanding	 about	 why	 only	 a	 few	 cell	 therapies	 reach	 standard	 patient	 care,	 hurdles	
restraining	late-phase	clinical	development	were	analysed.	
Academic	hurdle:	science-driven	instead	of	product-driven	




late-phase	 clinical	 trials	 nor	 further	 product	 development	 such	 as	 optimization,	 standardization	 and	
quality	 improvements.	 Thus,	 so	 far	 academic	 institutes	 receive	 little	 stimulation	 to	 progress	 cell	
therapies	further	from	exploratory	studies	toward	standard	patient	care.	
In	contrast	to	the	pharmaceutical	industry,	academic	scientists	are	not	used	to	designing	their	products	
for	 long-term	 goals,	 or	 to	 improving	 the	 product	 continuously.	 Target	 product	 profiles	 (TPP)	 are	 not	
	
being	drafted	or	even	discussed	by	the	academic	research	teams.	The	technology	transfer	offices	(TTOs)	




increasing	 experience	 with	 cell	 therapies	 has	 improved	 the	 interpretation	 thereof	 by	 regulatory	
authorities	 such	 as	 the	 FDA	 and	 EMA[22].	 Investment	 in	 GMP-compliant	 facilities	 has	 resulted	 in	
adequate	quality	management	systems	and	cell	therapy	development	expertise	 in	academic	 institutes.	
However,	 academic	 product	 quality	 assurance	 aims	 for	 GMP	 and	 Investigational	 Medicinal	 Product	
Dossier	 (IMPD)	 compliance,	 and	 does	 not	 take	 into	 account	 the	 more	 detailed	 set	 of	 regulatory	
requirements	 that	 is	 expected	 for	 an	MA	 application.	 As	 a	 consequence,	 successful	 academic-driven	
product	development	only	has	been	achieved	when	partnering	with	(larger)	pharmaceutical	companies	
(Box	 2)[6].	 In	 the	 absence	 of	 academic	 staff	 with	 appropriate	 regulatory	 expertise,	 academic	 cell	
therapies	cannot	efficiently	be	transferred	to	(commercial)	late-stage	development[5,14,22].	
Academic	hurdle:	limited	funding	
Early	 clinical	 trial	 development	 of	 cell	 therapies	 in	 academic	 institutes	 is	 supported	 by	 a	 variety	 of	
financial	 sources.	 Governmental	 programs	 enable	 establishment	 and	 utilization	 of	 high	 level	
infrastructure	 for	 academic	 research	 and	 development[23–25].	 In	 addition,	 governmental	 funding,	
usually	 allocated	 by	 national	 grant	 funding	 agencies,	 is	 available	 to	 support	 specific	 projects.	 These	
governmental	 grants	 synergize	 with	 charities	 and	 philanthropy	 to	 drive	 innovative	 preclinical	 cell	
therapy	 research	 and	 translation	 effectively	 toward	 exploratory	 clinical	 research.	 However,	 because	
these	grants	are	given	for	a	limited	timeframe,	the	continuity	of	financial	support	is	hindered,	but	this	is	
needed	for	persistent	drug	development.	
That	 transfer	 to	 commercial	 development	 with	 for-profit	 investment	 can	 result	 in	 highly	 safe	 and	
effective	 cell	 therapies	 to	 be	marketed	 (Box	 2).	 However,	 only	 the	 commercially	 most	 attractive	 cell	
therapies	will	be	transferred	to	commercial	development	(figure	1),	and	the	majority	of	potential	useful	
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Figure	 1.	Cell	 therapy	 development	 originating	 from	 academic	 institutes.	 Cell	 therapies	 originating	 in	 academic	
institutes	can	be	picked	up	by	commercial	companies	or			can	stay	in	the	academic	setting.	Cell	therapies	that	have	
a	 potentially	 high	 commercial	 value,	 or	 include	 low-risk	 for	 a	 company,	 can	 be	 transferred	 during	 preclinical	





institutes.	 To	 improve	 the	 level	 of	 academic	 cell	 therapy	 development,	 we	 propose	 a	 set	 of	
recommendations	for	the	specific	stakeholders	(summarized	in	figure	3).		
Academic	research	groups:	aim	for	the	target	product	profile	
A	 very	 straightforward	 and	 feasible	 recommendation	 for	 academic	 principal	 investigators	 leading	 cell	
therapy	 research	would	be	 to	draft	 a	 TPP.	Many	academic	 researchers	will	 see	 the	 TPP	as	 something	
relevant	only	to	commercial	drug	developers.	However,	putting	patients	at	risk	in	a	Phase	I/II	trial	is	only	
ethical	 if,	 in	 the	event	 the	 trial	was	successful,	 this	would	be	developed	 further	so	 that	 the	 therapy	 is	
made	 available	 to	 standard	 patient	 care.	 The	 design	 of	 a	 TPP	 could	 be	 drafted	most	 realistically	 and	
effectively	with	a	broad	multidisciplinary	cell	 therapy	development	team	within	the	 institute.	 It	should	
include	sufficient	details	and	provide	a	path	for	further	product	development[27],	and	be	drafted	with	
realistic	timelines	(http://agora-gmp.org	provides	a	TPP	outline).	The	TPP	can	be	used	to	align	priorities	
and	 financial	 planning	 over	 time,	 and	 facilitate	 communication	 with	 other	 stakeholders	 including	







Figure	 2.	Available	 strengths	 and	 limitations	 in	 academic	drug	development.	Academic	 institutes	have	 strengths	




product	 development	 efficiently	 by	 a	 central	 coordinating	 body[10,12].	 A	 strategic	 and	 product-
independent	 advisory	 board	 could	 be	 key	 to	 shape	 the	 organization	 to	 become	 more	 suitable	 for	
product	 development,	 including	 investments	 in	 facilities,	 equipment	 and	 expertise,	 and	 to	 initiate	




Importantly,	 besides	 the	 scientific	 output,	 additional	 success	 parameters	 should	 be	 defined	 and	
rewarded,	including	improvements	in	quality	systems,	product	development	milestones	and	funding	or	
collaboration	with	appropriate	partners.	
Although	 academic	 institutes	 could	 hesitate	 to	 invest	 in	 product	 development	 instead	 of	 merely	 in	
scientific	 research,	 the	 cell	 therapies	 in	 early	 clinical	 trials	 could	 become	 much	 more	 attractive	 for	
transfer	to	commercial	partners.	Apart	from	the	ethical	reasons	to	develop	better	therapies,	successful	
transfer	of	cell	 therapies	 toward	commercial	development	might	 result	 in	 significant	 financial	 rewards	
(http://ir.kitepharma.com/releasedetail.cfm?releaseid=	901985)[18],	which	can	be	directly	 invested	for	
self-sustaining	 not-for-profit	 product	 development	 and	manufacturing[3].	 A	 successful	 example	 is	 the	
Canadian	Centre	for	Commercialization	of	regenerative	Medicine	(CCRM).	
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institutes	can	be	picked	up	by	commercial	companies	or			can	stay	in	the	academic	setting.	Cell	therapies	that	have	
a	 potentially	 high	 commercial	 value,	 or	 include	 low-risk	 for	 a	 company,	 can	 be	 transferred	 during	 preclinical	
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Figure	 2.	Available	 strengths	 and	 limitations	 in	 academic	drug	development.	Academic	 institutes	have	 strengths	
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Figure	3.	Organizational	model	 for	academic	development	of	 cell	 therapies.	The	actions	 in	 the	central	panel	are	
proposed	to	improve	the	yield	of	cell	therapies	that	reach	standard		patient	care.	
Academic	institutes:	provide	regional	GxP	cell	therapy	services	
To	 progress	 academic	 cell	 therapies	 further	 toward	 later	 stage	 development,	 it	 might	 be	 efficient	 to	
establish	synergistic	collaborations	for	GMP	manufacturing	and	good	distribution	practice	(GDP)	supply	
among	 multiple	 academic	 institutes,	 and	 share	 facilities,	 equipment	 and	 expertise[29].	 Collaborative	
investment	 could	 more	 efficiently	 increase	 the	 manufacturing	 and	 quality	 control	 and	 assurance	
capacities	 and	 might	 reduce	 the	 associated	 costs.	 An	 example	 of	 a	 huge	 collaborative	 effort	 on	 cell	
therapy	development	and	GMP/GDP-compliant	operations	 is	 the	Cell	Therapy	Catapult	 in	 the	UK.	This	
initiative	provides	the	possibility	of	academic	research	teams	to	connect	with	excellent	GMP-compliant	
and	 GDP-compliant,	 but	 also	 regulatory-compliant,	 development	 and	 manufacturing	 teams,	 and	 is	
expected	to	boost	the	cell	therapy	field	in	the	UK.	
We	 think	 these	 recommendations	 provided	 are	 important	 to	 improve	 academic	 cell	 therapy	
development.	Nevertheless,	academic	institutes	should	remain	aware	that	their	academic	strengths	are	





The	 regulatory	 framework	 for	cell	 therapie	 requires	central	application	 for	MA	 in	 the	USA	and	 the	EU	
and	evaluation	through	the	USA	FDA	Cellular,	Tissue	and	Gene	Therapies	Advisory	Committee,	and	the	
EU	EMA	Committee	for	Advanced	Therapies.	In	the	EU	it	is	also	possible	to	request	scientific	advice	at	a	
national	 level	 and	 several	 national	 regulatory	 agencies	 have	 opened	 this	 scientific	 advice	 possibility	
specifically	for	not-for-profit	organizations.	Early	interaction	with	the	regulatory	authorities	provides	an	
excellent	 and	 accessible	 opportunity	 for	 academic	 cell	 therapy	 development	 teams	 to	 discuss	 their	
product	dossier,	and	use	 the	 regulatory	advice	 to	direct	 further	 steps.	 Simultaneously,	 these	 scientific	
discussions	increase	the	knowledge	of	the	national	regulatory	agency	experts	on	cell	therapies,	and	will	
also	contribute	 to	discussions	 in	 central	procedures.Funders:	 reward	product	development	milestones	
and	support	specific	academic	programs	
Currently,	 several	 governmental	 funders	 and	 charities,	 such	 as	 the	 EU	 H2020	 program	 and	 the	 USA	
Cancer	Research	Institute,	are	exploring	possibilities	to	aim	for	real	patient	benefit	in	standard	care,	by	
stimulating	 research	 teams	 to	 develop	 their	 research	 results	 toward	 successive	 stages	 of	 clinical	




In	 addition,	 philanthropic	 funders	 will	 be	 interested	 in	 contributing	 to	 not-for-profit	 development	 of	
specific	 innovative	 cell	 therapies.	 The	 open	 academic	 setting	 is	 suitable	 to	 enable	 close	 interactions	
between	product	development	 teams	and	philanthropic	 funders.	Many	principal	 investigators	and	cell	
therapy	manufacturing	teams,	including	ours,	are	open	for	visits.	Furthermore,	large	numbers	of	citizens	
interested	 to	 support	 specific	 not-for-profit	 product	 development	might	 be	 attracted	 by	 social	media	
and	 online	 in	 crowdfunding	 campaigns[13,30].	 Initial	 attempts	 resulted	 in	 relevant	 funding,	 and	
academic	development	of	exciting	new	cell	therapy	modalities	might	be	even	more	attractive[30].	 It	 is	
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Concluding	remarks	
It	 is	 now	 well	 recognized	 that	 cell	 therapies	 have	 enormous	 potential	 in	 the	 fields	 of	 cancer	
immunotherapy,	 gene	 modified	 stem	 cell	 therapy	 and	 regenerative	 medicine.	 These	 cell	 therapies	
originate	 naturally	 in	 the	 academic	 setting	 because	 of	 their	 direct	 access	 to	 patients	 and	 donors.	
Unfortunately,	the	system	of	academic	research	has	rarely	driven	development	of	promising	cell	therapy	
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the	 EU.	 Recognizing	 the	 major	 developments	 in	 the	 ATMP	 field,	 starting	 mostly	 in	 academic	
institutions,	 we	 investigated	 which	 hurdles	 were	 experienced	 in	 the	 whole	 pathway	 of	 ATMP	
development	 towards	 clinical	 care.	 Methods.	 Quality	 interviews	 were	 executed	 with	 different	
stakeholders	 in	 The	Netherlands	 involved	 in	 the	ATMP	development	 field,	 e.g.	 academic	 research	
groups,	 national	 authorities	 and	 patient	 organizations.	 Based	 on	 the	 hurdles	 mentioned	 in	 the	
interviews,	questionnaires	were	subsequently	sent	to	the	academic	principal	investigators	(PIs)	and	
ATMP	 good	 manufacturing	 practice	 (GMP)	 facility	 managers	 to	 quantify	 these	 hurdles.	 Results.	
Besides	the	familiar	regulatory	routes	of	marketing	authorization	(MA)	and	hospital	exemption	(HE),	
a	part	of	the	academic	PIs	perceived	that	ATMPs	should	become	available	by	the	Tissues	and	Cells	
Directive	 or	 did	 not	 anticipate	 on	 the	 next	 development	 steps	 towards	 implementation	 of	 their	
ATMP	towards	regular	clinical	care.	The	main	hurdles	identified	were:	inadequate	financial	support,	
rapidly	evolving	 field,	 study-related	problems,	 lacking	 regulatory	knowledge,	 lack	of	collaborations	
and	 responsibility	 issues.	 Discussion.	 Creating	 an	 academic	 environment	 stimulating	 and	 planning	





The	 field	 of	 cell	 therapy,	 gene	 therapy	 and	 tissue	 engineered	medicinal	 products	 (CTMPs,	GTMPs	
and	 TEPs)	 is	 innovative	 and	 evolving	 rapidly[1].	 However,	 only	 14	 products	 have	 applied	 for	
marketing	authorization	(MA)	in	Europe,	from	which	six	have	received	MA	approval[2].	Since	2009,	




performed,	 172	 Scientific	 Advices	 have	 been	 issued[2],	 and	 considerably	more	 ATMP	 (pre)clinical	
trials	 have	 been	 performed[6].	 On	 the	 basis	 of	 the	 numbers	 provided	 by	 the	 EMA,	 it	 seems	 that	
ATMP	development	 toward	MA	application	has	a	 low	success	 rate.	Besides	 the	standard	EMA	MA	
route,	 the	ATMP	regulation	defines	a	second	route	to	reach	clinical	care	with	ATMPs:	 the	hospital	




In	 the	Netherlands,	ATMPs	manufactured	 in	compliance	with	Good	Manufacturing	Practice	 (GMP)	
may	be	eligible	 for	HE	 therapy	after	evaluation	of	quality,	 safety	and	efficacy	by	 the	Dutch	health	
care	 inspectorate[13].	 HEs	 can	 be	 approved	 for	 1	 year	 and	 for	 either	 10	 or	 50	 batches[14,15].	
Subsequently,	it	is	possible	to	apply	for	an	extension	of	the	HE[15].	As	many	as	92	clinical	trials	and	
even	more	preclinical	research	projects	with	ATMPs	have	been	performed	in	the	Netherlands	so	far,	
and	 only	 one	MA	 has	 been	 granted	 for	 alipogene	 tiparvovec	 (Glybera®)[16,17].	 As	 of	 December	
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trials	 have	 been	 performed[6].	 On	 the	 basis	 of	 the	 numbers	 provided	 by	 the	 EMA,	 it	 seems	 that	
ATMP	development	 toward	MA	application	has	a	 low	success	 rate.	Besides	 the	standard	EMA	MA	
route,	 the	ATMP	regulation	defines	a	second	route	to	reach	clinical	care	with	ATMPs:	 the	hospital	




In	 the	Netherlands,	ATMPs	manufactured	 in	compliance	with	Good	Manufacturing	Practice	 (GMP)	
may	be	eligible	 for	HE	 therapy	after	evaluation	of	quality,	 safety	and	efficacy	by	 the	Dutch	health	
care	 inspectorate[13].	 HEs	 can	 be	 approved	 for	 1	 year	 and	 for	 either	 10	 or	 50	 batches[14,15].	
Subsequently,	it	is	possible	to	apply	for	an	extension	of	the	HE[15].	As	many	as	92	clinical	trials	and	
even	more	preclinical	research	projects	with	ATMPs	have	been	performed	in	the	Netherlands	so	far,	
and	 only	 one	MA	 has	 been	 granted	 for	 alipogene	 tiparvovec	 (Glybera®)[16,17].	 As	 of	 December	














and	Development	 (ZonMw)	and	 the	Dutch	Cancer	Society	 (DCS),	ATMP	projects	were	 selected	 for	
interviews.	 Projects	 were	 independently	 classified	 as	 ATMPs	 according	 to	 ATMP	 regulation	
1394/2007	by	two	authors	(LVD	and	PM,	researchers	with	>5-year	experience	in	ATMP	development	
and	manufacturing).	Projects	aiming	for	at	least	a	phase	I	clinical	trial	with	an	ATMP	were	selected.	
In	 the	 second	 and	 third	 quarters	 of	 2014,	 qualitative	 interviews	 were	 conducted	 with	 the	
corresponding	 29	 academic	 principal	 investigators	 and	 project	 leaders	 (PIs),	 from	 10	 institutions.	
During	the	interviews,	45	ATMPs	were	discussed.	
In	 addition	 to	 the	 PIs,	 other	 stakeholders	were	 selected	 on	 the	 basis	 of	 their	 role	 in	 the	 path	 of	
ATMP	 development	 toward	 regular	 clinical	 care:	 authorities	 covering	 regulatory	 affairs,	 health	
technology	 assessment	 (HTA),	 health	 insurance	 or	 patient	 representation,	 ATMP	 GMP	 facility	





(PM,	 SdW,	 or	 both).	 All	 answers	 were	 considered	 to	 be	 personal	 opinions	 from	 the	 individual	
persons	 interviewed,	unrelated	 to	 the	 formal	position	of	 their	employers	or	 to	 the	opinion	of	 the	
authors	who	conducted	the	interviews.	
The	 two	key	questions	 for	all	 interviews,	asked	as	open	questions,	were,	 for	both	 the	PIs	and	 the	
other	 stakeholders:	 “How	 should	 an/your	 ATMP	 be	 implemented	 in	 regular	 clinical	 care	 after	
successful	 clinical	 phase	 I/II	 trials?”	 and	 “What	 are	 the	 main	 hurdles	 experienced	 during	
development	and	implementation	of	an	ATMP?”	
Questionnaires	







meaning	 “it	 is	 a	 substantial	 hurdle.”	 The	 mean	 score	 per	 sub-classification	 of	 the	 hurdles	 was	
calculated	and	a	cutoff	score	of	2.5	was	used	for	identification	of	relevant	hurdles.	
The	questionnaire	was	sent	to	29	PIs:	26	PIs	(90%)	began	the	questionnaire,	and	19	(66%)	completed	
it.	 Only	 completed	 questionnaires	were	 included	 for	 analysis.	 The	 questionnaire	was	 also	 sent	 to	
eight	 ATMP	 GMP	 facility	 managers,	 of	 which	 seven	 were	 completed.	 GMP	 facilities	 were	 a	
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Figure	 1.	 Overview	 of	 ATMPs	 discussed	 in	 interviews.	 (A)	 ATMP	 sub-classification:	 CTMP,	 cell	 therapy	
medicinal	 product;	 GTMP,	 gene	 therapy	 medicinal	 product;	 GTMP—ex	 vivo,	 genetic	 modification	 in	 target	





HE	 followed	by	MA	 approval.	 Furthermore,	 26%	of	 the	 PIs	 thought	 it	would	 be	 possible	 to	 reach	
clinical	 care	 via	 the	 Tissues	 and	 Cells	 Directive	 and	 19%	 did	 not	 yet	 have	 a	 future	 plan	 for	
implementation.	PIs	 involved	 in	the	development	of	GTMPs	saw	more	opportunities	to	obtain	MA	
for	their	product	(50%)	compared	with	PIs	involved	in	the	development	of	CTMPs/TEPs	(33%).	
On	 the	 basis	 of	 the	 questionnaires,	 which	 were	 sent	 a	 year	 after	 the	 interviews,	 an	 increasing	
percentage	of	PIs	intended	to	reach	clinical	care	after	successful	safety	and	efficacy	trials,	via	either	
MA	 (47%)	 or	 HE	 (20%)	 or	 first	 HE	 followed	 by	 MA	 (11%),	 as	 shown	 in	 Figure	 2.	 The	 other	 22%	
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The	differ nt	subtypes	 f	ATMPs	that	 er 	 i 	 ri g	the	interviews	are	shown	in	Figure	1A.	
The	 main	 group	 consi ted	 of	 CT Ps/TEPs	 (71 ).	 ithin	 is	 group,	 personalized	 CTMPs/TEPs,	
generated	from	autologous	or	specific	allogeneic	cells,	were	the	biggest	group	(66%).	Twenty-nine	
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The	ATMP	GMP	 facility	managers	 and	 the	 other	 stakeholders	mentioned	both	MA	 and	HE	 as	 the	








The	 following	 five	 categories	 were	 identified,	 based	 on	 the	 interviews,	 as	main	 hurdles	 in	 ATMP	
development	 (percentage	 of	 all	 the	 interviewed	PIs	 and	 other	 stakeholders):	 inadequate	 financial	
support	 (76%),	 rapidly	 evolving	 field	 (48%),	 study-related	 problems	 (48%),	 lacking	 regulatory	
knowledge	 (45%)	 and	 lack	 of	 collaborations	 and	 responsibility	 issues	 (28%).	 On	 the	 basis	 of	 data	
from	the	 interviews,	more	specific	hurdles	were	subdivided	 into	these	main	categories	of	hurdles.	
For	 the	 PIs	 and	 the	 ATMP	 GMP	 facility	 managers,	 the	 scores	 for	 all	 subclassified	 hurdles	 are	
presented	in	Figures	3	and	4,	respectively.	
Inadequate	financial	support	
The	 main	 hurdle	 identified	 in	 the	 PI	 group	 was	 inadequate	 financial	 support,	 which	 was	 also	
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Figure	2.	R i l	care	a cording	to	the	questionnair 	results.	Route	according	to	respondent	PIs	on	
how	they	t i 	 s	should	reach	clinical	care	after	safety	and	efficacy	hav 	been	shown.	
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indicated	as	a	major	hurdl 	by	 the	other	 takeholders	 i 	 the	 interviews.	All	 interviewees	obtained	
grants	for	their	product	development	because	the	selection	of	the	products	for	this	study	w s	based	
on	grants	provided	by	DCS	and	ZonMw.	Other	funding	sources	were	companies	(18%)	and	insurance	
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HE	 followed	by	MA	 approval.	 Furthermore,	 26%	of	 the	 PIs	 thought	 it	would	 be	 possible	 to	 reach	
clinical	 care	 via	 the	 Tissues	 and	 Cells	 Directive	 and	 19%	 did	 not	 yet	 have	 a	 future	 plan	 for	
implementation.	PIs	 involved	 in	the	development	of	GTMPs	saw	more	opportunities	to	obtain	MA	
for	their	product	(50%)	compared	with	PIs	involved	in	the	development	of	CTMPs/TEPs	(33%).	
On	 the	 basis	 of	 the	 questionnaires,	 which	 were	 sent	 a	 year	 after	 the	 interviews,	 an	 increasing	
percentage	of	PIs	intended	to	reach	clinical	care	after	successful	safety	and	efficacy	trials,	via	either	
MA	 (47%)	 or	 HE	 (20%)	 or	 first	 HE	 followed	 by	 MA	 (11%),	 as	 shown	 in	 Figure	 2.	 The	 other	 22%	












Figure	 1.	 Overview	 of	 ATMPs	 discussed	 in	 interviews.	 (A)	 ATMP	 sub-classification:	 CTMP,	 cell	 therapy	
medicinal	 product;	 GTMP,	 gene	 therapy	 medicinal	 product;	 GTMP—ex	 vivo,	 genetic	 modification	 in	 target	





HE	 followed	by	MA	 approval.	 Furthermore,	 26%	of	 the	 PIs	 thought	 it	would	 be	 possible	 to	 reach	
clinical	 care	 via	 the	 Tissues	 and	 Cells	 Directive	 and	 19%	 did	 not	 yet	 have	 a	 future	 plan	 for	
implementation.	PIs	 involved	 in	the	development	of	GTMPs	saw	more	opportunities	to	obtain	MA	
for	their	product	(50%)	compared	with	PIs	involved	in	the	development	of	CTMPs/TEPs	(33%).	
On	 the	 basis	 of	 the	 questionnaires,	 which	 were	 sent	 a	 year	 after	 the	 interviews,	 an	 increasing	
percentage	of	PIs	intended	to	reach	clinical	care	after	successful	safety	and	efficacy	trials,	via	either	
MA	 (47%)	 or	 HE	 (20%)	 or	 first	 HE	 followed	 by	 MA	 (11%),	 as	 shown	 in	 Figure	 2.	 The	 other	 22%	




The	differ nt	subtypes	 f	ATMPs	that	 er 	 i 	 ri g	the	interviews	are	shown	in	Figure	1A.	
The	 main	 group	 consi ted	 of	 CT Ps/TEPs	 (71 ).	 ithin	 is	 group,	 personalized	 CTMPs/TEPs,	
generated	from	autologous	or	specific	allogeneic	cells,	were	the	biggest	group	(66%).	Twenty-nine	





Figure	 1.	 Overview	 of	 ATMPs	 discussed	 in	 interviews.	 (A)	 ATMP	 sub-classification:	 CTMP,	 cell	 therapy	
medicinal	 product;	 GTMP,	 gene	 therapy	 medicinal	 product;	 GTMP—ex	 vivo,	 genetic	 modification	 in	 target	





HE	 followed	by	MA	 approval.	 Further ore,	 26 	 of	 the	 PIs	 though 	 it	would	 be	 possible	 to	 reach	
clinical	 care	 via	 the	 Tis ues	 and	 Cells	 i i 	 	 	 did	 not	 yet	 have	 a	 future	 plan	 for	
implementation.	PIs	 involved	 in	the	devel s	saw	more	o portun ties	t 	obtain	MA	
for	their	product	(50%)	compared	with	PIs	i 	 velopment	of	CTMPs/TEPs	(33%).	
On	 the	 basis	 of	 the	 question aires,	 hic 	 r 	 s t	 	 year	 after	 the	 interviews,	 an	 increasing	
percentage	of	PIs	intended	to	reach	clinical	care	after	successful	safety	and	efficacy	trials,	via	either	
MA	 (47%)	 or	 HE	 (20%)	 or	 first	 HE	 followed	 by	 MA	 (11%),	 as	 shown	 in	 Figure	 2.	 The	 other	 22%	




The	ATMP	GMP	 facility	managers	 and	 the	 other	 stakeholders	mentioned	both	MA	 and	HE	 as	 the	








The	 following	 five	 categories	 were	 identified,	 based	 on	 the	 interviews,	 as	main	 hurdles	 in	 ATMP	
development	 (percentage	 of	 all	 the	 interviewed	PIs	 and	 other	 stakeholders):	 inadequate	 financial	
support	 (76%),	 rapidly	 evolving	 field	 (48%),	 study-related	 problems	 (48%),	 lacking	 regulatory	
knowledge	 (45%)	 and	 lack	 of	 collaborations	 and	 responsibility	 issues	 (28%).	 On	 the	 basis	 of	 data	
from	the	 interviews,	more	specific	hurdles	were	subdivided	 into	these	main	categories	of	hurdles.	
For	 the	 PIs	 and	 the	 ATMP	 GMP	 facility	 managers,	 the	 scores	 for	 all	 subclassified	 hurdles	 are	
presented	in	Figures	3	and	4,	respectively.	
Inadequate	financial	support	
The	 main	 hurdle	 identified	 in	 the	 PI	 group	 was	 inadequate	 financial	 support,	 which	 was	 also	
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(4%).	 Difficulties	 in	 acquiring	 financial	 support	 for	 phase	 III	 and	 IV	 trials	 and	 for	 MA	 and	
reimbursement	after	HE	approval	are	major	hurdles	for	all	groups	(PIs:	mean	4.6;	ATMP	GMP	facility	
managers:	 mean	 4.5).	 For	 the	 PIs,	 lack	 of	 financial	 support	 already	 formed	 a	 problem	 in	 the	
preclinical	 phase	 and	ATMP	GMP	 facility	managers	 experienced	 this	 as	 a	hurdle	 from	 the	 start	 of	
phase	I/II	trials.	For	both	groups,	acquiring	financial	support	seems	to	be	an	increasing	hurdle	during	
later	 stages	 of	 development.	 During	 the	 interviews,	 all	 stakeholders	 mentioned	 that	 financial	
support	 is	not	an	issue	in	obtaining	HE	approval.	Most	ATMP	GMP	facility	managers	also	indicated	







full	 product	 dossier	 toward	 obtaining	 an	 MA	 was	 lacking	 (mean:	 3.4	 vs	 3.5,	 respectively).	 The	
knowledge	 and	 documentation	 needed	 to	 acquire	 a	 clinical	 trial	 authorization	 (CTA)	 was	 not	
experienced	as	a	 substantial	hurdle	by	 the	ATMP	GMP	facility	managers,	whereas	 for	 the	PIs,	 this	
was	perceived	as	a	more	substantial	hurdle	(mean:	1.7	vs	3.2,	respectively).	Intellectual	property	(IP)	
management	was	not	perceived	as	a	major	hurdle	by	either	group.	Furthermore,	as	mentioned	by	
the	 authorities	 in	 the	 interviews,	 lacking	 knowledge	 concerning	MA	 application	 could	 lead	 to	 PIs’	
underestimating	how	complicated	the	MA	route	may	be.	
A	 major	 portion	 of	 the	 questionnaire	 responders	 (72%)	 and	 the	 majority	 of	 the	 interviewed	 PIs	
thought	it	would	be	helpful	if	there	were	a	knowledge	platform	to	support	the	development	route	




is	 innovative	 and	 dynamic,	 with	 new	 developments	 rapidly	 succeeding	 others.	 Therefore,	 PIs	
expressed	difficulty	in	deciding	to	continue	with	one	specific	ATMP	for	an	MA,	perceiving	that	it	was	
not	 possible	 to	 further	modify	 the	 product	 in	 later	 stages	 of	 product	 development	 based	 on	 the	
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consequence	of	 the	 field’s	 dynamics	 is	 the	 risk	 of	 a	 selected	promising	ATMP	 to	be	overtaken	by	
other	innovative	medicinal	products	before	reaching	MA	(mean:	2.9).	
Study-related	problems	
The	 study-related	 problems	 were	 scored	 as	 substantial	 hurdles	 by	 both	 groups.	 Material-related	
problems,	 such	 as	 limited	 availability	 of	 human	 starting	 material	 (e.g.	 tissue,	 blood)	 and	 raw	
materials	 (reagents	used	 for	manufacturing),	were	considered	by	PIs	as	 the	main	problem	for	 this	




(mean:	 3.6	 and	 2.8,	 respectively)	 because	 it	may	 conflict	with	 long	 term	development	 goals.	 This	




In	collaborative	ATMP	development,	uncertainty	about	who	 is	 responsible	 for	development	of	 the	

















explain	 the	 low	success	 rate	of	 implementation	of	ATMPs	 in	 regular	clinical	 care.	 Lacking	 financial	
support	is	being	perceived	as	the	major	hurdle	for	clinical	trials	and	the	MA	trajectory,	which	is	also	
seen	 in	 the	United	 States[18].	 Reimbursement	 for	 ATMPs	 is	 lacking,	 especially	 after	 HE	 approval.	
Furthermore,	 knowledge	 about	 regulation	 and	documentation	with	 regard	 to	ATMP	development	
and	MA	 applications	 is	 limited	 in	 academic	 institutions.	 The	 field’s	 dynamics	 produce	 anxiety	 to	
create	 increasingly	 innovative	products,	 and	PIs	perceive	 that	 it	 is	 impossible	 to	modify	a	product	
after	 the	 decision	 has	 been	made	 to	 proceed	 toward	 further	 development.	 The	 design	 of	 pivotal	
clinical	 trials	 is	 often	 difficult,	 as	 is	 patient	 enrollment	 and	 obtaining	 suitable	 starting	 and/or	 raw	
materials.	
Of	the	interviewed	PIs,	26%	thought	that	ATMPs	should	become	available	according	to	the	Tissues	
and	 Cells	 Directive,	 2004/23/EC[19].	We	 conclude	 that	 PIs	 are	 not	 fully	 aware	 of	 the	 regulations	
toward	 implementation	 into	 regular	 clinical	 care.	 The	 fact	 that	 the	 Tissues	 and	 Cells	 Directive	 is	
mentioned	might	be	because	some	of	these	responders	are	familiar	with	stem	cell	transplantation	
and	 experience	 fewer	 hurdles	 in	 that	 particular	 regulatory	 framework.	 We	 experienced	 that	
conducting	 these	 interviews,	 in	 itself,	 led	 to	 an	 increase	 in	 awareness	 concerning	 the	 ATMP	
regulation.	Comparing	the	results	of	the	interviews	held	in	2014	and	the	questionnaires	completed	a	
year	 later,	when	only	4%	of	 the	PIs	preferred	 to	use	 the	Tissues	and	Cells	Directive,	 it	 seems	 that	
more	PIs	realized	that	implementation	of	ATMPs	in	regular	clinical	care	is	only	possible	by	HE	or	MA.	
We	indeed	confirmed	that	many	PIs	changed	from	this	perspective	of	the	Tissues	and	Cells	Directive	
toward	HE	and/or	MA	as	 the	means	 to	 reach	regular	clinical	care.	However,	 response	bias	cannot	
fully	 be	 excluded	 for	 the	 questionnaire-completed	 PIs	 because	 not	 all	 PIs	 who	 mentioned	 the	
Tissues	 and	 Cells	 Directive	 did	 complete	 this	 questionnaire.	 The	 research	 groups	 were	 better	
informed	about	ways	to	reach	patients	in	clinical	care	with	their	ATMP	due	to	the	interviews	as	well	
as	 increasing	 awareness	 (e.g.,	 achieved	 by	 attending	 congresses).	 To	 improve	 knowledge	 of	 the	
development	 routes,	 we	 propose	 that	 research	 groups	 (and	 PIs)	 who	 are	 involved	 in	 the	
development	 of	medicinal	 products	 should	 be	 encouraged	 to	 extend	 their	 knowledge	 on	 product	
development	 and	 issues	 such	 as	 MA	 and	 IP	 regulations.	 Furthermore,	 a	 (national)	 ATMP	
development	knowledge	platform	could	be	established.	Remarkably,	16%	of	the	PIs	did	not	have	a	
future	 plan	 for	 their	 product	 to	 be	 implemented	 into	 regular	 clinical	 care.	 It	may	 be	 valuable	 to	
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explain	 the	 low	success	 rate	of	 implementation	of	ATMPs	 in	 regular	clinical	 care.	 Lacking	 financial	
support	is	being	perceived	as	the	major	hurdle	for	clinical	trials	and	the	MA	trajectory,	which	is	also	
seen	 in	 the	United	 States[18].	 Reimbursement	 for	 ATMPs	 is	 lacking,	 especially	 after	 HE	 approval.	
Furthermore,	 knowledge	 about	 regulation	 and	documentation	with	 regard	 to	ATMP	development	
and	MA	 applications	 is	 limited	 in	 academic	 institutions.	 The	 field’s	 dynamics	 produce	 anxiety	 to	
create	 increasingly	 innovative	products,	 and	PIs	perceive	 that	 it	 is	 impossible	 to	modify	a	product	
after	 the	 decision	 has	 been	made	 to	 proceed	 toward	 further	 development.	 The	 design	 of	 pivotal	
clinical	 trials	 is	 often	 difficult,	 as	 is	 patient	 enrollment	 and	 obtaining	 suitable	 starting	 and/or	 raw	
materials.	
Of	the	interviewed	PIs,	26%	thought	that	ATMPs	should	become	available	according	to	the	Tissues	
and	 Cells	 Directive,	 2004/23/EC[19].	We	 conclude	 that	 PIs	 are	 not	 fully	 aware	 of	 the	 regulations	
toward	 implementation	 into	 regular	 clinical	 care.	 The	 fact	 that	 the	 Tissues	 and	 Cells	 Directive	 is	
mentioned	might	be	because	some	of	these	responders	are	familiar	with	stem	cell	transplantation	
and	 experience	 fewer	 hurdles	 in	 that	 particular	 regulatory	 framework.	 We	 experienced	 that	
conducting	 these	 interviews,	 in	 itself,	 led	 to	 an	 increase	 in	 awareness	 concerning	 the	 ATMP	
regulation.	Comparing	the	results	of	the	interviews	held	in	2014	and	the	questionnaires	completed	a	
year	 later,	when	only	4%	of	 the	PIs	preferred	 to	use	 the	Tissues	and	Cells	Directive,	 it	 seems	 that	
more	PIs	realized	that	implementation	of	ATMPs	in	regular	clinical	care	is	only	possible	by	HE	or	MA.	
We	indeed	confirmed	that	many	PIs	changed	from	this	perspective	of	the	Tissues	and	Cells	Directive	
toward	HE	and/or	MA	as	 the	means	 to	 reach	regular	clinical	care.	However,	 response	bias	cannot	
fully	 be	 excluded	 for	 the	 questionnaire-completed	 PIs	 because	 not	 all	 PIs	 who	 mentioned	 the	
Tissues	 and	 Cells	 Directive	 did	 complete	 this	 questionnaire.	 The	 research	 groups	 were	 better	
informed	about	ways	to	reach	patients	in	clinical	care	with	their	ATMP	due	to	the	interviews	as	well	
as	 increasing	 awareness	 (e.g.,	 achieved	 by	 attending	 congresses).	 To	 improve	 knowledge	 of	 the	
development	 routes,	 we	 propose	 that	 research	 groups	 (and	 PIs)	 who	 are	 involved	 in	 the	
development	 of	medicinal	 products	 should	 be	 encouraged	 to	 extend	 their	 knowledge	 on	 product	
development	 and	 issues	 such	 as	 MA	 and	 IP	 regulations.	 Furthermore,	 a	 (national)	 ATMP	
development	knowledge	platform	could	be	established.	Remarkably,	16%	of	the	PIs	did	not	have	a	
future	 plan	 for	 their	 product	 to	 be	 implemented	 into	 regular	 clinical	 care.	 It	may	 be	 valuable	 to	
stimulate	 product	 and	 implementation-oriented	 thinking,	 including	 realistic	 future	 development	
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plans,	 for	 academic	 institutions.	Writing	 a	 product	 dossier	 (e.g.	 based	 on	 a	 target	 product	 profile	
(TPP))	would	help	research	groups	make	future	plans	for	their	ATMPs	early	in	development.	This	TPP	
can	 also	 be	 directive	 in	 making	 important	 product	 decisions	 such	 as	 when	 to	 (dis)continue	
investments	 in	 one	 specific	 ATMP	 at	 a	 certain	 stage,	 creating	 awareness	 and	 a	 proper	 risk	
assessment	on	 the	chance	 that	 the	product	would	be	 surpassed	by	other	new	 therapies	before	 it	
could	be	 introduced	 into	practice.	A	TPP	would	also	be	helpful	 to	start	 fruitful	collaborations	with	
partners	 to	 move	 the	 ATMP	 further	 in	 the	 development	 trajectory.	 Furthermore,	 when	 several	
partners	 are	 involved,	 this	 TPP	 could	 be	 used	 to	 address	 the	 partners’	 responsibilities	 in	 the	
development	process	or	to	clarify	specific	parts	of	the	product.	Academic	institutions	may	consider	
expanding	 the	 scientific	 reward	 system	 of	 publication	 rates	 with	 milestones	 in	 the	 development	
route	[20].	Finally,	proper	clinical	trial	design	is	essential	for	reaching	the	end	goals	as	defined	in	the	
TPP.	 These	 end	 goals	 should	 help	 start	 discussions	 on	 reimbursement	 with	 the	 appropriate	
authorities	 in	 early	 development.	 It	 is	 important	 to	 realize	 that	 the	 assessments	may	 differ	 from	
stakeholder	to	stakeholder,	and,	 in	addition,	 it	 is	 important	to	realize	that	positive	assessment	not	
necessarily	means	that	the	product	or	clinical	trial	will	be	serving	the	end	goal	as	defined	in	the	TPP.		
In	the	Netherlands,	the	HE	clause	is	 increasingly	being	used.	Currently,	academic	 institutions	often	
pay	 for	 treatment	 with	 HE-approved	 ATMPs,	 which	 limits	 the	 number	 of	 patients	 who	 can	
potentially	benefit	from	the	treatment.	The	opportunity	to	receive	reimbursement	from	the	health	
insurers	 is	 limited	 because	 the	 Dutch	 HTA	 board	 evaluates	 safety	 and	 comparative	 effectiveness	
based	 on	 well-designed	 controlled	 trials.	 Academic	 institutions	 experience	 great	 difficulty	
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and	 experience	 fewer	 hurdles	 in	 that	 particular	 regulatory	 framework.	 We	 experienced	 that	
conducting	 these	 interviews,	 in	 itself,	 led	 to	 an	 increase	 in	 awareness	 concerning	 the	 ATMP	
regulation.	Comparing	the	results	of	the	interviews	held	in	2014	and	the	questionnaires	completed	a	
year	 later,	when	only	4%	of	 the	PIs	preferred	 to	use	 the	Tissues	and	Cells	Directive,	 it	 seems	 that	
more	PIs	realized	that	implementation	of	ATMPs	in	regular	clinical	care	is	only	possible	by	HE	or	MA.	
We	indeed	confirmed	that	many	PIs	changed	from	this	perspective	of	the	Tissues	and	Cells	Directive	
toward	HE	and/or	MA	as	 the	means	 to	 reach	regular	clinical	care.	However,	 response	bias	cannot	
fully	 be	 excluded	 for	 the	 questionnaire-completed	 PIs	 because	 not	 all	 PIs	 who	 mentioned	 the	
Tissues	 and	 Cells	 Directive	 did	 complete	 this	 questionnaire.	 The	 research	 groups	 were	 better	
informed	about	ways	to	reach	patients	in	clinical	care	with	their	ATMP	due	to	the	interviews	as	well	
as	 increasing	 awareness	 (e.g.,	 achieved	 by	 attending	 congresses).	 To	 improve	 knowledge	 of	 the	
development	 routes,	 we	 propose	 that	 research	 groups	 (and	 PIs)	 who	 are	 involved	 in	 the	
development	 of	medicinal	 products	 should	 be	 encouraged	 to	 extend	 their	 knowledge	 on	 product	
development	 and	 issues	 such	 as	 MA	 and	 IP	 regulations.	 Furthermore,	 a	 (national)	 ATMP	
development	knowledge	platform	could	be	established.	Remarkably,	16%	of	the	PIs	did	not	have	a	
future	 plan	 for	 their	 product	 to	 be	 implemented	 into	 regular	 clinical	 care.	 It	may	 be	 valuable	 to	
stimulate	 product	 and	 implementation-oriented	 thinking,	 including	 realistic	 future	 development	
	
specific	 for	 development	 in	 academic	 institutions.	 The	 main	 hurdles	 identified	 in	 this	 study,	
inadequate	 financial	 support	 and	 lacking	 regulatory	 knowledge,	 are	 more	 specific	 to	 academic	
development	than	to	ATMPs[21].	
In	 conclusion,	 for	 both	 academic	 PIs	 and	 other	 stakeholders,	 this	 article	 offers	 advice	 on	 several	
ways	 to	 improve	ATMP	development	 to	 facilitate	reaching	regular	clinical	care	 for	 (Dutch)	ATMPs.	
(1)	 Academic	 research	 groups	 should	 be	 encouraged	 to	 write	 a	 TPP	 for	 promising	 ATMPs	 and	
subsequently	(2)	design	proper	clinical	trials	for	further	development.	Improvement	of	(regulatory)	
knowledge	in	drug	development	may	be	organized	by	governmental	and/or	academic	institutions	by	
providing	 education	 and	 training	 (3).	 All	 these	 measures	 should	 result	 in	 more	 awareness	 and	
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plans,	 for	 academic	 institutions.	Writing	 a	 product	 dossier	 (e.g.	 based	 on	 a	 target	 product	 profile	
(TPP))	would	help	research	groups	make	future	plans	for	their	ATMPs	early	in	development.	This	TPP	
can	 also	 be	 directive	 in	 making	 important	 product	 decisions	 such	 as	 when	 to	 (dis)continue	
investments	 in	 one	 specific	 ATMP	 at	 a	 certain	 stage,	 creating	 awareness	 and	 a	 proper	 risk	
assessment	on	 the	chance	 that	 the	product	would	be	 surpassed	by	other	new	 therapies	before	 it	
could	be	 introduced	 into	practice.	A	TPP	would	also	be	helpful	 to	start	 fruitful	collaborations	with	
partners	 to	 move	 the	 ATMP	 further	 in	 the	 development	 trajectory.	 Furthermore,	 when	 several	
partners	 are	 involved,	 this	 TPP	 could	 be	 used	 to	 address	 the	 partners’	 responsibilities	 in	 the	
development	process	or	to	clarify	specific	parts	of	the	product.	Academic	institutions	may	consider	
expanding	 the	 scientific	 reward	 system	 of	 publication	 rates	 with	 milestones	 in	 the	 development	
route	[20].	Finally,	proper	clinical	trial	design	is	essential	for	reaching	the	end	goals	as	defined	in	the	
TPP.	 These	 end	 goals	 should	 help	 start	 discussions	 on	 reimbursement	 with	 the	 appropriate	
authorities	 in	 early	 development.	 It	 is	 important	 to	 realize	 that	 the	 assessments	may	 differ	 from	
stakeholder	to	stakeholder,	and,	 in	addition,	 it	 is	 important	to	realize	that	positive	assessment	not	
necessarily	means	that	the	product	or	clinical	trial	will	be	serving	the	end	goal	as	defined	in	the	TPP.		
In	the	Netherlands,	the	HE	clause	is	 increasingly	being	used.	Currently,	academic	 institutions	often	
pay	 for	 treatment	 with	 HE-approved	 ATMPs,	 which	 limits	 the	 number	 of	 patients	 who	 can	
potentially	benefit	from	the	treatment.	The	opportunity	to	receive	reimbursement	from	the	health	
insurers	 is	 limited	 because	 the	 Dutch	 HTA	 board	 evaluates	 safety	 and	 comparative	 effectiveness	
based	 on	 well-designed	 controlled	 trials.	 Academic	 institutions	 experience	 great	 difficulty	
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explain	 the	 low	success	 rate	of	 implementation	of	ATMPs	 in	 regular	clinical	 care.	 Lacking	 financial	
support	is	being	perceived	as	the	major	hurdle	for	clinical	trials	and	the	MA	trajectory,	which	is	also	
seen	 in	 the	United	States	 [18].	Reimbursement	 for	ATMPs	 is	 lacking,	especially	 after	HE	approval.	
Furthermore,	 knowledge	 about	 regulation	 and	documentation	with	 regard	 to	ATMP	development	
and	MA	 applications	 is	 limited	 in	 academic	 institutions.	 The	 field’s	 dynamics	 produce	 anxiety	 to	
create	 increasingly	 innovative	products,	 and	PIs	perceive	 that	 it	 is	 impossible	 to	modify	a	product	
after	 the	 decision	 has	 been	made	 to	 proceed	 toward	 further	 development.	 The	 design	 of	 pivotal	
clinical	 trials	 is	 often	 difficult,	 as	 is	 patient	 enrollment	 and	 obtaining	 suitable	 starting	 and/or	 raw	
materials.	
Of	the	interviewed	PIs,	26%	thought	that	ATMPs	should	become	available	according	to	the	Tissues	
and	 Cells	 Directive,	 2004/23/EC[19].	We	 conclude	 that	 PIs	 are	 not	 fully	 aware	 of	 the	 regulations	
toward	 implementation	 into	 regular	 clinical	 care.	 The	 fact	 that	 the	 Tissues	 and	 Cells	 Directive	 is	
mentioned	might	be	because	some	of	these	responders	are	familiar	with	stem	cell	transplantation	
and	 experience	 fewer	 hurdles	 in	 that	 particular	 regulatory	 framework.	 We	 experienced	 that	
conducting	 these	 interviews,	 in	 itself,	 led	 to	 an	 increase	 in	 awareness	 concerning	 the	 ATMP	
regulation.	Comparing	the	results	of	the	interviews	held	in	2014	and	the	questionnaires	completed	a	
year	 later,	when	only	4%	of	 the	PIs	preferred	 to	use	 the	Tissues	and	Cells	Directive,	 it	 seems	 that	
more	PIs	realized	that	implementation	of	ATMPs	in	regular	clinical	care	is	only	possible	by	HE	or	MA.	
We	indeed	confirmed	that	many	PIs	changed	from	this	perspective	of	the	Tissues	and	Cells	Directive	
toward	HE	and/or	MA	as	 the	means	 to	 reach	regular	clinical	care.	However,	 response	bias	cannot	
fully	 be	 excluded	 for	 the	 questionnaire-completed	 PIs	 because	 not	 all	 PIs	 who	 mentioned	 the	
Tissues	 and	 Cells	 Directive	 did	 complete	 this	 questionnaire.	 The	 research	 groups	 were	 better	
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as	 increasing	 awareness	 (e.g.,	 achieved	 by	 attending	 congresses).	 To	 improve	 knowledge	 of	 the	
development	 routes,	 we	 propose	 that	 research	 groups	 (and	 PIs)	 who	 are	 involved	 in	 the	
development	 of	medicinal	 products	 should	 be	 encouraged	 to	 extend	 their	 knowledge	 on	 product	
development	 and	 issues	 such	 as	 MA	 and	 IP	 regulations.	 Furthermore,	 a	 (national)	 ATMP	
development	knowledge	platform	could	be	established.	Remarkably,	16%	of	the	PIs	did	not	have	a	
future	 plan	 for	 their	 product	 to	 be	 implemented	 into	 regular	 clinical	 care.	 It	may	 be	 valuable	 to	
stimulate	 product	 and	 implementation-oriented	 thinking,	 including	 realistic	 future	 development	
	
specific	 for	 development	 in	 academic	 institutions.	 The	 main	 hurdles	 identified	 in	 this	 study,	
inadequate	 financial	 support	 and	 lacking	 regulatory	 knowledge,	 are	 more	 specific	 to	 academic	
development	than	to	ATMPs[21].	
In	 conclusion,	 for	 both	 academic	 PIs	 and	 other	 stakeholders,	 this	 article	 offers	 advice	 on	 several	
ways	 to	 improve	ATMP	development	 to	 facilitate	reaching	regular	clinical	care	 for	 (Dutch)	ATMPs.	
(1)	 Academic	 research	 groups	 should	 be	 encouraged	 to	 write	 a	 TPP	 for	 promising	 ATMPs	 and	
subsequently	(2)	design	proper	clinical	trials	for	further	development.	Improvement	of	(regulatory)	
knowledge	in	drug	development	may	be	organized	by	governmental	and/or	academic	institutions	by	
providing	 education	 and	 training	 (3).	 All	 these	 measures	 should	 result	 in	 more	 awareness	 and	
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Abstract	
In	 the	 last	 decade,	 many	 clinical	 trials	 with	 gene	 and	 cell-based	 therapies	 were	 performed	 and	
increasing	 interest	 in	 the	 development	 was	 established	 by	 (national)	 authorities,	 academic	
developers,	 and	 commercial	 companies.	 However,	 until	 now	 only	 eight	 products	 have	 received	
marketing	 authorization	 (MA)	 approval.	 In	 this	 study,	 a	 comprehensive	 overview	 of	 the	 clinical	
development	 of	 gene	 and	 cell-based	 therapies	 in	 Europe	 is	 presented,	 with	 a	 strong	 focus	 on	
product-technical	 aspects.	 Public	 data	 regarding	 clinical	 trials	 with	 gene	 and	 cell-based	 therapies,	
obtained	 from	 the	 European	Union	 (EU)	 clinical	 trial	 database	 (EudraCT)	 between	 2004	 and	 2014	
were	 analysed,	 including	 product-technical	 variables	 as	 potential	 determinants	 affecting	
development.	198	unique	gene	and	cell	therapy	products	were	identified,	which	were	studied	in	278	
clinical	 trials,	mostly	 in	phase	1/2	trials	and	with	cell	 therapies	as	major	group.	Furthermore,	most	
products	 were	 manufactured	 from	 autologous	 starting	 material	 mostly	 manufactured	 from	 stem	
cells.	The	majority	of	the	trials	were	sponsored	by	academia,	whereas	phase	3	trials	mostly	by	large	
companies.	 Academia	 dominated	 early-stage	 development	 by	mainly	 using	 bone	marrow	 derived	
products	and	stem	cells.	Conversely,	commercial	sponsors	were	more	actively	pursuing	in	vivo	gene	









evolving	 technology,	 development	 of	 regenerative	 and	 immunotherapeutic	 drugs	 is	 being	
pursued[1].	 In	 the	 European	 Union	 (EU),	 gene	 and	 cell-based	 therapies	 are	 defined	 as	 advanced	
therapy	medicinal	products[2].	The	majority	of	these	therapies	find	their	origin	in	academic	research	
settings[3],	 and	 small	 companies	 have	 increasingly	 been	 involved.	 Recently,	major	 pharmaceutical	
companies	have	invested	in	gene	and	cell-based	therapy	development	as	well	in	both	the	EU	and	in	
the	United	States[4,5].	
Current	 interest	 in	 the	 (pre)clinical	 development	 of	 these	 promising	 products	 is	 illustrated	 by	 a	
substantial	amount	of	12,000	publications	in	regenerative	medicine	and	tissue	engineered	products	
in	PubMed	between	2012	and	2015	and	15,618	on	advanced	therapy	medicinal	products	in	the	last	5	
years	 (PubMed	 search:	 “advanced	 therapy	 medicinal	 products	 OR	 advanced	 therapy	 medicinal	
products	 OR	 gene	 therapy	 product	 OR	 cell	 therapy	 medicinal	 products	 OR	 Tissue	 engineered	
products”	 search	 performed	 on	 14	 August	 2016)[6].	 However,	 despite	 this	 impressive	 scientific	
output,	 only	 few	of	 the	 products	 have	 received	marketing	 authorization	 approval,	with	 the	 result	
that	 there	 is	 only	 limited	 benefit	 for	 patients[6–8].	 Inherent	 product-technical	 aspects	 may	 have	
hampered	clinical	development,	such	as	the	availability	of	human	starting	material,	or	small-scale	or	
even	fully	personalized	manufacturing	strategies[9].	The	fact	that	this	is	a	relatively	new	field,	which	
used	 to	 rely	 on	 the	 academic	 institutions,	 also	might	 have	 impacted	 this	 outcome.	 To	 be	 able	 to	




European	 gene	 and	 cell	 therapy	 clinical	 trials	 based	on	 the	 European	pharmacovigilance	database	
EudraCT	in	the	period	of	2004	until	2010[10].	More	recently,	a	global	overview	of	cell	therapy	clinical	
trials	was	generated	by	Bersenev[11].	However,	this	latter	overview	was	not	peer-reviewed,	and	was	
incomplete	 due	 to	 exclusion	 of	 gene	 and	 tissue	 engineered	 therapies[11].	 Despite	 providing	 an	
overview	of	the	field,	both	analytical	studies	provided	limited	information	on	the	product-technical	
aspects,	which	 are	of	 vital	 importance	 to	 identify	 gene	and	 cell	 therapy-specific	 hurdles	 in	 clinical	
development.	 To	 be	 able	 to	 identify	 the	 reasons	 for	 failure	 of	 products	 to	 achieve	 marketing	
authorization	 in	 the	 future,	 it	 is	 important	 to	 first	 have	 a	 comprehensive	 overview	 of	 the	 clinical	
development	of	the	gene	and	cell-based	therapy	products.	This	overview	is	also	focused	on	product-
technical	 features,	 such	as	product	subtype	and	starting	material	 sources.	 In	 this	study,	we	aim	to	
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{A.1-Member	 State	 submission}	 {A.2-EudraCT	 number}	 {A.3-Full	 title	 trial}	 {A.3.2.-Name	 of	
abbreviated	 title}	 {A.7-Is	 the	 trial	 part	 of	 a	 PIP?}	 {A.8-EMEA	 decision	 number	 PIP}B.3.1/2-Status	
Sponsor}	 {B.5-Functional	 name	 contact	 point	 sponsor}	 {B.5.3.1	 t/m	 B.5.3.6-Address	 contact	 point	
sponsor}	{D.1.1-IMP	number}	{D.1.2-IMP	being	tested}	{D.1.3-IMP	used	as	a	comparator}	{D.2.1-Has	
this	 IMP	 to	 be	 used	 in	 the	 trial	 a	 marketing	 authorisation?}	 {D.2.5-Orphan	 drug	 designation?}	
{D.2.5.1-Orphan	 drug	 designation	 number}	 {D.3.1-Product	 name}	 {D.3.2-Product	 code}	 {D.3.4-
Pharmaceutical	 form}	 {D.3.7-Route	 of	 administration}	 {D.3.8-(proposed)	 INN}	 {D.3.11.2-Active	
substance	 of	 biological/biotechnological	 origin	 (other	 than	 ATIMP)?}	 {D.3.11.3-TIMP?}	 {D.3.11.3.1-
sCTMP?}	{GTMP?}	{D.3.11.3.3-TEP?}	{D.3.11.3.4-Combination	ATIMP}	{D.3.11.3.5-CAT	classification?}	
{3.11.3.5.1-ATIMP	classification	number}	 {D.3.12-Mode	of	action}	 {E.1.1-Medical	 condition(s)	 to	be	
investigated}	 {E.1.1.2-Therapeutic	 area}	 {E.1.2-MedRA	 version,	 level,	 term,	 number}	 {E.1.3-Rare	
disease?}	 {E.2.1-Main	 objective}	 {E.2.2-Secondary	 objective}	 {E.5.1-Primary	 endpoint}	 {E.5.2-
Secondary	 endpoint}	 {E.6.3-Therapy}	 {E.6.4-Safety}	 {E.6.5-Efficacy}	 {E.6.9-Dose	 Response}	 {E.7.1-
Phase	1}	{7.1.1-First	administration	to	humans}	{E.7.1.3-Other}	{E.7.2-Phase	2}	{E.7.3-Phase	3}	{E.7.4-
Phase	 4}	 {E.8.1-Controlled	 trial}	 {E.8.1.1-Randomised	 trial}	 {E.8.1.2-Open	 trial}	 {E.8.1.3-Single	 blind	
trial}	 {E.8.1.4-Double	blind	 trial}	 {E.8.1.5-Parallel	group}	 {E.8.1.6-Cross-over}	 {E.8.2.1-Control	group:	
Other	 medicinal	 product}	 {E.8.2.2-Control	 group:	 placebo}	 {E.8.2.3-Control	 group:	 other}	 {E.8.3-
Single	site	in	member	State}	{E.8.4-Multiple	sites	in	Member	State}	{E.8.4.1-Numbers	of	sites}	{E.8.5-











the	 classification	 by	 consensus.	 In	 case	 a	 product	 received	 a	 scientific	 recommendation	 on	
classification	 of	 the	 product	 by	 the	 EMA	 CAT[20],	 this	 classification	 was	 used.	 The	 gene	 therapy	
products	 were	 divided	 into	 two	 subtypes:	 in	 vivo	 gene	 therapy	 products,	 meaning	 that	 genetic	
material	 is	 administered	 directly	 into	 the	 patient,	 and	 ex	 vivo	 gene	 therapy	 products,	 when	
autologous	or	allogeneic	cells	are	genetically	modified	ex	vivo	and	(re)administered	into	the	patient.	




records	 for	 analysis.	 Coupling	 of	 the	 multicentre	 (multinational)	 performed	 trial	 data	 records	
towards	 one	 trial	 data	 record,	 corresponding	with	 the	 same	 product	 record,	was	 done	 based	 on:	
product	 name,	 product	 subtype,	 and	 sponsor	 name	 and	 resulted	 in	 278	 trial	 data	 records,	
corresponding	with	198	unique	product	records	(Figure	1a).	
To	 ensure	 reliability,	 security,	 (error)	 sensitivity	 with	 the	 trial	 data	 records	 and	 the	 product	 data	
records,	 a	web-based	database,	Project	Manager	 Internet	Server	 (ProMISe)	was	used[21].	All	data	
and	 product	 records	 were	 exported	 from	 the	 Microsoft	 Excel	 file	 towards	 ProMISe	 in	 a	 specific	








Product-technical	 specifications:	product	 subtypes	and	 starting	material	 sources	were	classified	by	
three	authors	 independently	 (Table	1).	 In	case	of	any	disagreement,	 the	product	was	discussed	by	
the	three	authors	to	reach	consensus	about	the	product-technical	specifications.	
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the	 classification	 by	 consensus.	 In	 case	 a	 product	 received	 a	 scientific	 recommendation	 on	
classification	 of	 the	 product	 by	 the	 EMA	 CAT[20],	 this	 classification	 was	 used.	 The	 gene	 therapy	
products	 were	 divided	 into	 two	 subtypes:	 in	 vivo	 gene	 therapy	 products,	 meaning	 that	 genetic	
material	 is	 administered	 directly	 into	 the	 patient,	 and	 ex	 vivo	 gene	 therapy	 products,	 when	
autologous	or	allogeneic	cells	are	genetically	modified	ex	vivo	and	(re)administered	into	the	patient.	




records	 for	 analysis.	 Coupling	 of	 the	 multicentre	 (multinational)	 performed	 trial	 data	 records	
towards	 one	 trial	 data	 record,	 corresponding	with	 the	 same	 product	 record,	was	 done	 based	 on:	
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To	 ensure	 reliability,	 security,	 (error)	 sensitivity	 with	 the	 trial	 data	 records	 and	 the	 product	 data	
records,	 a	web-based	database,	Project	Manager	 Internet	Server	 (ProMISe)	was	used[21].	All	data	
and	 product	 records	 were	 exported	 from	 the	 Microsoft	 Excel	 file	 towards	 ProMISe	 in	 a	 specific	
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three	authors	 independently	 (Table	1).	 In	case	of	any	disagreement,	 the	product	was	discussed	by	
the	three	authors	to	reach	consensus	about	the	product-technical	specifications.	










The	 data	 in	 ProMISe	 was	 analysed	 in	 both	 ProMISe	 and	 Microsoft	 Access	 2010.	 By	 generating	
frequency	 tables	of	different	variables,	 cross	 tables,	overviews	of	 the	gene	and	cell-based	 therapy	
development	 in	 Europe	were	 created.	 The	 following	 variables	were	analysed:	 gene	and	 cell-based	




















From	 public	 domain	 of	 the	 EudraCT	 database	 (since	 phase	 1	 clinical	 trials	 are	 not	 in	 the	 public	
domain	of	EudraCT	and	processing	of	trials	in	EudraCT	can	be	delayed,	clinical	trials	may	be	missing),	
278	 gene	 and	 cell-based	 therapy	 clinical	 trials	 were	 identified	 over	 the	 period	 2004	 until	 2014,	




trial	 phase.	 The	 dominant	 indication	 areas	were	 cancer	 (31%),	 cardiovascular	 diseases	 (17%),	 and	
skin	and	connective	tissue	diseases	(11%)	(Figure	2a;	total	n	=	278).	
The	 total	 number	 of	 clinical	 trials	 increased	 to	maximum	numbers	 between	 2007	 and	 2009,	 after	
which	the	numbers	in	the	database	showed	a	decrease	towards	2014	(Figure	2b).	Half	of	the	clinical	
trials	were	phase	2,	while	23	and	19%	were	phase	1/2	or	phase	3	trials,	respectively	(Figure	2c;	total	
n=278).	 Since	 data	 about	 phase	 1	 clinical	 trials	 are	 not	 available	 in	 the	 public	 domain	 of	 the	




n	 =	 499).	 Most	 trials	 were	 performed	 in	 Spain	 (18%),	 investigating	 predominantly	 cell	 therapy	
products	(71%),	and	in	the	United	Kingdom	(17%),	where	half	of	the	trials	were	executed	with	gene	
therapy	products	(Supplementary	Figure	S1).	The	other	three	countries	in	which	there	is	a	clear	high	
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of	 the	 indication	 areas	 for	 the	 gene-	 and	 cell-based	 therapy,	 showing	 absolute	 numbers	 derived	 from	 the	
public	 domain	 of	 the	 EudraCT	 database*;	 (b)	 Absolute	 numbers	 of	 clinical	 trials	with	 the	 of	 gene-	 and	 cell-
based	therapy	product	types	per	year;	(c)	Numbers	(represented	in	percentages,	n	=	278)	of	different	clinical	
trials	study	phases	performed	with	gene-	and	cell-based	therapy	products.	*	Since	phase	1	clinical	trials	are	not	




Sponsor	 types	 identified	 were	 academia,	 small	 and	 medium-sized	 enterprise	 (SMEs)	 and	 large	
pharmaceutical	companies.	More	than	half	of	the	trials	was	sponsored	by	academic	institutes	(56%),	
while	36%	of	the	trials	was	sponsored	by	SMEs	and	only	8%	by	large	companies	(Figure	4a;	total	n	=	
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and	sponsor d	more	th n	half	of	the	phase	3	trials	(54%;	n	=	13).	Further ore,	ano her	interesting	
finding	is	that	single	centre	and	national	trials	were	predominantly	sponsored	by	academic	institutes	
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(68%),	 while	 ne ly	 all	 multinati nal	 trials were	 spon ored	 by	 SMEs	 or	 large	 companies	 94 ).	








Next,	 we	 systematically	 analysed	 the	 product-technical	 characteristics	 of	 gene	 and	 cell-based	
therapy	products	in	clinical	development	within	the	EU	in	more	detail.	
The	major	product	subtypes	were	 in	vivo	gene	therapy	products	 (22%;	n	=	44),	 stem	cell	products	
(19%;	n	=	38)	and	mesenchymal	stromal	cells	(16%;	n	=	32).	Whereas	most	of	the	stem	cell	products	
were	 developed	 for	 treating	 cardiovascular	 diseases	 (51%;	 n	 =	 29)	 and	 differentiated	 tissue	 cell	
products	 for	skin	and	connective	 tissue	diseases	 (45%;	n	=	20)	 (Supplementary	Figure	S5),	most	of	
the	dendritic	cell	products	(89%;	n	=	32),	lymphocyte-based	products	(82%;	n	=	9),	and	gene	therapy	
products	 (52%;	 n	 =	 43)	 were	 designed	 for	 cancer	 treatment.	 Academic	 sponsors	 (total	 n	 =	 116)	
mainly	 performed	 clinical	 trials	with	 stem	 cells,	 dendritic	 cells,	 and	mesenchymal	 stromal	 cells	 as	
largest	subtypes	(24,	20,	and	20%,	respectively),	while	both	SMEs	(total	n	=	61)	and	large	companies	
(total	n	=	20)	performed	clinical	trials	with	in	vivo	gene	therapy	products	as	the	largest	group	(31	and	
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Figure	 3.	 Country-specific	 variations	 in	 gene-	 and	 cell-based	 therapy	 development.	 (a)	 Percentage	 of	 clinical	
trials	with	gene-	and	cell-based	therapies	per	country	derived	from	the	public	domain	of	the	EudraCT	database*	
depicted	 in	color	and	absolute	numbers	of	clinical	trials	performed	per	country	(written	 in	country).	 (b)	Ratio	of	
the	 number	 of	 clinical	 trials	with	 gene-	 and	 cell-based	 therapy	 products	 performed	 in	 a	 country	 per	 the	 total	
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Figure	 3.	 Country-specific	 variations	 in	 gene-	 and	 cell-based	 therapy	 development.	 (a)	 Percentage	 of	 clinical	
trials	with	gene-	and	cell-based	therapies	per	country	derived	from	the	public	domain	of	the	EudraCT	database*	
depicted	 in	color	and	absolute	numbers	of	clinical	trials	performed	per	country	(written	 in	country).	 (b)	Ratio	of	
the	 number	 of	 clinical	 trials	with	 gene-	 and	 cell-based	 therapy	 products	 performed	 in	 a	 country	 per	 the	 total	






























0,2 – 0,4% 
0,5 - 0,7% 
0,8 - 1,0% 
1,1 - 1,3% 

























68  | Part I - Chapter 4
	
	
autologous	 starting	 material	 (73%;	 n	 =	 117),	 of	 which	 most	 often	 stem	 cell	 products	 were	
manufactured	(31%;	n	=49)	(Figure	4d	and	(Supplementary	Figures	S7	and	S8).	Although	in	general	
differentiated	 tissue	 was	 most	 frequently	 used	 as	 source	 for	 starting	 material	 (31%;	 n	 =	 68),	
autologous	products	were	mostly	generated	using	bone	marrow	derived	starting	materials	(33%;	n	=	
52)	 (Supplementary	 Figure	 S9).	 Academic	 sponsors	 and	 SMEs	 mainly	 used	 autologous	 starting	
material	for	the	manufacturing	of	their	products	(78%;	n	=	80	and	69%;	n	=	31	respectively),	which	
were	most	 frequently	derived	 from	bone	marrow	 in	case	of	academic	 sponsored	studies	 (29%;	n=	




n=	45),	whereas	 the	majority	of	 the	cardiovascular	disease	therapy	products	were	generated	 from	
autologous	bone	marrow	(63%;	n	=	30)(Supplementary	Figure	S12).	
Most	 of	 the	 allogeneic	 products	 were	 manufactured	 toward	 differentiated	 tissue	 cells	 and	
mesenchymal	stromal	cells	 (31%;	n	=	19	each).	Half	of	the	products	generated	by	 large	companies	
were	 allogeneic	 products	 and	 were	 mostly	 derived	 from	 differentiated	 tissues	 (23%;	 n	 =	 5).	
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major	 group,	might	 be	 explained	by	 the	 fact	 that	 the	 EU	directive	 2001/83/EC,	which	 defines	 the	
gene	and	cell-based	therapy	products,	was	renewed	in	2007	adopting	tissue-engineered	products.12	
The	other	peak	in	2009	might	be	due	to	the	specific	regulation	for	gene	and	cell-based	therapies	(EC)	
a. Sponsor type (n=206)
b. Type gene and cell based therapy per sponsor
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no	 1394/2007	 that	 came	 into	 force	on	30	December	 2008.	Most	 therapies	were	designed	 for	 the	
treatment	 of	 cancer	 and	 cardiovascular	 diseases,	 which	 can	 be	 explained	 by	 the	 fact	 that	 these	




performed.	 Interestingly,	 gene	 and	 cell-based	 therapy	 development	 has	 been	 stimulated	 in	 these	
countries	 by	 specific	 initiatives	 for	 facilitating	 financial	 resources,	 knowledge	 and	 (design	 of)	
centralized	good	manufacturing	practice	 facilities[14,15].	As	such,	 infrastructure	appears	 to	have	a	
relevant	 impact	on	further	development	of	these	promising	therapies,	regional	and	national	public	
stakeholders	are	encouraged	to	consider	similar	approaches.	
The	majority	of	 the	products	were	sponsored	by	academia,	whereas	61%	of	 the	clinical	 trials	with	
conventional	medicinal	products	originated	from	commercial	companies	in	the	European	Economic	
Area	 (EEA)[16].	From	earlier	 research,	 the	 (regulatory)	 route	 toward	marketing	authorization	 (MA)	
was	 found	 to	 comprise	many	hurdles	 for	 academic	 research	 groups	 [9].	 Indeed,	 all	 gene	 and	 cell-	
based	 therapies	 that	 received	MA	approval	were	 sponsored	 (in	 later	 stages	of	 development)	by	 a	
commercial	 party.	 In	 our	 database,	 it	 is	 shown	 that	 nearly	 all	 phase	 3	 trials	 were	 performed	 by	
commercial	 sponsors,	 supposing	 that	 they	 have	 appropriate	 financial	 resources	 and	 (regulatory)	
knowledge.	
	
The	slight	 increase	(40%	to	44%)	 in	commercially	sponsored	trials	 from	2010	to	2014,	 including	an	
increase	from	2	to	8%	of	the	large	companies	involved,	suggest	increasing	interest	in	gene	and	cell-





However,	 all	 cell-based	 therapies	 (n=4)	 with	 MA	 approval	 in	 Europe	 were	 generated	 from	
autologous	 starting	 material	 (Chondrocelect®,	 Holoclar®,	 MACI®	 (currently	 suspended),	 and	
Provenge®	 (retracted	 in	 2015))	 and	 had	 a	 commercial	 sponsor,	 indicating	 that	 personalized	







an	 increasing	 involvement	of	 the	commercial	 sector	 in	 this	 young	 field	of	medicinal	products[4,5].	
We	expect	 that	 this	 trend	of	more	 involvement	 from	 commercial	 parties	will	 continue	 to	date.	 In	
particular,	academic-commercial	partnerships	may	be	very	efficient	to	drive	the	best	gene	and	cell-
based	 products	 from	 early	 academic	 research	 toward	 proper	 late-stage	 clinical	 development.	 The	
number	of	Committee	for	Advanced	Therapies	(CAT)	classifications	and	scientific	advice	applications	
for	gene	and	cell-based	therapy	products	has	 increased	over	the	 last	years.	A	proactive	attitude	of	
regulators,	 as	 recommended	 by	Maciulaitis	 et	 al.,	may	 have	 contributed	 to	 this	 increase[10].	 The	
involvement	 of	 and	 regulatory	 advice	 from	 the	 central	 expertise	 of	 the	 EMA	 CAT	 is	 expected	 to	
support	 increasing	 numbers	 of	 MAs	 over	 the	 next	 years[8,17,18].	 Since	 gene	 and	 cell-based	
therapies	are	developed	globally,	the	question	 is	whether	their	development	results	more	often	 in	
MA	 approval	 in	 other	 jurisdictions.	 In	 the	 United	 States,	 Canada,	 and	 Japan,	 whose	 systems	 for	
protection	of	the	public	health	are	corresponding	to	the	European	system[19],	six,	one	and	two	gene	
and	cell-based	therapies,	respectively	received	MA	approval.	This	supports	the	idea,	that	this	lack	in	
further	 development	 of	 these	 therapies	 is	 global.	 In	 contrary,	 South	 Korea	 has	 18	 gene	 and	 cell-




explained	 by	 the	 fact	 that	 these	 stem	 cell	 products	 have	 similarity	with	 hematopoietic	 stem	 cells	





trials	were	 not	 included,	 resulting	 in	 an	 underestimation	 of	 the	 total	 number	 of	 clinical	 trials	 and	
products.	Moreover,	some	clinical	trials	may	not	have	been	included	in	the	public	database	due	to	
delayed	processing	of	clinical	trials	into	EudraCT.	
In	 order	 to	 stimulate	 clinical	 development	 of	 autologous	 products	 toward	 MA,	 academic,	 and	
commercial	 parties	may	 collaborate	 efficiently	 in	 public-private	 partnerships.	 Furthermore,	 public	
stakeholders	 should	 consider	 stimulating	 efficient	 development	 of	 gene	 and	 cell-based	 therapies	
toward	patient	benefit,	e.g.,	via	regional	or	national	initiatives.	
Based	 on	 these	 results,	 future	 studies	 are	 necessary	 to	 further	 identify	 factors	 associated	 with	
success	 and	 failure	 of	 gene	 and	 cell-based	 therapy	 development.	 These	 insights	 may	 help	
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Figure	S6.	Gene	and	cell	based	therapy	subtype	per	sponsor.		 	 	 	 														
CTMP	=	cell	 therapy	medicinal	product;	GTMP	=	gene	therapy	medicinal	product;	SME	=	small	and	medium-
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In	 the	 past	 decade,	 many	 clinical	 trials	 with	 gene-	 and	 cell-based	 therapies	 (GCTs)	 have	 been	
performed.	 Increased	 interest	 in	 the	development	of	 these	drug	products	by	 various	 stakeholders	
has	 become	 apparent.	 Despite	 this	 growth	 in	 clinical	 studies,	 the	 number	 of	 therapies	 receiving	
marketing	 authorization	 approval	 (MAA)	 is	 lagging	 behind.	 To	 enhance	 the	 success	 rate	 of	 GCT	
development,	 it	 is	 essential	 to	 better	 understand	 the	 clinical	 development	 of	 these	 products.	
Chimeric	antigen	receptor	(CAR)	T	cells	are	a	GCT	product	subtype	with	promising	efficacy	in	cancer	
treatment	which	are	tested	in	many	clinical	trials,	but	have	not	yet	received	MAA.		
We	 generated	 an	 overview	of	 the	 characteristics	 of	 CAR	 T-cell	 clinical	 development	 in	 the	United	




which	 49	 were	 linked	 to	 a	 subsequent	 trial	 and	 57	 were	 not.	 The	 majority	 of	 the	 trials	 had	 an	





encourage	 sponsors	 to	 plan	 clinical	 development	 ahead	 for	 a	 higher	 efficiency	 of	 product	





Over	 the	 past	 decade,	 many	 clinical	 trials	 with	 gene-	 and	 cell-based	 therapies	 (GCTs)	 have	 been	
performed.	 Historically,	 clinical	 trials	 with	 GCTs	 have	 primarily	 been	 performed	 by	 academic	
institutes,	 although	 involvement	 of	 commercial	 companies	 in	 clinical	 development	 of	 these	
medicinal	 products	 has	 rapidly	 increased[1,2].	 In	 addition,	 development	 of	 these	 innovative	 and	
promising	 therapies	 is	 also	 receiving	 increasing	 interest	 of	 other	 stakeholders,	 such	 as	 regulatory	
authorities	 and	 funding	 organizations[3].	 However,	 the	 number	 of	 therapies	 that	 have	 reached	
marketing	authorization	approval	 (MAA)	 is	 lagging	behind[4,5].	 Indeed,	 in	Canada,	Europe	and	the	
United	States,	only	1,	8	and	6	GCTs,	respectively,	have	been	approved.	To	gain	more	insight	into	the	
low	number	of	MAAs,	 the	clinical	development	of	such	products	should	be	 investigated.	However,	
predicting	 a	 successful	 development	 of	medicinal	 products	 is	 challenging,	 even	when	 a	medicinal	
product	shows	promising	results	in	(pre)clinical	trials[6].	Furthermore,	the	complexity	of	GCTs	makes	
them	more	 challenging	 compared	with	 conventional	 products[6].	 Therefore,	 to	 better	 understand	
this	development	field,	the	characteristics	of	the	GCT	clinical	trials	should	be	analysed	and	compared	
to	 see	 whether	 further	 development	 of	 a	 product	 can	 be	 related	 to	 one	 or	 more	 clinical	 trial	
characteristics.		
Chimeric	antigen	receptor	(CAR)	T	cells	are	a	GCT	product	subtype	with	promising	efficacy	in	cancer	
treatment	 that	 have	 been	 tested	 in	many	 clinical	 trials	 globally[6–8].	 CARs	 generally	 contain	 two	
domains,	an	antigen-recognition	and	a	signalling	domain,	 inserted	by	gene	transfer,	through	which	
the	 T	 cells	 can	 specifically	 recognize	 and	 attack	 unwanted	 target	 cells.	 These	 CAR	 T	 cells	 are	
developed	for	the	treatment	of	malignancies,	with	B-cell	acute	lymphoblastic	leukaemia	one	of	the	
main	 indications[9].	 Despite	 the	 demonstrated	 efficacy,	 it	 has	 not	 resulted	 in	 MAA[10].	 Various	
hurdles	 are	 experienced	 in	 the	 clinical	 development	 with	 GCTs	 in	 general	 and	 with	 CAR	 T	 cells	
specifically[11,12].	Nevertheless,	multiple	CAR	T-cell	products	are	expected	to	receive	U.S.	Food	and	
Drug	 Administration	 and	 European	 Medicines	 Agency	 approval	 in	 coming	 years[13,14].	 CD19	
targeting	CAR	T	cells	are	 likely	to	be	the	first	engineered	T	cells	to	receive	marketing	authorization	
[15].	
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databases	 were	 selected	 in	 June	 2016	 from	 the	 public	 websites	 www.clinicaltrials.gov	 and	
www.clinicaltrialsregister.eu.	 For	 the	 European	 public	 websites,	 phase	 1	 clinical	 trials	 are	 not	











main	countries	because	of	 their	similar	 regulatory	 frameworks	concerning	GCTs	and	because	most	
Canadian,	U.S.	and	European	clinical	trials	are	submitted	to	these	databases	[4].	













been	 submitted	 for	marketing	 authorization,	 this	 definition	of	 success	 cannot	 be	used	 at	 present.	
Therefore,	 for	 each	 CAR	 T	 cell	 clinical	 trial,	 it	 was	 determined	 whether	 there	 was	 a	 subsequent	
clinical	 trial	 using	 the	 same	 product.	 This	 included	 clinical	 trials	 that	 were	 followed	 by	 another	





















used	 to	 create	 overviews	 of	 the	 overall	 clinical	 trial	 characteristics	 and	 subgroup	 (follow-up	 trials	
versus	non–	 follow-up	trials)	comparisons.	Subsequently,	 the	characteristics	of	 the	 trials	without	a	
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trials	 that	were	 analysed	 is	 shown	 in	 Table	 III.	 The	majority	 (91%)	 of	 the	 CAR	 T	 cells	 did	 have	 an	




was	safety	 (51%),	and	combined	end	points	were	defined	 in	31%	of	 the	trials,	 in	which	safety	was	





Sponsor	type	 	 	 	 	 	 	 							Academic				 96		 	 (91%)	
Commercial	 10		 	 (9%)	
Study	phase	 	 	 	 	 		 	 																Pilot	 7		 	 (7%)	
	 	 	 	 Phase	1	 72		 	 (68	%)	
Phase	2	 9		 	 (9%)	
Phase	1/2	 15		 	 (14%)	
Phase	2/3	 3	 	 (3%)	
Starting	Material		 	 				 													 																																																									Autologous	 96		 	 (89%)	
Allogeneic	 12		 	 (9%)	
Autologous	&	Allogeneic	 2	 	 (2%)	
Number	of	patients	recruited		 	 	 																																																						<17	 34		 	 (32,1%)	
17-33	 34		 	 (32,1%)	
>33	 37		 	 (34,9%)	
Trial	Design	-	Centres		 	 	 																																																							Single	centre	 76			 	 (72%)	
Multicentre	 30	 	 (28%)	
Trial	Design	–	Countries	 	 	 	 	 																	Single	country	 100	 	 (94%)	
Multinational	 6		 	 (6%)	
Patient	cohort		 	 	 	 																																																															Children	 4		 	 (4%)	
Adults	 67		 	 (63%)	
Adults/children	 35		 	 (33%)	
Primary	Endpoint	 	 	 	 	 	 	 											Efficacy	 7	 	 (7%)	
Safety	 54	 	 (51%)	
Serum	concentrationsa	 -	 -	
Doseb	 12	 	 (11%)	
Combined	 33	 	 (31%)	
Secondary	Endpoint	 	 	 	 	 	 								Efficacy	 28	 	 (26%)	
Safety	 11		 	 (1%)	
Serum	concentrationsa	 4		 	 (4%)	
Doseb	 1	 	 (1%)	












the	 case	 in	 a	 slightly	 lower	 percentage	 (45%)	 of	 the	 trials	 with	 a	 subsequent	 clinical	 trial	 (Figure	
2A).The	 clinical	 trials	 that	 were	 terminated	 were	 more	 frequently	 seen	 in	 the	 group	 without	 a	
subsequent	trial	(16%)	compared	with	the	trials	with	a	subsequent	trial	(6%).	From	the	subsequently	
followed-up	 trials,	 one	 trial	 was	 terminated	 and	 incorporated	 into	 another	 clinical	 trial,	 and	 two	
trials	 did	 not	 reach	 the	 recruitment	 deadline.	 However,	 these	 two	 are	 currently	 still	 open	 for	
recruitment.	 In	 contrast,	nine	clinical	 trials	without	a	 subsequent	 trial	 failed	 in	 recruitment	before	
the	indicated	deadline	or	were	stopped.	From	these	nine	trials,	four	were	still	open	for	recruitment,	
others	were	terminated	due	to	safety	issues	or	unknown	reasons.	As	shown	in	Figure	2B,	there	was	
no	 difference	 in	 the	 number	 of	 clinical	 trials	 with	 or	 without	 a	 subsequent	 clinical	 trial	 per	 trial	








trials	 with	 and	 without	 subsequent	 trials,	 which	 was	 used	 as	 a	 proxy	 for	 the	 successful	 clinical	
development	of	the	CAR	T-cell	products.	As	shown	in	Figure	3A,	most	studies	without	a	subsequent	
clinical	 trial	had	an	academic	 sponsor	 (97%),	whereas	 this	percentage	 is	 lower	 in	 the	 clinical	 trials	
with	a	follow-up	clinical	trial	(84%).		
Clinical	 trials	 without	 a	 subsequent	 clinical	 trial	 more	 frequently	 used	 allogeneic	 material	 (14%)	
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the	 case	 in	 a	 slightly	 lower	 percentage	 (45%)	 of	 the	 trials	 with	 a	 subsequent	 clinical	 trial	 (Figure	
2A).The	 clinical	 trials	 that	 were	 terminated	 were	 more	 frequently	 seen	 in	 the	 group	 without	 a	
subsequent	trial	(16%)	compared	with	the	trials	with	a	subsequent	trial	(6%).	From	the	subsequently	
followed-up	 trials,	 one	 trial	 was	 terminated	 and	 incorporated	 into	 another	 clinical	 trial,	 and	 two	
trials	 did	 not	 reach	 the	 recruitment	 deadline.	 However,	 these	 two	 are	 currently	 still	 open	 for	
recruitment.	 In	 contrast,	nine	clinical	 trials	without	a	 subsequent	 trial	 failed	 in	 recruitment	before	
the	indicated	deadline	or	were	stopped.	From	these	nine	trials,	four	were	still	open	for	recruitment,	
others	were	terminated	due	to	safety	issues	or	unknown	reasons.	As	shown	in	Figure	2B,	there	was	
no	 difference	 in	 the	 number	 of	 clinical	 trials	 with	 or	 without	 a	 subsequent	 clinical	 trial	 per	 trial	








trials	 with	 and	 without	 subsequent	 trials,	 which	 was	 used	 as	 a	 proxy	 for	 the	 successful	 clinical	
development	of	the	CAR	T-cell	products.	As	shown	in	Figure	3A,	most	studies	without	a	subsequent	
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Figure	3.	Comparison	of	 clinical	 trial	 characteristics	between	 trials	with	or	without	a	 subsequent	 trial.	 (A)	


























In	 this	study,	an	overview	of	characteristics	of	clinical	 trials	performed	with	CAR	T	cells	 in	Canada,	
Europe	and	 the	United	 States	was	 created.	 The	 clinical	 trials	were	divided	 in	 clinical	 trials	with	or	
without	a	subsequent	clinical	trial	to	compare	the	clinical	trial	designs.	At	the	time	of	data	collection,	
based	 on	 106	 clinical	 trials,	 57	 were	 not	 followed	 up,	 and	 49	 had	 a	 follow-up	 clinical	 trial.	 The	
majority	of	the	trials	had	an	academic	sponsor,	 from	which	most	did	not	proceed	to	a	subsequent	


















to	 phase	 1	 with	 a	 slightly	 different	 design,	 such	 as	 another	 patient	 cohort	 or	 a	 different	 clinical	
indication).	 This	differs	 in	 the	definition	of	 further	development	 from	 trials	 that	were	 followed-up	
with	a	clinical	trial	in	a	later	phase	(e.g.,	from	phase	1	to	phase	2).	However,	because	we	assume	that	
using	another	 indication	as	broadening	 the	 indication	 for	 that	product	and	another	patient	cohort	
can	 also	 extend	 the	 population	 for	 which	 the	 product	 can	 be	 used	 once	 licensed,	 this	 is	 also	
considered	 further	development.	The	majority	of	 the	clinical	 trials,	both	 for	 followed	up	and	non–
followed	 up	 trials,	 use	 CAR	 T	 cells	 from	 autologous,	 rather	 than	 allogeneic,	 starting	 material.	 An	
important	aspect	that	has	to	be	taken	into	account	concerning	the	allogeneic	starting	material	is	that	
it	 can	 be	 derived	 from	 the	 donor	 from	 whom	 the	 patient	 received	 a	 hematopoietic	 stem	 cell	
transplantation	 (HSCT)	 if	HSCT	patients	are	 included	 in	 the	 trial.	 Therefore,	a	difference	should	be	
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noted	 in	 non-personalized	 and	 personalized	 (HSCT-donor-derived)	 allogeneic	 starting	 material.	
Personalized	 allogeneic	 starting	 material	 is	 most	 frequently	 used	 for	 CAR	 T-cell	 products.	 When	
autologous	 or	 personalized	 allogeneic	 starting	 material	 is	 used,	 a	 specific	 product	 has	 to	 be	
manufactured	for	every	patient,	and	large-scale	manufacturing	is	not	possible;	this	 leads	to	logistic	
challenges	and	suggests	a	more	time-consuming	and	expensive	procedure.	Interestingly,	most	GCTs	
with	MAA	 from	 the	 European	Medicines	 Agency	 and	 U.S.	 Food	 and	 Drug	 Administration	 and	 are	
generated	from	autologous	starting	material	[17,18].	
A	clinical	trial	design	with	more	than	33	patients	recruited	was	seen	more	often	in	the	followed-up	
clinical	 trials.	 When	 a	 larger	 number	 of	 subjects	 is	 recruited	 for	 a	 clinical	 trial,	 there	 is	 greater	
incentive	for	other	parties	to	collaborate.	That	most	clinical	trials	(~60%)	are	performed	with	smaller	
(≤33)	patient	groups	can	be	explained	by	the	fact	that	most	of	these	studies	are	in	phase	1/2	clinical	
development	 and	 for	 small	 (orphan)	 indications.	 These	 (very)	 small	 patient	 numbers	may	 lead	 to	
suboptimal	 clinical	 design	 to	 distinguish	 reliable	 effect(s)	 of	 the	 product,	 which	 may	 lead	 to	 less	
frequent	follow-up	with	a	subsequent	trial.		
Clinical	 trials	 with	 multicentre	 design	 were	 also	 more	 often	 in	 the	 group	 with	 follow-up	 trials	
compared	with	single	center	clinical	trials.	Phase	2	clinical	trials	that	were	followed	up	were	mostly	
designed	with	more	than	33	patients	recruited	and	were	multi	center.	The	majority	of	the	followed-
up	clinical	 trials	 in	phase	1	were	also	multicentre.	This	strengthens	 the	 idea	that	multicentre	 trials	
might	have	a	superior	clinical	trial	design	because	experts	from	more	than	centre	are	involved	[19];	
this	results	in	a	better	chance	of	a	follow-up	trial.	Some	of	the	differences	found	in	this	study	might	









the	most	 frequently	defined	primary	end	point	 in	 the	phase	1	clinical	 trials	because	most	phase	1	
clinical	trials	determine	the	safety	of	a	medicinal	product.		
From	 the	 queries	 performed	 in	 the	 public	 U.S.	 and	 EU	 clinical	 trial	 registers,	 the	 EU	 database	
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Because	 of	 the	 large	 variety	 of	 the	 GCT	 subtypes,	 we	 focused	 on	 the	 promising	 CAR	 T	 cells.	 The	
overviews	provided	a	general	impression	of	the	CAR	T-cell	field	and	some	trends	for	what	may	lead	
to	 subsequent	 clinical	 trials,	 such	 as	 multicentre	 design,	 larger	 patient	 cohorts	 and	 having	 a	
commercial	 sponsor.	 It	 should	 be	 investigated	 whether	 these	 variables	 also	 apply	 to	 other	 GCT	
subtypes.	A	recommendation	for	 investigators	would	be	to	take	these	variables	 into	account	when	
designing	 clinical	 trials	 with	 CAR	 T-cell	 products,	 starting	 from	 phase	 1/2.	 For	 the	 regulatory	
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products	 (ATMPs)	 towards	marketing	authorization	 (MA).	 In	 the	EU	a	 special	 regulation	came	 into	
force	 in	 2009	 to	 regulate	 ATMPs.	 However,	 systemic	 insight	 into	 decision-making	 for	 approval	 is	
limited.	 Therefore,	 we	 aim	 to	 evaluate	 how	 EU	 regulators	 reached	 opinions	 on	 benefit/risk	 for	
ATMPs	based	on	product	profiles,	scientific	evidence	and	within	the	context	of	a	regulatory	process.	
European	 public	 assessments	 report	 (EPARs)	 of	 submitted	 and	 evaluated	ATMPs	 for	MA	between	
2009	 and	 December	 2016,	 were	 analysed	 using	 a	 mixed	 quantitative-qualitative	 study	 design	 to	
compare	 different	 regulatory	 opinions:	 standard	 approval,	 expedited	 approval,	 or	 non-approval.	
Analysis	consisted	of	3	steps:	(1)	descriptive	quantitative	cohort	analysis	of	product	profile,	scientific	
evidence	 and	 regulatory	 processes,	 (2)	 qualitative	 analysis	 of	 major	 scientific	 issues	 and	 (3)	
qualitative	 analysis	 of	 the	 benefit/risk-assessments	 conducted	 by	 the	 Committee	 for	 Medicinal	
Products	for	Human	Use	(CHMP)	of	the	EMA.	
Relevant	 quality	 issues	were	 raised	 in	 all	 assessment	 procedures.	Most	 robust	 clinical	 trial	 design	
and	 clinical	 outcomes	 were	 evident	 for	 standard	 approved	 ATMPs	 (n=5).	 All	 expedited	 approvals	
were	granted	for	orphan	ATMPs,	for	which	considerations	of	unmet	medical	need	counterbalanced	
clinical	uncertainties	 and	 risks.	 For	non-approved	ATMPs	 lack	of	 clinical	 efficacy	and	 severe	 safety	
risks	were	decisive	for	negative	benefit/risk	opinions.	
Our	findings	suggest	that	setting	appropriate	standards	for	ATMP	approval	in	Europe,	like	elsewhere,	
is	 a	 learning	 experience.	 The	 experimental	 characteristics	 of	 approved	 ATMPs	 urge	 regulators,	






In	 the	 last	 decade	 there	 has	 been	 increased	 interest	 in	 the	 development	 of	 advanced	 therapy	
medicinal	products	(ATMPs)	towards	marketing	authorization.	In	2009,	Regulation	EC	No.1394/2007	
came	 into	 force	as	 the	 first	 specific	 regulatory	 framework	approval	of	 this	potentially	new	class	of	
medicinal	products	in	the	European	Union	(EU)[1,2].	Due	to	the	novelty	and	complexity	of	ATMPs,	a	
special	Committee	 for	Advanced	Therapies	 (CAT)	was	 founded	by	 the	European	Medicines	Agency	
(EMA)	 to	 support	 the	 Committee	 for	 Medicinal	 Products	 for	 Human	 use	 (CHMP)	 in	 benefit/risk	
assessments,	 to	 stimulate	 early	 dialogues	 between	 the	 developers	 and	 the	 authorities	 and	 to	
encourage	 the	 development	 of	 these	 promising	 medicinal	 products	 towards	 marketing	
authorization[2,3].	The	CAT	advises	the	CHMP	on	benefit/risk,	who	in	turn	makes	a	recommendation	




It	 is	well	 known	 that	ATMP	developers	 face	various	 scientific	and	 technological	 challenges	 ranging	
from	 manufacturing	 and	 quality	 issues[8]	 to	 preclinical	 and	 clinical	 efficacy	 and	 safety	 issues[9].	
Moreover,	 additional	 hurdles	 in	 the	 trajectory	 towards	 approval	 are	 experienced	 by	 academic	
developers,	 such	 as	 a	 lack	 of	 regulatory	 knowledge,	 insufficient	 financial	 support	 and	 clinical	 trial	
related	 problems,	 such	 as	 recruitment[10].	 Regulation	 EC	 No.	 1394/2007	 includes	 high-level	
requirements	 for	 approval,	 however,	 as	 the	 field	 is	 rapidly	 evolving,	 standardization	 of	 regulatory	
requirements	 for	 approval	 is	 difficult	 and	 perhaps	 undesirable.	 Consequently,	 decision-making	 for	
approval	of	ATMPs	largely	occurs	on	a	case-by-case	basis[11].	Considering	these	developmental	and	
regulatory	complexities,	scientific	uncertainties	during	benefit/risk	assessments	are	highly	prevalent.	
In	 this	 study	 we	 aim	 to	 provide	 insight	 into	 decision-making	 for	 approval	 of	 ATMPs	 in	 Europe	
between	2009-2016.	We	compare	1)	product	profiles,	scientific	evidence	and	regulatory	procedures,	






the	 EMA	 website,	 using	 the	 European	 Public	 Assessment	 reports	 (EPARs)[12].	 Since	 2009,	 16	
applications	were	submitted	in	the	EU,	of	which	eight	procedures	led	to	approval	by	the	EC.	Seven	
applications	 were	 either	 rejected	 by	 the	 authorities	 (n=3)	 or	 withdrawn	 by	 the	 applicants	 (n=4)	
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the	 EMA	 website,	 using	 the	 European	 Public	 Assessment	 reports	 (EPARs)[12].	 Since	 2009,	 16	
applications	were	submitted	in	the	EU,	of	which	eight	procedures	led	to	approval	by	the	EC.	Seven	
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before	 regulatory	 decision-making[13].	 Two	 non-approved	 applications	 for	 one	 product	 (Cerepro)	
were	analysed	at	final	decision	as	one	assessment	procedure,	because	the	initial	scientific	evidence	
was	 only	 substituted	 in	 the	 second	 application.	 In	 2017,	 the	 CHMP	 recommended	 approval	 of	
Spherox®,	 however,	 because	 it	 is	 not	 yet	 approved	 by	 the	 EC,	 this	 assessment	 procedure	 was	
excluded.	In	total,	eight	approved	and	six	non-approved	ATMPs	were	included	for	analysis.	
Drawing	 from	 previous	 work[14–16],	 a	 preliminary	 set	 of	 variables	 was	 designed	 to	 characterize	
assessment	 procedures	 based	 on	 the	 three	 elements	 (product	 profile,	 scientific	 evidence,	 and	
regulatory	procedures).	This	set	was	tested	in	a	pilot	study.	Consequently,	additional	variables	were	
added	 to	 optimize	 specificity	 for	 assessment	 procedures	 for	 ATMPs	 from	 all	 included	 assessment	
procedures,	 see	 supplementary	 1,	 table	 1.	 Scientific	 evidence	 was	 divided	 into	 four	 categories:	
quality,	preclinical	 studies,	 clinical	 trial	design,	 and	clinical	outcome.	These	variables	were	used	 to	
perform	the	three	steps	of	the	mixed	quantitative-qualitative	analysis,	as	described	below,	in	order	




and	 DC)	 independently	 scored	 the	 characteristics	 of	 each	 ATMP.	 In	 case	 of	 disagreement	 a	
discussion	was	held	until	 the	 final	 score	by	consensus.	 In	case	of	uncertainty,	a	 third	 independent	




Major	objections,	major	 concerns,	major	deficiencies	 and	grounds	 for	 refusal	were	 collected	 from	
the	 EPARs	 in	 order	 to	 identify	 scientific	 issues	 that	were	 interpreted	 as	 critical	 in	 the	 assessment	
process.	 Similar	 to	 step	1,	 this	 collection	was	 independently	 performed	by	 two	authors	 (SdW	and	
DC),	using	the	search	function	(eg,	‘objections’,	‘concerns’,	‘deficiencies’)	and	by	distinguishing	major	
from	non-major.	 Also,	whether	 regulators	 considered	 such	major	 issue	 to	 be	 resolved	 or	 not	was	
identified.	Obtained	 text	 elements	 from	 the	 EPARs	were	 qualitatively	 coded	 in	NVivo	 11.4.1.1064	
Pro.	Codes	were	linked	to	the	corresponding	scientific	evidence	category	(quality,	preclinical,	clinical	
trial	 design	 and	 clinical	 outcome)	 to	 facilitate	 categorization	 of	 the	 major	 issues.	 Codes	 were	
compared	between	authors,	and	in	case	of	disagreement	a	discussion	was	held	until	consensus.	
Step	3:	Qualitative	analysis	of	benefit/risk-assessment	
For	 each	 scientific	 evidence	 category	 (quality,	 preclinical,	 clinical	 trial	 design,	 clinical	 outcome),	
relevant	 text	 elements	 were	 extracted	 from	 the	 ‘benefit/risk-balance’	 and	 ‘recommendation’	
	
	
sections	of	 the	EPARs	 in	order	 to	 identify	 the	decisive	determinants	 for	positive	and	negative	 final	
regulatory	outcomes	(approval	versus	non-approval).	For	each	assessment	procedure,	variables	that	
were	mentioned	in	the	‘benefit/risk-balance’	and/or	‘recommendation’	section	and	major	issues	or	
uncertainties	 mentioned	 by	 regulators	 were	 identified	 and	 coded	 in	 NVivo	 11.4.1.1064	 Pro.	
Regulatory	 interpretations	 on	 scientific	 evidence	 were	 included	 in	 codes,	 for	 example	 whether	
scientific	 evidence	 category	 was	 deemed	 satisfactory,	 uncertain	 or	 considered	 to	 be	 a	 major	
objection.	
Per	scientific	evidence	category,	codes	were	transferred	to	scores	ranging	from		unsatisfactory	(--),	
to	 neutral	 (+/-),	 to	 satisfactory	 (++)	 to	 depict	 regulatory	 consideration	 of	 decisive	 elements	 and	
outcome	 per	 benefit/risk-assessment.	 Uncertainty	 in	 long-term	 efficacy/safety	 was	 not	 shown,	





From	 the	 14	 included	 ATMPs,	 5	 were	 standard	 approvals,	 3	 were	 approved	 via	 the	 expedited	
pathway,	 and	 6	 were	 non-approved.	 In	 table	 1,	 the	 product	 profiles	 of	 all	 assessed	 ATMPs	 are	
shown.	 Characteristics	 such	 as	 ATMP	 subtype,	 starting	material,	 administration	 route	 and	 storage	
conditions	 were	 diverse	 for	 the	 different	 regulatory	 outcomes.	 Orphan	 drug	 designation	 was	
assigned	to	all	expedited	approved	products,	whereas	only	1	(out	of	5)	standard	approved	product	
and	 half	 (n=3	 out	 of	 6)	 of	 the	 non-approved	 products	 were	 designated	 orphan	 drugs.	 For	 the	
expedited	approved	products	no	alternative	treatment	was	available,	whereas	this	applied	only	to	1	
out	of	5	standard	approved	products	and	2	(out	of	6)	non-approved	products.	
Potency	 assays	 were	 part	 of	 all	 the	 applications.	 All	 standard	 approvals	 were	 tested	 as	 being	
according	 to	 standards	 on	 sterility,	 purity	 and	 viability	 upon	 release.	 However,	 for	 the	 expedited	
approvals	 these	 release	 tests	 were	 not	 always	 discussed	 in	 the	 EPARs	 (available	 release	 tests:	
sterility	(n=1	out	of	3),	purity	(n=1	out	of	3)	and	viability	(n=2	out	of	3)).	This	also	applied	to	the	non-
approved	products	(available	release	tests:	sterility	(n=4	out	of	6),	purity	(n=4	out	of	6)	and	viability	
(n=2	 out	 of	 6)).	 Remarkable	 is	 the	 unspecified	 shelf-life	 and	 storage	 condition	 for	 non-approved	
products	(n=4	out	of	6).	
Design	of	pivotal	clinical	trials	were	more	robust	for	standard	versus	expedited	approved	and	non-
approved	 products.	 For	 the	 majority	 (n=4	 out	 of	 5)	 of	 the	 standard	 approvals	 a	 randomized	
controlled	 phase	 III	 clinical	 trial	 was	 performed.	 In	 contrast,	 for	 all	 expedited	 approved	 products	
non-randomized	controlled	data	were	submitted.	For	only	2	(out	of	6)	of	the	non-approved	products	
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trial	 design	 and	 clinical	 outcome)	 to	 facilitate	 categorization	 of	 the	 major	 issues.	 Codes	 were	
compared	between	authors,	and	in	case	of	disagreement	a	discussion	was	held	until	consensus.	
Step	3:	Qualitative	analysis	of	benefit/risk-assessment	
For	 each	 scientific	 evidence	 category	 (quality,	 preclinical,	 clinical	 trial	 design,	 clinical	 outcome),	
relevant	 text	 elements	 were	 extracted	 from	 the	 ‘benefit/risk-balance’	 and	 ‘recommendation’	
	
	
sections	of	 the	EPARs	 in	order	 to	 identify	 the	decisive	determinants	 for	positive	and	negative	 final	
regulatory	outcomes	(approval	versus	non-approval).	For	each	assessment	procedure,	variables	that	
were	mentioned	in	the	‘benefit/risk-balance’	and/or	‘recommendation’	section	and	major	issues	or	
uncertainties	 mentioned	 by	 regulators	 were	 identified	 and	 coded	 in	 NVivo	 11.4.1.1064	 Pro.	
Regulatory	 interpretations	 on	 scientific	 evidence	 were	 included	 in	 codes,	 for	 example	 whether	
scientific	 evidence	 category	 was	 deemed	 satisfactory,	 uncertain	 or	 considered	 to	 be	 a	 major	
objection.	
Per	scientific	evidence	category,	codes	were	transferred	to	scores	ranging	from		unsatisfactory	(--),	
to	 neutral	 (+/-),	 to	 satisfactory	 (++)	 to	 depict	 regulatory	 consideration	 of	 decisive	 elements	 and	
outcome	 per	 benefit/risk-assessment.	 Uncertainty	 in	 long-term	 efficacy/safety	 was	 not	 shown,	





From	 the	 14	 included	 ATMPs,	 5	 were	 standard	 approvals,	 3	 were	 approved	 via	 the	 expedited	
pathway,	 and	 6	 were	 non-approved.	 In	 table	 1,	 the	 product	 profiles	 of	 all	 assessed	 ATMPs	 are	
shown.	 Characteristics	 such	 as	 ATMP	 subtype,	 starting	material,	 administration	 route	 and	 storage	
conditions	 were	 diverse	 for	 the	 different	 regulatory	 outcomes.	 Orphan	 drug	 designation	 was	
assigned	to	all	expedited	approved	products,	whereas	only	1	(out	of	5)	standard	approved	product	
and	 half	 (n=3	 out	 of	 6)	 of	 the	 non-approved	 products	 were	 designated	 orphan	 drugs.	 For	 the	
expedited	approved	products	no	alternative	treatment	was	available,	whereas	this	applied	only	to	1	
out	of	5	standard	approved	products	and	2	(out	of	6)	non-approved	products.	
Potency	 assays	 were	 part	 of	 all	 the	 applications.	 All	 standard	 approvals	 were	 tested	 as	 being	
according	 to	 standards	 on	 sterility,	 purity	 and	 viability	 upon	 release.	 However,	 for	 the	 expedited	
approvals	 these	 release	 tests	 were	 not	 always	 discussed	 in	 the	 EPARs	 (available	 release	 tests:	
sterility	(n=1	out	of	3),	purity	(n=1	out	of	3)	and	viability	(n=2	out	of	3)).	This	also	applied	to	the	non-
approved	products	(available	release	tests:	sterility	(n=4	out	of	6),	purity	(n=4	out	of	6)	and	viability	
(n=2	 out	 of	 6)).	 Remarkable	 is	 the	 unspecified	 shelf-life	 and	 storage	 condition	 for	 non-approved	
products	(n=4	out	of	6).	
Design	of	pivotal	clinical	trials	were	more	robust	for	standard	versus	expedited	approved	and	non-
approved	 products.	 For	 the	 majority	 (n=4	 out	 of	 5)	 of	 the	 standard	 approvals	 a	 randomized	
controlled	 phase	 III	 clinical	 trial	 was	 performed.	 In	 contrast,	 for	 all	 expedited	 approved	 products	
non-randomized	controlled	data	were	submitted.	For	only	2	(out	of	6)	of	the	non-approved	products	
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randomized	controlled	data	were	 in	 the	dossier.	The	number	of	patients	 recruited	was	substantial	
higher	 for	 the	standard	approved	products	 (mean:	244	patients,	 range:	12-341)	compared	 to	non-
approved	products	(mean:	120	patients,	range:	26-241)	and	expedited	approved	products	(mean:	57	



































		 	 		 SA	(n=5)	 CA	(n=2)	 UEC	(n=1)	 NA	(n=6)	
										1.	Product	profile	 	 	 	 	 	
Product	Type	 GTMP	 2	 0	 1	 3	
		 CTMP	 1	 1	 0	 1	
		 TEP	 1	 1	 0	 2	
		 Combined	 1	 0	 0	 0	
Starting	Material	 Autologous	 4	 1	 0	 2	
		 Allogeneic	 0	 1	 0	 1	
		 Not	applicable	 1	 0	 1	 3	
End	product	 Refrigerated	 2	 0	 0	 0	
		 Room	Temperature	 2	 1	 0	 0	
		 Nitrogen-cryopreserved	 0	 1	 0	 1	
		 Other-cryopreserved	 1	 0	 1	 1	
		 Unspecified	 0	 0	 0	 4	
Previous	approved	in	other	jurisdictions	 Yes	 3	 0	 0	 0	
Indication	area	 Cancer	 2	 0	 0	 2	
		 Congenital,	hereditary,	neonatal	diseases	 1	 0	 1	 2	
		 Eye	diseases	 0	 1	 0	 1	
		 Immune	system	diseases	 0	 1	 0	 0	
		 Musculoskeletal	diseases	 2	 0	 0	 1	
Lack	alternative	treatment	 	Yes	 1	 2	 1	 2	




Potency	assay	 5	 2	 1	 6	
Release	-	sterility	 5	 1	 0	 4	
Release	-	Purity	 5	 1	 0	 4	
Release	-	Viability	 5	 2	 0	 2	
Release	-	activity	 3	 1	 1	 3	
Preclinical	 Toxicity	 4	 2	 1	 6	
	 Efficacy	 5	 1	 1	 6	
	 Dose	 3	 1	 1	 6	
Pivotal	trial	Design	 RCT	 4	 0	 0	 2	
	 Clinical	prim.	EP	 5	 1	 0	 4	
	 Clinical	Relevance	prim.	EP	 5	 2	 0	 3	
	 Significant	Outcome	 5	 1	 0	 1	
Clinical	Outcome		 Significant	primary	EP	 5	 1	 0	 1	
	 Beneficial	Effect	 1	 2	 1	 0	
										3.	Regulatory	process	 Scientific	advice	 5	 2	 1	 4	
	 Restricted	Labelling	 5	 1	 1	 0	
ATMP	 =	 advanced	 therapy	 medicinal	 product,	 CA	 =	 conditional	 approved,	 CTMP	 =	 cell	 therapy	 medicinal	
product,	 EP	 =	 endpoint,	 GTMP	 =	 gene	 therapy	 medicinal	 product,	 NA	 =	 non-approved,	 RCT	 =	 randomized	
controlled	 trial,	 SA	 =	 standard	 approved,	 TEP	 =	 tissue	 engineering	 product,	 UEC	 =	 under	 exceptional	
circumstances	
	
The	 CAT	 consulted	 expert	 panels	 for	 advice	 on	 clinical	 relevance	 of	 outcomes	 in	 3	 assessment	
procedures	(standard	approval:	n=2	out	of	5	and	non-approval:	n=1	out	of	6).	Scientific	advice	was	
provided	for	almost	all	applications	(n=13	out	of	15),	but	for	only	4	(3	approved	and	1	non-approved)	
applications	 the	 first	 interaction	 between	 developer	 and	 regulators	 was	 before	 the	 start	 of	 the	
clinical	 trials.	 The	 time	 between	 submission	 and	 final	 decision,	 including	 clock-stop	 time,	 was	
comparable	 for	 standard	 approved	 (mean:	 633	 days,	 range:	 371-857	 days)	 and	 non-approved	
products	(mean:	668	days,	range:	321-1538	days).	However,	this	duration	was	substantial	longer	for	
expedited	approvals	(mean:	882	days,	range:	713-1037	days).	Labels	were	restricted	to	either	reflect	
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release	 specifications	 (standard	 approved:	 n=1	 out	 of	 5)	 and	 specific	 release	 tests	 (standard	
approved:	 n=1	 out	 of	 5,	 expedited	 approved:	 n=3	 out	 of	 3,	 non-approved:	 n=5	 out	 of	 6).	 While	
developers	 of	 the	 approved	 products	 were	 able	 to	 resolve	 the	 objections	 before	 final	 regulatory	






decision-making.	Nevertheless,	 it	was	 agreed	 on	 the	 applicant	 that	 no	 suitable	 animal	model	was	
available	 and	 the	 discussed	 literature	 was	 sufficient	 for	 approval	 UEC.	 In	 contrast,	 major	 issues	
indicated	for	non-approved	products	were	still	unresolved	at	time	of	final	decision-making.	
For	 clinical	 trial	 design,	most	major	 issues	were	 also	 raised	 for	 non-approved	 products	 (Table	 2).	
These	 issues	 concerned	 methodological	 issues	 or	 invalid	 clinical	 trial	 design	 (n=5	 out	 of	 6)	 and	
change	 of	 endpoints	 or	 uncertain	 clinical	 relevance	 of	 an	 endpoint	 (n=2	 out	 of	 6).	 A	 change	 of	
endpoints	was	also	noted	as	major	issue	for	1	(out	of	5)	standard	approved	product	and	1	(out	of	3)	
expedited	 approved	 product.	 For	 the	 approved	 products,	 the	 major	 concerns	 were	 considered	














Table	 2.	 Major	 issues	 mentioned	 in	 the	 assessment	 reports	 for	 marketing	 authorization.	 Per	 category	
(quality,	 preclinical,	 clinical	 trial	 design,	 and	 clinical	 outcome)	 the	 major	 issues	 including	 the	 number	 of	
products	 for	 which	 that	 major	 objection	 was	 raised	 is	 mentioned.	 Light	 grey	 =	 resolved	 at	 time	 of	 final	
decision;	grey	=	acceptable	at	time	of	final	decision;	dark	grey	=	unresolved	at	time	of	final	decision.		







Standard	(n	=	5)	 In	process	control	(1)		 		 Endpoint	(1)	 		
	 Release	specification	(1)	 	 	 	
		 Specific	release	test	(1)		 		 		 		
Conditional	(n=2)	 Specific	release	test	(2)		 		 		 		
UEC	(n=1)	 Vector	(1)		 Toxicology		(1)	 Endpoint	(1)		 Efficacy	(1)	






		 Vector	(2)	 Toxicology	(4)		 Design	(5)	 PD	(2)	
		 GMP	Facility	(3)	 Animal	model	(1)		 Endpoint	(2)	 GCP	(3)	
	 In	process	control	(2)	 Efficacy	(1)		 	 Efficacy	(6)	
		 GMO	test	(1)	 	 		 Safety	(5)	
	 Starting	material	(1)	 	 	 	
	 Specific	Release	Test	(1)	 	 	 	




Major	 issues	 related	 to	 clinical	 outcomes	 were	 raised	 for	 all	 non-approved	 products	 and	 for	






when	 clinical	 outcomes	were	 judged	 as	 unsatisfactory	 (--).	Unmet	medical	 need	did	not	 outweigh	
unsatisfactory	clinical	outcomes.	The	benefit/risk-assessments	per	regulatory	outcome	are	described	
below.	 	












release	 specifications	 (standard	 approved:	 n=1	 out	 of	 5)	 and	 specific	 release	 tests	 (standard	
approved:	 n=1	 out	 of	 5,	 expedited	 approved:	 n=3	 out	 of	 3,	 non-approved:	 n=5	 out	 of	 6).	 While	
developers	 of	 the	 approved	 products	 were	 able	 to	 resolve	 the	 objections	 before	 final	 regulatory	






decision-making.	Nevertheless,	 it	was	 agreed	 on	 the	 applicant	 that	 no	 suitable	 animal	model	was	
available	 and	 the	 discussed	 literature	 was	 sufficient	 for	 approval	 UEC.	 In	 contrast,	 major	 issues	
indicated	for	non-approved	products	were	still	unresolved	at	time	of	final	decision-making.	
For	 clinical	 trial	 design,	most	major	 issues	were	 also	 raised	 for	 non-approved	 products	 (Table	 2).	
These	 issues	 concerned	 methodological	 issues	 or	 invalid	 clinical	 trial	 design	 (n=5	 out	 of	 6)	 and	
change	 of	 endpoints	 or	 uncertain	 clinical	 relevance	 of	 an	 endpoint	 (n=2	 out	 of	 6).	 A	 change	 of	
endpoints	was	also	noted	as	major	issue	for	1	(out	of	5)	standard	approved	product	and	1	(out	of	3)	
expedited	 approved	 product.	 For	 the	 approved	 products,	 the	 major	 concerns	 were	 considered	














Table	 2.	 Major	 issues	 mentioned	 in	 the	 assessment	 reports	 for	 marketing	 authorization.	 Per	 category	
(quality,	 preclinical,	 clinical	 trial	 design,	 and	 clinical	 outcome)	 the	 major	 issues	 including	 the	 number	 of	
products	 for	 which	 that	 major	 objection	 was	 raised	 is	 mentioned.	 Light	 grey	 =	 resolved	 at	 time	 of	 final	
decision;	grey	=	acceptable	at	time	of	final	decision;	dark	grey	=	unresolved	at	time	of	final	decision.		







Standard	(n	=	5)	 In	process	control	(1)		 		 Endpoint	(1)	 		
	 Release	specification	(1)	 	 	 	
		 Specific	release	test	(1)		 		 		 		
Conditional	(n=2)	 Specific	release	test	(2)		 		 		 		
UEC	(n=1)	 Vector	(1)		 Toxicology		(1)	 Endpoint	(1)		 Efficacy	(1)	






		 Vector	(2)	 Toxicology	(4)		 Design	(5)	 PD	(2)	
		 GMP	Facility	(3)	 Animal	model	(1)		 Endpoint	(2)	 GCP	(3)	
	 In	process	control	(2)	 Efficacy	(1)		 	 Efficacy	(6)	
		 GMO	test	(1)	 	 		 Safety	(5)	
	 Starting	material	(1)	 	 	 	
	 Specific	Release	Test	(1)	 	 	 	




Major	 issues	 related	 to	 clinical	 outcomes	 were	 raised	 for	 all	 non-approved	 products	 and	 for	






when	 clinical	 outcomes	were	 judged	 as	 unsatisfactory	 (--).	Unmet	medical	 need	did	not	 outweigh	
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concerns	 and	 risks,	 trend	 towards	 unsatisfactory	 (-);	 neutral,	 mentioned	 but	 no	 clear	 judgement	 (+/-);	
uncertainty,	trend	towards	satisfactory	(+);	satisfactory	(++),	not	mentioned	(empty	box),	unmet	medical	need	
considered	in	benefit/risk-assessment	( );		





Standard	approval	 	 	 	 	 	 	 	
	 Chondrocelect®	 ++	 +/-	 --	 +	 ++	 	 ++	
Imlygic®	 	 	 -	 +	 +	 	 +	
MACI®	 ++	 	 ++	 ++	 ++	 	 ++	
Provenge®	 --	 	 +/-	 ++	 -	 	 +	
Strimvelis®	 	 	 +/-	 ++	 -	 	 ++	
Conditional	approval	 	 	 	 	 	 	 	
	 Holoclar®	 -	 	 +/-	 +	 +	 	 ++	
Zalmoxis®	 	 	 +/-	 +/-	 -	 	 +	
Under	exceptional	circumstances	 	 	 	 	 	 	
	 Glybera®	 --	 	 +/-	 +/-	 +/-	 	 +	
	Non-approval	 	 	 	 	 	 	 	
	 Advexin	 --	 --	 --	 --	 --	 	 --	
CLG	 --	 --	 	 --	 --	 	 --	
Cerepro	 +	 +	 --	 --	 --	 	 --	
Heparesc	 	 	 --	 --	 +/-	 	 -	
Hyalograft	 --	 --	 --	 +/-	 --	 	 --	




The	 beneficial	 efficacy	 outcomes	 and	 favourable	 safety	 profile,	 resulted	 in	 a	 positive	 opinion	 for	
MACI®.	 The	 beneficial	 efficacy	 trend	 for	 Chondrocelect®	 and	 Imlygic®	 combined	 with	 satisfactory	
safety	profiles	resulted	in	standard	approval,	despite	ample	regulatory	discussion	about	the	clinical	
trial	 design.	 Significant	 and	 clinically	 relevant	 efficacy	 of	 Provenge®	 combined	 with	 the	
acknowledged	unmet	medical	 need	 for	 the	 target	 indication	 (oncology),	 outweighed	 the	 risks	 and	
uncertainties	 related	 to	 the	 safety	 profile.	 Compelling	 efficacy	 outcomes	 for	 Strimvelis®	
demonstrated	 in	 clinical	 practice,	with	 the	 acknowledged	unmet	medical	 need	 (lack	of	 alternative	
pharmacological	 treatment	 for	 a	 life-threatening	 disease)	 outweighed	 risks	 and	 uncertainties	
surrounding	 latent	 severe	 adverse	 events[17].	 Despite	 these	 favourable	 regulatory	 opinions,	
divergent	positions	were	submitted	for	2	approved	products	(Imlygic®:	n=1	;	Provenge®:	n=13).	
As	 conditional	 approval	 pathways	 prerequisite,	 the	 body	 of	 evidence	 is	 overall	 less	 robust	 and	
associated	with	more	uncertainty	compared	to	standard	approved	ATMPs.	Uncertainties	have	to	be	
resolved	 or	 managed	 through	 post-marketing	 obligations.	 Considerations	 of	 unmet	 medical	 need	
were	 part	 of	 all	 decision-making	 under	 conditional	 approval.	 Uncertainty	 on	 significant	 clinical	
benefits	 for	 Holoclar®	 was	 recognized	 due	 to	 the	 retrospective,	 non-randomised,	 uncontrolled	
observational	 study	 design.	 Yet,	 this	was	 outweighed	 by	 the	manageable	 risks	 and	 acknowledged	
unmet	medical	need.	Unmet	medical	need	outweighed	non-confirmatory	clinical	benefit	and	safety	




Glybera®	 was	 the	 only	 ATMP	 approved	 UEC	 after	 a	 long	 and	 extensive	 assessment	 procedure,	
involving	many	re-evaluations	by	the	CAT	and	CHMP[18].	Many	uncertainties	on	quality,	efficacy	and	
safety	 led	 to	 unfavourable	 recommendations	 for	 approval	 twice.	 Before	 the	 final	 re-examination,	
after	 previous	 negative	 recommendations,	 lack	 of	 robust	 efficacy	 outcomes	 was	 considered	 as	 a	
major	 concern.	 Yet,	 a	 post-hoc	 analysis	 revealed	 a	 beneficial	 effect	 with	 Glybera®	 for	 lipoprotein	
lipase	(LPL)	deficient	patients	(n=5).	The	unmet	medical	need	for	this	subgroup	was	crucial	to	reach	
approval	 UEC,	 taking	 the	 ultra-orphan	 status	 into	 consideration.	 Consequently,	 the	 label	 was	
restricted	 to	 this	 patient	 group.	 The	 final	 CHMP	 opinion	was	 not	 supported	 by	 16	members	who	
undersigned	a	divergent	positions.		
Non-approval	 of	 ATMPs	was	 associated	with	 numerous	 scientific	 deficiencies.	More	 specifically,	 3	
(out	of	6)	non-approved	products	had	an	unsatisfactory	profile	for	all	scientific	evidence	elements:	
quality,	preclinical	studies,	clinical	trial	design	and	clinical	efficacy	and	safety.	For	all	non-approved	
products	 the	 clinical	 trial	 design	 was	 regarded	 as	 unsatisfactory	 which	 hindered	 regulators	 to	
evaluate	 the	 clinical	 data.	 Positive	 results	 related	 to	 quality	 and	 preclinical	 studies	 were	






















In	 this	 study	 we	 demonstrated	 how	 characteristics	 related	 to	 ATMP	 product	 profiles,	 scientific	
evidence	and	regulatory	processes	were	considered	in	the	regulatory	assessment	of	the	first	cohort	
of	 ATMPs	 under	 the	 Regulation	 EC	 No.	 1394/2007.	 Our	 results	 suggest	 that	 EU	 regulators	 are	
currently	exploring	an	appropriate	regulatory	standard	for	ATMPs,	i.e.	we	are	learning	to	implement	
this	 regulation	 in	 the	 most	 appropriate	 way.	 Unmet	 medical	 need	 has	 been	 often	 considered	 to	
outweigh	 scientific	 uncertainties.	 In	 particular	 this	 was	 the	 case	 for	 expedited	 approved	 ATMPs,	
which	 were	 all	 orphan	 drugs.	 Non-approval	 was	 associated	 with	 a	 lack	 of	 clinical	 efficacy	 and	




GMP	 requirements	 are	 more	 stringent	 compared	 to	 other	 jurisdictions	 and	 may	 impose	
development	 hurdles.	 For	 example,	 in	 the	 USA,	 GMP	 requirements	 for	 gene	 and	 cell	 products	
increase	as	the	product	continues	towards	a	later	stage	clinical	trial[19].	However,	the	disadvantage	
of	this	concept	is	that	GMP	adherence	may	be	insufficient	upon	approval,	in	particular	when	phase	
III	clinical	 trials	are	not	conducted.	EU	regulators	are	also	searching	for	 justified	flexibility	 for	GMP	
compliance	 for	 ATMPs,	 which	 is	 illustrated	 by	 the	 development	 of	 a	 new	 GMP	 guideline	 for	
ATMPs[20].			
Potency	also	frequently	raised	major	objections	for	both	approved	and	non-approved	ATMPs.	ATMP	
developers	 experience	 difficulties	 in	 proper	 potency	 testing,	 due	 to	 the	 lack	 of	 suitable	 animal	
models,	little	or	even	lacking	knowledge	about	the	mechanism	of	action,	and	therefore	also	lack	of	
validated	 biomarkers.	 Developers	 may	 prevent	 failure	 in	 late	 stage	 development	 through	 early	
investment	 in	 potency	 evaluation[21].	 Vector-related	 problems	 of	 in	 vivo	 gene	 therapy	medicinal	
products	(GTMPs),	such	as	unaddressed	functionality,	and	dissatisfactory	assay	replications,	belong	
to	 the	 fundamental	 development	 aspects	 of	 such	 product	 and	 should	 have	 been	 resolved	 before	





often	 resolved	 by	 the	 development	 of	 a	 rapid-release	 test	 for	 approved	 ATMPs.	 Furthermore,	
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Glybera®	 was	 the	 only	 ATMP	 approved	 UEC	 after	 a	 long	 and	 extensive	 assessment	 procedure,	
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In	 this	 study	 we	 demonstrated	 how	 characteristics	 related	 to	 ATMP	 product	 profiles,	 scientific	
evidence	and	regulatory	processes	were	considered	in	the	regulatory	assessment	of	the	first	cohort	
of	 ATMPs	 under	 the	 Regulation	 EC	 No.	 1394/2007.	 Our	 results	 suggest	 that	 EU	 regulators	 are	
currently	exploring	an	appropriate	regulatory	standard	for	ATMPs,	i.e.	we	are	learning	to	implement	
this	 regulation	 in	 the	 most	 appropriate	 way.	 Unmet	 medical	 need	 has	 been	 often	 considered	 to	
outweigh	 scientific	 uncertainties.	 In	 particular	 this	 was	 the	 case	 for	 expedited	 approved	 ATMPs,	
which	 were	 all	 orphan	 drugs.	 Non-approval	 was	 associated	 with	 a	 lack	 of	 clinical	 efficacy	 and	




GMP	 requirements	 are	 more	 stringent	 compared	 to	 other	 jurisdictions	 and	 may	 impose	
development	 hurdles.	 For	 example,	 in	 the	 USA,	 GMP	 requirements	 for	 gene	 and	 cell	 products	
increase	as	the	product	continues	towards	a	later	stage	clinical	trial[19].	However,	the	disadvantage	
of	this	concept	is	that	GMP	adherence	may	be	insufficient	upon	approval,	in	particular	when	phase	
III	clinical	 trials	are	not	conducted.	EU	regulators	are	also	searching	for	 justified	flexibility	 for	GMP	
compliance	 for	 ATMPs,	 which	 is	 illustrated	 by	 the	 development	 of	 a	 new	 GMP	 guideline	 for	
ATMPs[20].			
Potency	also	frequently	raised	major	objections	for	both	approved	and	non-approved	ATMPs.	ATMP	
developers	 experience	 difficulties	 in	 proper	 potency	 testing,	 due	 to	 the	 lack	 of	 suitable	 animal	
models,	little	or	even	lacking	knowledge	about	the	mechanism	of	action,	and	therefore	also	lack	of	
validated	 biomarkers.	 Developers	 may	 prevent	 failure	 in	 late	 stage	 development	 through	 early	
investment	 in	 potency	 evaluation[21].	 Vector-related	 problems	 of	 in	 vivo	 gene	 therapy	medicinal	
products	(GTMPs),	such	as	unaddressed	functionality,	and	dissatisfactory	assay	replications,	belong	
to	 the	 fundamental	 development	 aspects	 of	 such	 product	 and	 should	 have	 been	 resolved	 before	





often	 resolved	 by	 the	 development	 of	 a	 rapid-release	 test	 for	 approved	 ATMPs.	 Furthermore,	






In	 this	 study	 we	 demonstrated	 how	 characteristics	 related	 to	 ATMP	 product	 profiles,	 scientific	
evidence	and	regulatory	processes	were	considered	in	the	regulatory	assessment	of	the	first	cohort	
of	 ATMPs	 under	 the	 Regulation	 EC	 No.	 1394/2007.	 Our	 results	 suggest	 that	 EU	 regulators	 are	
currently	exploring	an	appropriate	regulatory	standard	for	ATMPs,	i.e.	we	are	learning	to	implement	
this	 regulation	 in	 the	 most	 appropriate	 way.	 Unmet	 medical	 need	 has	 been	 often	 considered	 to	
outweigh	 scientific	 uncertainties.	 In	 particular	 this	 was	 the	 case	 for	 expedited	 approved	 ATMPs,	
which	 were	 all	 orphan	 drugs.	 Non-approval	 was	 associated	 with	 a	 lack	 of	 clinical	 efficacy	 and	




GMP	 requirements	 are	 more	 stringent	 compared	 to	 other	 jurisdictions	 and	 may	 impose	
development	 hurdles.	 For	 example,	 in	 the	 USA,	 GMP	 requirements	 for	 gene	 and	 cell	 products	
increase	as	the	product	continues	towards	a	later	stage	clinical	trial[19].	However,	the	disadvantage	
of	this	concept	is	that	GMP	adherence	may	be	insufficient	upon	approval,	in	particular	when	phase	
III	clinical	 trials	are	not	conducted.	EU	regulators	are	also	searching	for	 justified	flexibility	 for	GMP	
compliance	 for	 ATMPs,	 which	 is	 illustrated	 by	 the	 development	 of	 a	 new	 GMP	 guideline	 for	
ATMPs[20].			
Potency	also	frequently	raised	major	objections	for	both	approved	and	non-approved	ATMPs.	ATMP	
developers	 experience	 difficulties	 in	 proper	 potency	 testing,	 due	 to	 the	 lack	 of	 suitable	 animal	
models,	little	or	even	lacking	knowledge	about	the	mechanism	of	action,	and	therefore	also	lack	of	
validated	 biomarkers.	 Developers	 may	 prevent	 failure	 in	 late	 stage	 development	 through	 early	
investment	 in	 potency	 evaluation[21].	 Vector-related	 problems	 of	 in	 vivo	 gene	 therapy	medicinal	
products	(GTMPs),	such	as	unaddressed	functionality,	and	dissatisfactory	assay	replications,	belong	
to	 the	 fundamental	 development	 aspects	 of	 such	 product	 and	 should	 have	 been	 resolved	 before	





often	 resolved	 by	 the	 development	 of	 a	 rapid-release	 test	 for	 approved	 ATMPs.	 Furthermore,	
	
	
incomparability	 of	 the	 commercial	 product	 and	 clinical	 trial	 product	 also	 raised	major	 objections.	
This	 should	 and	 could	 be	 avoided	 by	 considering	 future	 aspects	 of	 development	 already	 in	 early	
stages	of	ATMP	development	and	proper	clinical	trial	design[10,22].	
The	observed	suboptimal	clinical	trial	designs	that	create	uncertainty	on	clinical	outcomes	are	in	line	
with	earlier	 reports	of	development	hurdles	experienced	 in	 the	 field[7,23].	Only	 for	one	approved	
ATMP	 the	 clinical	 trial	 design	was	 considered	 satisfactory.	 Yet,	 half	 of	 currently	 approved	 ATMPs	
target	orphan	diseases	for	which	robust	clinical	trial	design	is	not	always	possible	as	a	result	of	small	
patient	 populations	 or	 a	 lack	 of	 alternative	 treatment[7,24,25].	 Our	 observations	 of	 suboptimal	
study	 designs	 under	 expedited	 approval	 are	 also	 in	 line	 with	 findings	 for	 conditionally	 approved	
products	in	the	EU.	For	example,	RCTs	are	not	commonly	conducted	under	conditional	approval[16].	
	
Here,	a	 relatively	high	proportion	of	orphan	drugs	among	 the	approved	ATMPs	skews	 the	 level	of	
scientific	evidence	to	a	non-confirmatory	nature.	There	is	ample	concern	that	in	the	field	of	orphan	
drugs,	 but	 also	 of	 targeted	 oncology	 products,	 the	 non-confirmatory	 nature	 of	 the	 evidence	
becomes	less	confirmatory	with	the	use	of	non-randomized	data	and	surrogate	endpoints[26].	The	
relatively	 large	 ratio	 of	 orphan	 ATMPs	 will	 impact	 the	 regulatory	 considerations	 for	 marketing	
approval	 in	 the	 future[27].	 Unmet	 medical	 need	 plays	 an	 important	 role	 in	 decision-making	 for	
approval	of	ATMPs,	provided	that	the	data	should	at	least	show	some	beneficial	trends	of	efficacy	or	
a	 favorable	 safety	 profile	 to	 receive	 approval.	 This	 feature	 is	 also	 seen	 in	 the	 field	 of	 regulating	
orphan	drugs[14].	Yet,	considerations	of	unmet	medical	need	did	not	lead	to	a	higher	rate	of	positive	
opinions	 on	 orphan	 drug	 approval	 compared	 to	 treatments	 without	 unmet	 medical	 need[15].	
Surprisingly,	conditional	approval	and	approval	UEC	 for	orphan	ATMPs	 is	not	primarily	 initiated	by	
the	 developers,	 but	 by	 the	 regulators.	 In	 line	 with	 previous	 work,	 our	 findings	 suggest	 that	
conditional	approval	is	frequently	used	as	a	rescue	option	for	approval[16].	
Some	major	concerns	related	to	clinical	trial	design,	such	as	a	change	of	primary	endpoint,	were	also	
raised	 for	 standard	approved	ATMPs.	Yet,	 regulators	evaluated	 scientific	evidence	as	 sufficient	 for	
standard	approval.	 In	addition,	unmet	medical	need	was	acknowledged	and	taken	into	account	for	
decision-making,	also	for	standard	approval,	such	as	for	Strimvelis®[17].	In	contrast,	a	robust	clinical	
trial	 design	 and	 clinical	 outcomes	 are	mandatory	 for	 standard	 approval	 of	 conventional	 products	
[15].	This	suggests	that	EU	regulators	are	exploring	an	appropriate	regulatory	standard	for	ATMPs,	,	
where	conventional	products	may	be	used	as	a	useful	reference.	By	all	means	it	remains	crucial	that	
developers	adequately	design	 their	 clinical	 trials	prospectively	 to	 reduce	 the	 risk	 that	major	 issues	
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standard	approval.	 In	addition,	unmet	medical	need	was	acknowledged	and	taken	into	account	for	
decision-making,	also	for	standard	approval,	such	as	for	Strimvelis®[17].	In	contrast,	a	robust	clinical	
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of	 conventional	medicinal	 products	 shows	 that	major	 issues	 that	were	unresolved	at	 time	of	 final	
decision	 often	 led	 to	withdrawal	 by	 the	 applicant[23].	 Applications	 for	most	 of	 the	 non-approved	
ATMPs	were	withdrawn	 after	 a	 negative	 opinion	 as	 a	 result	 of	major	 issues.	 Furthermore,	 earlier	
research	 on	 conventional	 medicinal	 products	 showed	 that	 beneficial,	 clinically	 relevant	 efficacy	
outcomes	are	determinants	for	approval[14].	Strikingly,	scientific	evidence	for	non-approved	ATMPs	
was	unsatisfactory	to	great	extent	as	a	result	of	unresolved	major	issues	related	to	quality,	efficacy	
and	 safety.	 These	 findings	underline	 the	 challenges	 in	 development	of	ATMPs[8,9,21].	Glybera®	 is	
the	only	approved	product	that	appears	to	be	an	exception	to	the	rule	to	be	approved	despite	of	its	
uncertain	benefit/risk	profile.	It	was	approved	after	a	long	regulatory	process	with	a	restricted	label	




as	 well	 as	 the	 underlying	 science	 and	 technology[28].	 As	 the	 field	 develops,	 it	 is	 important	 that	
regulatory	 standards	 (incrementally)	 co-evolve	 to	 tailor	 procedures	 and	 decision-making	 for	 these	






time.	 Thus	 the	 current	 analysis	 reflects	 decision-making	 for	 a	 small	 sample	 of	 first	 generation	
ATMPs,	making	it	difficult	to	draw	generalizable	conclusions	for	the	future.	 It	 is	possible	that	some	




needs	 and	 critical	 scientific	 uncertainties	 that	 may	 hamper	 marketing	 approval.	 in	 this	 context,	
defining	 appropriate	 regulatory	 standards	 taking	 into	 account	 the	 complexities	 inherit	 to	 these	
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trial	 design	 and	 clinical	 outcomes	 are	mandatory	 for	 standard	 approval	 of	 conventional	 products	
[15].	This	suggests	that	EU	regulators	are	exploring	an	appropriate	regulatory	standard	for	ATMPs,	,	
where	conventional	products	may	be	used	as	a	useful	reference.	By	all	means	it	remains	crucial	that	
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of	 conventional	medicinal	 products	 shows	 that	major	 issues	 that	were	unresolved	at	 time	of	 final	
decision	 often	 led	 to	withdrawal	 by	 the	 applicant[23].	 Applications	 for	most	 of	 the	 non-approved	
ATMPs	were	withdrawn	 after	 a	 negative	 opinion	 as	 a	 result	 of	major	 issues.	 Furthermore,	 earlier	
research	 on	 conventional	 medicinal	 products	 showed	 that	 beneficial,	 clinically	 relevant	 efficacy	
outcomes	are	determinants	for	approval[14].	Strikingly,	scientific	evidence	for	non-approved	ATMPs	
was	unsatisfactory	to	great	extent	as	a	result	of	unresolved	major	issues	related	to	quality,	efficacy	
and	 safety.	 These	 findings	underline	 the	 challenges	 in	 development	of	ATMPs[8,9,21].	Glybera®	 is	
the	only	approved	product	that	appears	to	be	an	exception	to	the	rule	to	be	approved	despite	of	its	
uncertain	benefit/risk	profile.	It	was	approved	after	a	long	regulatory	process	with	a	restricted	label	




as	 well	 as	 the	 underlying	 science	 and	 technology[28].	 As	 the	 field	 develops,	 it	 is	 important	 that	
regulatory	 standards	 (incrementally)	 co-evolve	 to	 tailor	 procedures	 and	 decision-making	 for	 these	






time.	 Thus	 the	 current	 analysis	 reflects	 decision-making	 for	 a	 small	 sample	 of	 first	 generation	
ATMPs,	making	it	difficult	to	draw	generalizable	conclusions	for	the	future.	 It	 is	possible	that	some	




needs	 and	 critical	 scientific	 uncertainties	 that	 may	 hamper	 marketing	 approval.	 in	 this	 context,	
defining	 appropriate	 regulatory	 standards	 taking	 into	 account	 the	 complexities	 inherit	 to	 these	
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needs	 and	 critical	 scientific	 uncertainties	 that	 may	 hamper	 marketing	 approval.	 in	 this	 context,	
defining	 appropriate	 regulatory	 standards	 taking	 into	 account	 the	 complexities	 inherit	 to	 these	
products	 in	 critical.	 The	 development,	 regulation	 and	 clinical	 application	 of	 most	 ATMPs	 are	 still	
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needs	 and	 critical	 scientific	 uncertainties	 that	 may	 hamper	 marketing	 approval.	 in	 this	 context,	
defining	 appropriate	 regulatory	 standards	 taking	 into	 account	 the	 complexities	 inherit	 to	 these	




and	 clinical	 practice	 need	 to	 pay	 accurate	 attention	 to	 post-marketing	 surveillance	 and	 risk-
minimization	 measures	 of	 such	 products	 to	 limit	 possible	 patient	 risks.	 For	 the	 field	 to	 flourish,	
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	 Indication	 Oncology,	 cardiovascular	 disease,	 congenital/	 hereditary/	
neonatal	 disease,	 eye	 disease,	 immune	 system	 disease,	
musculoskeletal	disease,	skin	and	connective	tissue	disease	
Target	population	 Lack	of	alternative	therapy	 Yes	 (no	 specific	 medicinal	 product	 treatment	 available	 –	
including	standard	care),	No	
	 Orphan	designation	 Yes,	No	

























































Clinical	outcome	 Significant	 outcome	 on	 primary	
endpoint	
Yes,	No	(trend,	no	effect)	







	 Added	clinical	benefit	 Yes	 (superiority	 over	 alternative	 treatment,	 first	 available	
treatment),	No	(superiority	not	shown	or	not	tested)	
3. Regulatory	process	 Sponsor	type		 Non-profit,	 small	 or	 medium	 sized	 enterprise,	 large	 private	
company	
	 Country	sponsor	 [Country]	












	 Category	 Topic	 Category	uncertainties/objections	
SA	 Quality	 IPC	 Issues	In-process-control	and	validation	
		 		 Release	specification	 Insufficient	release	specification	
		 		 Specific	Release	Test	 No	rapid	microbial	quality	control	due	short	shelf-life	
		 		 Specific	Release	Test	 Comparability	commercial	product	and	trial	product	unclear	
		 		 Specific	Release	Test	 Unvalidated	potency	assay		
		 Design	 Endpoint	 Change	of	endpoint,	GCP	non	compliance	
CA	 Quality	 Specific	Release	Test	 Potency	release	test	insufficient	
		 		 Specific	Release	Test	 Purity	not	demonstrated	(non-proliferation	of	target	cell	not	demonstrated)		
		 		 Specific	Release	Test	 No	rapid	microbial	quality	control	due	short	shelf-life	
UEC	 Quality	 Vector	 Oncogenicity	due	to	structure	
		 		 Specific	Release	Test	 Impurity	due	to	residual	viral	DNA	
		 		 Specific	Release	Test	 Lack	of	replication	assay	for	release	
		 		 Specific	Release	Test	 Potency	specification	unacceptable	
		 Preclinical	 Toxicology	 Lack	of	in	vivo	testing	tumourgenicity	/oncogenicity	
		 Design	 Endpoint	 Change	of	endpoint		
		 Outcome	 Efficacy		 Lack	of	robust	efficacy	outcomes	
		 		 Safety	 Uncertainty	severe	adverse	event	
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		 		 Vector	 Assay	replication	comptent	vector	dissatisfactory	
		 		 Vector	 Risk	associated	with	structure	of	vector	
		 		 Specific	Release	Test	 Inconsistency	of	batches	
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Most	medicinal	 products	dispensed	 to	patients	have	marketing	authorization	 (MA)	 to	ensure	high	
quality	of	the	product,	safety,	and	efficacy.	However,	in	daily	practice,	to	treat	patients	adequately,	
there	 is	 a	 medical	 need	 for	 drugs	 that	 do	 not	 hold	 MA.	 To	 meet	 this	 medical	 need,	 medicinal	
products	 are	 used	 in	 clinical	 care	 without	MA	 (unlicensed),	 such	 as	 products	 prepared	 by	 (local)	
pharmacies:	 the	 pharmaceutical	 preparations.	 Three	 types	 of	 pharmaceutical	 preparations	 are	
distinguished:	(i)	reconstitution	in	excess	of	summary	of	product	characteristics;	(ii)	adaptation	of	a	
licensed	 medicinal	 product	 (outside	 its	 official	 labelling);	 (iii)	 medicinal	 products	 from	 an	 active	
pharmaceutical	 ingredient.	 Although	 unlicensed,	 patients	 may	 expect	 the	 same	 quality	 for	 these	
unlicensed	 pharmaceutical	 preparations	 as	 for	 the	 licensed	 medicinal	 products.	 To	 assure	 this	




In	 this	 paper,	 the	 approach	 for	 good	 documentation	 including	 quality	 assurance	 and	 benefit-risk	






to	ensure	high	quality	of	 the	product,	 safety,	 and	efficacy.	However,	 in	daily	practice,	 it	 turns	out	
that	 there	 is	 a	medical	 need	 for	medicinal	 products	which	 are	 not	 licensed.	 To	meet	 this	medical	
need,	medicinal	products	are	used	in	clinical	care	without	gained	MA	(unlicensed),	such	as	off-label	
use	of	 licensed	medicinal	products[1],	 licensed	medicinal	products	which	are	 imported	 from	other	
countries[2,3],	and	products	prepared	by	(local)	pharmacies:	the	pharmaceutical	preparations[4,5].	
This	 last	 category	 is	 commonly	 used	 in	 regular	 clinical	 care;	 for	 example	 in	 The	 Netherlands,	
approximately	300	unlicensed	active	pharmaceutical	ingredients	(API)	preparations	are	listed	in	the	
Dutch	 drug	 database.	 An	 illustration	 of	 the	 various	 administration	 routes	 of	 the	 pharmaceutical	
preparations	adopted	in	this	Dutch	Drug	Database	per	producer	type	is	shown	in	box	1.	
Box	1.	Overview	of	the	unlicensed	pharmaceutical	preparation	adopted	in	the	Dutch	Drug	Database	




care.	 In	 contrary,	 the	 (hospital)	 pharmacies	 have	 fewer	 preparations	 adopted	 in	 this	 drug	 database;	 most	
frequently,	 high-risk	 preparations,	 eg,	 intravenous	 administration,	 are	 produced	 compared	 with	 the	 company	
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care.	 In	 contrary,	 the	 (hospital)	 pharmacies	 have	 fewer	 preparations	 adopted	 in	 this	 drug	 database;	 most	
frequently,	 high-risk	 preparations,	 eg,	 intravenous	 administration,	 are	 produced	 compared	 with	 the	 company	
preparations.	 The	 category	 “other”	 includes	 low	 numbers	 of	 products	 per	 administration	 route,	 such	 as	
inhalation	and	vaginal	administration.	
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Although	pharmaceutical	 preparations	have	not	been	officially	 approved,	patients	may	 expect	 the	
same	quality	as	the	licensed	medicinal	products.	However,	there	has	not	been	a	formal	benefit-risk	
assessment	 for	 these	 unlicensed	 products[3].	 In	 this	 paper,	 we	 discuss	 the	 different	 types	 of	
pharmaceutical	preparations	and	describe	the	possibilities	to	ensure	safe	use	of	these	products	by	
adequate	 quality	 and	 an	 appropriate	 benefit-risk	 assessment	 focused	 on	 Europe	 and	 The	
Netherlands	(see	box	2	for	a	short	description	of	the	situation	in	the	United	States).	Subsequently,	
the	approach	for	good	documentation	will	be	discussed	and	the	possible	use	of	patient	registries	is	








Magistral	 formulas,	 also	 known	 as	 extemporaneous	 preparations,	 are	 formulas	 prepared	 in	 a	
pharmacy	on	prescription	by	a	physician[9].	The	prescribed	medicinal	product	 is	 for	 individual	use,	
and	 no	 commercial	 product	 is	 available	 or	 sufficiently	 effective.	 Before	 preparation,	 a	 risk	
assessment	 on	 the	 pharmacotherapeutic	 field	 is	 executed	 by	 the	 producer	 and	 documented	 to	
perform	 a	 decision	 based	 on	 efficacy	 and	 safety	 of	 the	 preparation	 for	 treatment	 of	 the	 patient.	




In	 the	 USA	 a	magistral	 formula	 is	 defined	 as	 pharmaceutical	 compounding	 drug,	 which	 is	 described	 in	 the	 US	
Pharmacopoeia	as	a	preparation	produced	based	on	a	prescription	of	a	physician	or	based	on	the	 ‘practitioner-
patient-pharmacist-compounder	relationship6.	To	ensure	safety	and	quality	of	these	compounding	drugs	the	so-
called	 ‘Pharmaceutical	 Quality,	 Security	 and	 Accountability	 Act’	 was	 initiated	 by	 the	 Senate	 and	 House	
committees	of	the	USA[6].	Up	to	now,	the	assurance	of	drug	quality,	safety,	and	efficacy	has	to	be	performed	in	






The	 different	 types	 of	 pharmaceutical	 preparations	 are	 accompanied	 by	 different	 aims	 of	 quality	
levels	 depending	 on	 the	 associated	 risk.	 Whereas	 uniformity	 of	 these	 aims	 was	 lacking	 for	 the	
member	 states	 of	 the	 EU,	 recently,	 the	 Resolution	 CM/ResAP(2011)1[10]	 was	 adapted	 into	 the	
CM/Res(2016)1	to	assure	pharmaceutical	quality	and	estimate	the	risk	of	unlicensed	pharmaceutical	
preparations	using	a	risk	assessment	matrix[8,10].	In	case	of	high-risk	pharmaceutical	preparations,	
quality	 has	 to	 be	 guaranteed	 by	 meeting	 with	 good	 manufacturing	 practices	 (GMP)[8].	 The	




While	 health	 practitioners	 are	 obliged	 to	 report	 adverse	 events	 of	 both	 licensed	 and	 unlicensed	
medicinal	products,	there	is	no	systematic	check	on	safety,	efficacy,	and	pharmacovigilance	for	 the	
unlicensed	products.	According	 to	a	 review	from	the	European	Medicines	Agency	 (EMA),	 it	 turned	
out	 that	 adverse	 events	 of	 unlicensed	 (and	 off-label	 used)	 medicinal	 products	 were	 under	
registered[1,12].	Furthermore,	in	cases	of	registered	adverse	events,	unlicensed	medicinal	products	
were	more	 frequently	 associated	 with	 adverse	 events	 than	 licensed	medicinal	 products[1,12].	 To	
ensure	 safety	 for	 these	 patients	 the	 adverse	 events	 of	 unlicensed	 medicinal	 products	 should	 be	
documented.	This	 is	 in	 line	with	Regulation	 (EU)	No	1027/2012,	which	states	 that	 the	producer	of	





such	 individual	 cases,	both	 the	prescriber	and	 the	preparing	pharmacist	have	an	 important	 role	 in	
ensuring	 quality	 and	 safety	 of	 the	 product	 and	 informing	 the	 patient.	 There	 should	 be	 a	 good	
balance	between	the	benefit	of	the	magistral	formulas	and	the	risk	of	receiving	a	product	with	lower	
quality	 assurance	 than	 a	 product	 with	 MA.	 Finally,	 pharmaceutical	 quality	 and	 safety	 of	
pharmaceutical	 preparations	 practice	 should	 be	 verified	 via	 inspections	 executed	 by	 the	 national	
healthcare	inspectorate	or	other	competent	authorities[8].	
Whereas	 magistral	 formulas	 are	 based	 on	 physician’s	 prescriptions	 and	 intended	 for	 individual	
patients,	 for-stock	 pharmaceutical	 preparations	 can	 be	 prepared	 for	 a	 small	 (in-house)	 patient	
cohort[6].	 These	 for-stock	 unlicensed	 medicinal	 products	 are	 prepared	 by	 pharmacists	 or	 other	
institutions	with	a	“license	for	manufacturing”[8].	In	these	cases,	licensing	of	the	individual	products	
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The	 requirements	 for	 magistral	 and	 stock	 preparations	 are	 the	 same;	 however,	 for	 for-stock	
preparations	 more	 controls	 (eg,	 analytic	 end	 control)	 are	 needed	 compared	 with	 the	 magistral	




















the	 package	 leaflet”,	 according	 to	 the	 European	 Directorate	 of	 Quality	 of	 Medicines	 (EDQM)[8].	
















Figure	 1.	 Schematic	 overview	of	 pharmaceutical	 preparations.	Pharmaceutical	 preparations	 can	 be	 divided	
into	three	different	types:	reconstitution	in	excess	of	SmPC	preparation	 instructions,	adaptation	of	a	licensed	





The	 require ents	 for	 agistral	 and	 stock	 preparations	 are	 the	 sa e;	 however,	 for	 for-stock	
preparations	 ore	 controls	 (eg,	 analytic	 end	 control)	 are	 needed	 co pared	 with	 the	 agistral	
for ulas.	 For	 such	 preparations,	 docu entation	 is	 required	 in	 a	 for at	 of	 a	 product	 dossier	 as	
described	in	Resolution	C /Res(2016)1,[8]	which	is	 ore	extensive	than	for	 agistral	for ulas.[15]	
For	exa ple,	 infor ation	about	the	release	quality	control	(QC),	validation,	and	stability	should	be	






preparations	 including	 their	 require ents	 and	 practical	 elaboration	 of	 these	 require ents	 for	
quality	assurance	and	benefit-risk	assess ents,	see	figure	1,	consisting	of	reconstitution	in	excess	of	






Reconstitution	can	be	defined	as	“ anipulation	to	enable	the	use	or	ad inistration	of	a	 edicinal	
product	for	products	with	a	 arketing	authorisation	issued	by	any	co petent	 edicines	regulatory	
authority,	the	reconstitution	is	carried	out	in	accordance	with	the	instructions	given	in	the	S PC	or	
the	 package	 leaflet”,	 according	 to	 the	 European	 Directorate	 of	 Quality	 of	 edicines	 (EDQ )[8].	
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national	authorities[6,8].	Here,	we provide	an	over i w	of	the	different	types	of	pharmaceutical		
pre arations	 including	 their	 requirem nts	 and	 practical	 elaboration	 of these	 r quirem nts	 for	
quality	assurance	and	benefit-risk	asse ments,	see	figure	1,	consisting	of	reconstitu on	in	exc ss	of	
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Figure	 1.	 Schematic	 overvi w	 of	 pharmaceutical	 pre arations.	Pharm ceutical	 pre arations	 can	 be	 divi ed	
into	three	different	types:	reconstitu ion	 n	exc ss	of	SmPC	pre aration	 nstructions,	adaptation	 f	a	licens d	
medicinal	 product,	 and	 medicinal	 product	 from	 an	 active	 pharm ceutical	 ingredient.	 API	 =	 active	
pharm ceutical	 ngredient,	SmPC	=	Summary	of	Product	Characteristic .	
	
	
practice[15–17].	 In	 practice,	 reconstitution	 can	 be	 done	 in	 a	 more	 efficient	 way	 by	 preparing	
products	on	a	 larger	scale	 in	central	units;	eg,	 ready-to-administer	 syringes	can	be	used	as	service	
products	by	various	departments	 in	the	hospital.	These	pharmaceutical	preparations	are	graded	as	
high	risk[8].		Like	the	magistral	formulas,	these	preparations	are	based	on	the	SmPC	of	a	product	and	
reconstitution	 by	 the	 pharmacy	 reduces	 risks	 of	 miscalculations	 and	 contamination[18,19].	
Reconstitution	 can	 be	 executed	 conform	 good	 nursing	 practice	 in	 clinical	 areas,	 where	 upscaling	
above	a	certain	volume	leads	to	increasing	risks	because	a	deficient	product	may	affect	the	health	of	
a	considerable	number	of	patients.	This	requires	enhanced	quality	assurance	via	release	controls	and	
an	 increased	 level	 of	 documentation	 in	 the	 product	 dossier.	 Due	 to	 production	 of	 batches,	 the	
preservability	 of	 the	 products	 must	 be	 extended.	 Microbiological	 validation	 will	 require	 several	
actions	such	as	process	validation	and	environmental	monitoring[20].	Because	these	manipulations	
are	executed	with	 licensed	medicinal	products,	pharmacovigilance	would	be	possible.	 It	 is	possible	
to	submit	pharmaceutical	preparations	to	a	(national)	database	for	pharmacovigilance,	and	 in	case	
this	 preparation	 is	 based	 on	 a	 licensed	 product,	 the	 pharmacovigilance	 information	 is	 already	




medicinal	 products	 take	place	outside	 the	official	 labelling,	 eg,	 phenprocoumon	oral	 suspension	1	
mg/ml	prepared	 from	3-mg	 licensed	tablets[21].	An	example	 is	amending	 the	dissolution	stated	 in	
the	 SmPC	 or	 changing	 the	 concentration	 when	 needed	 to	 adequately	 treat	 a	 patient.	 To	 ensure	
patient	 safety,	 a	 concise	product	dossier,	 including	 a	 substantiated	 rationale,	 should	be	prepared.	
Furthermore,	 it	 is	 necessary	 to	 evaluate	 efficacy	 and	 safety	 of	 such	 manipulations	 and	 add	 this	
information	to	the	product	dossier[15].	When	there	 is	a	 frequent	need	for	this	manipulation	of	an	
existing	product,	 it	can	be	modified	from	magistral	 to	for	stock	preparation.	This	will	 lead	to	more	
extensive	 QC	 and	 documentation.	 Based	 on	 documentation	 in	 the	 product	 dossier	 of	 magistral	
formulas,	data	are	available	to	endorse	safety	and	efficacy	of	such	preparations.	Pharmacovigilance	
can	 be	 performed	based	on	 the	 information	 from	 the	 SmPC	of	 the	 licensed	 formulation,	which	 is	
again	the	responsibility	of	the	producer.		
2.7	Active	pharmaceutical	ingredient		
For	 some	 patients,	 preparing	 from	 APIs	 can	 be	 necessary[21].	 Examples	 of	 these	 products	 are	
polymyxin-neomycin	 tablets	 and	 isoniazid	 injections[22].	 As	 described	 in	 section	 2.6,	 for	 these	
unlicensed	 APIs,	 a	 concise	 product	 dossier	 to	 ensure	 safety	 is	 necessary.	 Results	 from	 studies	
investigating	efficacy	and	safety	can	improve	such	dossier[15].	Moreover,	risk	assessment	will	decide	





The	 requirements	 for	 magistral	 and	 stock	 preparations	 are	 the	 same;	 however,	 for	 for-stock	
preparations	 more	 controls	 (eg,	 analytic	 end	 control)	 are	 needed	 compared	 with	 the	 magistral	




















the	 package	 leaflet”,	 according	 to	 the	 European	 Directorate	 of	 Quality	 of	 Medicines	 (EDQM)[8].	
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Interestingly,	 the	 prices	 of	 these	 medicinal	 products	 sometimes	 increased	 excessively,	 e.g.	
amifampridine	 for	 Lambert-Eaton-myasthenic	 syndrome	 (LEMS)	 and	 zinc	 acetate	 for	 Wilson’s	
disease[23].	For	such	pharmaceutical	preparations,	it	may	be	interesting	to	assess	the	possibility	to	
start	an	MA	process	in	a	not-for-profit	organisation,	based	on	data	from	experience	in	regular	care	










of	 pharmaceutical	 preparations	 by	 standardization	of	 a	 series	 of	 pharmaceutical	 preparations[25],	





adverse	 events	 and	 safety	 issues.	 This	 example	 from	 the	 Netherlands	 shows	 that	 there	 are	
possibilities	of	performing	pharmacovigilance	with	unlicensed	pharmaceutical	preparations.	
Currently,	 international	organisations	are	also	 initiated	to	collect	and	analyze	adverse	drug	events,	
such	 as	 the	 worldwide	 Uppsala	 Monitoring	 Centre	 set	 up	 by	 the	 World	 Health	 Organization	
(WHO)[26].	By	combining	these,	the	quality	assurance,	and	pharmacovigilance	database,	safe	use	of	
products	is	well	monitored.		
Unfortunately,	 for	active	pharmaceutical	preparations	 indicated	 for	 (ultra)	orphan	 indications	such	
	
	
FNA	 license	 is	 often	not	 available,	 due	 to	 small	 patient	numbers	 and	 centralized	 treatment.	 Thus,	
quality	 and	 a	 proper	 benefit-risk	 assessments	 should	 be	 ensured	 by	 good	 documentation	 of	 the	
preparing	 pharmacy.	 Furthermore,	 pharmacotherapy	 control	 and	 pharmacovigilance	 are	 not	 yet	
standard	 available	 for	APIs.	 Pharmaceutical	 preparations	with	 a	 long	history	of	 use	 and	 for	 (ultra)	
orphan	indications,	such	as	3,4-DAP	(see	box	3),	should	leverage	on	the	available	documentation	in	
patient	 files	covering	 information	of	 the	treatment,	 including	preparation	batches,	adverse	events,	
and	 efficacy	 data.	 By	 collecting	 more	 data	 from	 clinical	 experience,	 eg,	 in	 patient	 registries,	 an	
appropriate	 benefit-risk	 assessment	 can	 be	 made,	 which	 also	 generates	 more	 possibilities	 in	
pharmacovigilance	for	these	products.		
Nowadays,	patient	registries	are	available	in	all	different	formats	and	can	be	organised	by	different	
organizations	 and/or	 different	 parties	 such	 as	 healthcare	 practitioners	 (including	 researchers)	 or	
patients,	 resulting	 in	 nonuniform	 data	 collections[27].	 By	 creating	 a	 (central)	 patient	 registry	 for	
specific	 orphan	medicinal	 conditions,	 the	 effectiveness	 of	 treatments	 can	 be	 collected	 and	 safety	
data	can	be	assessed	after	a	specific	time	of	use[28].	Patient-powered	patient	registries	are	mostly	
controlled	 by	 patients	 and/or	 their	 family	 and	 cannot	 be	 filled	 in	 by	 all	 patients	 correctly,	 for	





Centre,	 which	 creates	 opportunities	 to	 increase	 the	 pharmacovigilance	 for	 orphan	 unlicensed	
medicinal	products.	
	
In	 conclusion,	 ensuring	 pharmaceutical	 quality	 and	 performing	 a	 proper	 benefit-risk	 assessment,	
followed	 by	 good	 documentation	 will	 guarantee	 safe	 use	 of	 pharmaceutical	 preparations.	 While	
national	formulary	labels	confirm	quality	and	have	implemented	pharmacovigilance	of	the	products,	
this	 license	 is	mostly	unavailable	 for	ultra-orphan	preparations.	Therefore,	good	documentation	of	
these	 treatments	 can	 be	 collected	 in	 centralized	 patient	 registries	 and	 should	 be	 combined	 with	
existing	 information	 in	 (inter)national	databases	and	 self-reflection	of	patients.	 Such	 registries	will	
enable	 pharmacovigilance	 and	 control	 of	 the	 usage	 of	 these	 medicinal	 products.	 Linking	 these	
patient	 registries	 to	 a	 centralized	 database	 for	 adverse	 drug	 events	 is	 highly	 recommended	 as	 it	
increases	safety	control	of	 the	(ultra)	orphan	pharmaceutical	preparations.	Follow-up	of	a	recently	
started	patient	 registry	 for	 LEMS	and	Myasthenia	Gravis	patients	 is	an	 interesting	development	 to	
monitor	 the	 safe	 use	 of	 3,4-DAP.	 This	 approach	 provides	 a	 solution	 to	 ensure	 safe	 use	 of	
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Pharmaceutical	 preparations,	 produced	 by	 (hospital)	 pharmacies,	 usually	 do	 not	 have	 marketing	
authorization.	As	a	consequence,	some	of	these	pharmaceutical	preparations	can	be	picked-up	by	a	
pharmaceutical	 company	 to	 retrieve	marketing	 authorization,	 often	 leading	 to	 price	 increases.	 An	
example	is	the	3,4-diaminopyridine	slow	release	(3,4-DAP	SR)	tablets	for	Lambert-Eaton	Myasthenic	
Syndrome	(LEMS).	In	2009	marketing	authorization	was	given	for	the	commercial	immediate	release	
phosphate	 salt	 of	 the	 drug,	 including	 a	 fifty-fold	 price	 increase	 compared	 to	 the	 pharmaceutical	
preparation.	 Obtaining	 marketing	 authorization	 for	 3,4-DAP	 SR	 by	 academia	 might	 have	 been	 a	
solution	to	prevent	this	price	increase.	To	determine	whether	the	available	data	of	a	pharmaceutical	
preparation	 with	 long-term	 experience	 in	 regular	 care	 are	 adequate	 to	 retrieve	 marketing	
authorization,	3,4-DAP	SR	is	used	as	a	case	study.		
A	retrospective	qualitative	case-study	was	performed.	Initially,	document	analysis	was	executed	by	
collecting	 the	 required	data	 for	marketing	 authorization	 in	 general	 and	whether	data	of	 Firdapse®	
and	3,4-DAP	SR	met	these	requirements.	Secondly,	the	(non-)	available	data	of	the	two	formulations	
were	compared	with	each	other	to	determine	the	differences	in	availability.	
	At	 the	 time	 of	 approval,	 almost	 all	 data	 were	 available	 for	 both	 Firdapse®	 and	 3,4-DAP	 SR.	
Conversely,	 much	 of	 the	 data	 used	 for	 the	 approval	 of	 Firdapse®	 originated	 from	 the	 3,4-DAP	
immediate	release	(3,4-DAP	IR)	formulation.	Only	two	bioequivalence	studies	and	one	pharmacology	
safety	study	was	performed	with	Firdapse®	before	marketing	authorization	application.		
In	 conclusion,	 at	 time	 Firdapse®	 retrieved	 approval,	 the	 data	 available	 did	 not	 differ	 substantially	
from	3,4-DAP	SR,	 indicating	 that	approval	with	3,4-DAP	SR	would	have	been	possible.	We	make	a	






The	 Lambert-Eaton	 Myasthenic	 Syndrome	 (LEMS)	 is	 an	 ultra-orphan	 autoimmune	 disease	 of	 the	
neuromuscular	junction[1,2]	with	a	prevalence	of	0·35:100	000[3,4].	Currently,	due	to	lacking	curing	
treatment	 of	 LEMS,	 symptoms	 can	 be	 relieved	 by	 preferably	 symptomatic	 or	 immunomodulating	




in	 2009	 a	 third	 type	 of	 3,4-DAP	 received	 marketing	 authorization	 in	 Europe,	 Firdapse®[7],	 an	
immediate	 release	 phosphate	 salt,	 see	 table	 1.	 Due	 to	 the	 licensed	 status	 of	 Firdapse®	 and	 the	
obtained	orphan	designation	status,	including	ten	years	of	market	exclusivity,	the	two	other	3,4-DAP	
formulations	were	not	allowed	anymore	 for	 treating	 LEMS	 in	most	 countries	despite	 the	 fact	 that	





Name		 Base/phosphate	 Immediate/slow	release	 Trade	Name	
3,4-DAP	IR	 Base	 Immediate	 NA	(pharmaceutical	preparation)	
3,4-DAP	SR	 Base	 Slow	 NA	(pharmaceutical	preparation)	
3,4-DAP	phosphate	 Phosphate	 Immediate	 Firdapse®	
	
For	Firdapse®,	obtaining	complete	data	for	marketing	authorization	submission	was	not	possible	due	
to	 the	 rarity	 of	 the	 disease.	 Therefore,	 this	 medicinal	 product	 is	 approved	 ‘under	 exceptional	
circumstances’[7].	 After	 the	 approval	 of	 Firdapse®,	 a	 substantial	 increase	 in	 pricing	 occurred	
compared	to	the	costs	for	the	available	pharmaceutical	preparations	3,4-DAP	SR	and	IR[10].	This	rise	
in	costs	negatively	influenced	regular	LEMS	patient	care:	e.g.	in	the	United	Kingdom,	due	to	the	50-
fold	 increase	 in	 costs,	 health	 care	 insurances	were	 not	willing	 to	 pay	 these	 extra	 costs,	while	 the	
pharmaceutical	formulations	were	forbidden	to	be	provided	to	patients,	resulting	in	inaccessibility	of	
3,4-DAP	 as	 a	 treatment	 for	 LEMS	 patients[11,12].	 Alternatively,	 in	 The	 Netherlands	 the	 Dutch	
Minister	 of	 Health,	Welfare	 and	 Sport	 decided	 that	 due	 to	 the	modified	 release	 profile	 of	 the	 SR	
formulation	and	the	undesirable	additional	costs	of	Firdapse®,	estimated	at	€1·8	million	per	year	for	
the	40-70	treated	patients,	3,4-DAP	SR	was	still	allowed	for	the	treatment	of	LEMS	patients[10].	
Several	 pharmaceutical	 preparations,	 such	 as	 3,4-DAP	 IR	 and	 SR,	 are	 produced	 in	 the	 (fully	 Good	
Manufacturing	 Practices	 (GMP)	 licensed	 hospital)	 pharmacies.	 In	most	 cases,	 these	 are	medicinal	
products	for	(ultra-)	orphan	diseases	and	arise	from	ad	hoc	preparations.	Sometimes,	in	case	such	ad	
hoc	preparation	 is	prescribed	more	 frequently,	 these	preparations	can	be	scaled	up	 to	 (small)	 for-
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the	40-70	treated	patients,	3,4-DAP	SR	was	still	allowed	for	the	treatment	of	LEMS	patients[10].	
Several	 pharmaceutical	 preparations,	 such	 as	 3,4-DAP	 IR	 and	 SR,	 are	 produced	 in	 the	 (fully	 Good	
Manufacturing	 Practices	 (GMP)	 licensed	 hospital)	 pharmacies.	 In	most	 cases,	 these	 are	medicinal	
products	for	(ultra-)	orphan	diseases	and	arise	from	ad	hoc	preparations.	Sometimes,	in	case	such	ad	
hoc	preparation	 is	prescribed	more	 frequently,	 these	preparations	can	be	scaled	up	 to	 (small)	 for-
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hoc	preparation	 is	prescribed	more	 frequently,	 these	preparations	can	be	scaled	up	 to	 (small)	 for-
stock	preparations[13].	These	 for-stock	preparations	 increase	the	requirements	 for	documentation	
of	 the	 product	 and	 its	 quality	 assurance	 and	 lead	 to	 substantial	 experience	 with	 such	 medicinal	
products	 in	 regular	 care	 “Unpublished	 Observations,	 S.	 de	 Wilde	 et	 al.”[13].	 However,	 these	
unlicensed	pharmaceutical	preparations	can	easily	be	picked	up	by	the	pharmaceutical	industry,	and	
in	 some	 cases	 receive	 a	 license	 with	 a	 substantially	 higher	 price	 tag	 in	 comparison	 with	 the	




Licensing	of	 a	medicinal	product	guarantees	a	 level	of	quality,	 efficacy,	 and	 safety	of	 the	product.	
Moreover,	 industrial	 production	 is	 more	 rigidly	 monitored	 compared	 to	 pharmaceutical	
preparations[13].	Due	to	this	extra	monitoring,	it	is	reasonable	that	the	costs	for	treatment	increase	
compared	to	the	regular	therapy	with	pharmaceutical	preparations.	However,	due	to	the	ten	years	
market	exclusivity	and	 the	small	market	 size,	prices	 for	 (ultra-)	orphan	drugs	often	 rise	more	 than	
desired[15,16].	 In	some	cases,	 the	 increase	can	be	disproportionate	to	the	 limited	efforts	required	




a	 case	 study.	 The	 available	 data	 of	 3,4-DAP	 SR	 will	 be	 compared	 with	 the	 data	 of	 the	 licensed	
Firdapse®,	to	investigate	whether	3,4-DAP	SR	could	have	been	licensed	at	the	same	time	as	Firdapse®	
did	and/or	which	additional	 studies	are	 still	 required	 to	 retrieve	marketing	authorization	with	3,4-
DAP	 SR.	 The	 goal	 of	 investigating	 marketing	 authorization	 possibilities	 for	 the	 pharmaceutical	
preparation	3,4-DAP	SR	is	to	guarantee	regular	patient	care	at	a	reasonable	price.	Recommendations	













A	 retrospective	 qualitative	 case-study	 was	 performed	 with	 3,4-DAP	 SR	 and	 Firdapse®.	 Initially,	 a	

















1.	 The	 scored	 data	 were	 subcategorized	 in	 quality	 (see	 supplementary	 1),	 non-clinical	 (see	
supplementary	2)	and	clinical	aspects	(see	supplementary	3)	like	the	AR	of	Firdapse®.		
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Firdapse®	 and	 could	 be	 extended	 for	 3,4-DAP	 SR.	 Also,	 data	 from	 3,4-DAP	 IR,	 obtained	 from	
literature,	was	used	for	the	in	vivo	data	of	3,4-DAP	SR[21,22].	
Limited	 pharmacokinetic	 data	 were	 available	 for	 both	 product	 formulations,	 and	 absorption	 data	


















	 	 	 	 Missing	data	
	 	 Firdapse®	 3,4-DAP	SR	


























Firdapse®	 and	 could	 be	 extended	 for	 3,4-DAP	 SR.	 Also,	 data	 from	 3,4-DAP	 IR,	 obtained	 from	
literature,	was	used	for	the	in	vivo	data	of	3,4-DAP	SR[21,22].	
Limited	 pharmacokinetic	 data	 were	 available	 for	 both	 product	 formulations,	 and	 absorption	 data	















DAP	 IR.	A	pharmacokinetic	 study	 in	 healthy	 volunteers	was	 conducted	 after	 approval	 of	 Firdapse®	
and	published	 in	2014[24],	see	supplementary	3.	At	the	time	of	approval,	 these	data	were	not	yet	
provided,	 thus	 the	 available	 data	 were	 similar	 to	 3,4-DAP	 SR.	 Data	 about	 the	 pharmacokinetic	
interactions	and	pharmacokinetics	using	human	biomaterials	were	not	available	for	both	products.	
The	 presented	 pharmacodynamic	 data	 of	 3,4-DAP	 SR	 were	 the	 same	 as	 Firdapse®	 (see	
supplementary	 3).	 The	 primary	 pharmacology,	 the	 relation	 between	 plasma	 concentration	 and	
effect,	 and	 the	 pharmacodynamic	 interactions	 with	 other	medicinal	 products	 or	 substances	 were	
acquired	from	3,4-DAP	IR	for	both	products.	For	the	clinical	efficacy	and	safety	almost	all	 required	
data	 were	 available	 for	 both	 Firdapse®	 and	 3,4-DAP	 SR,	 with	 the	 exception	 of	 data	 for	 special	
populations,	 such	as	patients	with	hepatic	or	 renal	 impairment	 (see	supplementary	3).	Due	 to	 the	
long-term	availability	of	3,4-DAP	SR,	more	experience	in	patients	has	been	established	compared	to	
Firdapse®	
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In	 this	 study,	 the	 AR	 of	 the	 licensed	 Firdapse®	 and	 the	 product	 dossier	 of	 the	 pharmaceutical	









authorization[7].	 Due	 to	 the	 demonstrated	 bioequivalence	 studies,	 with	 equal	 areas	 under	 the	
curves	(AUC)	for	both	Firdapse®	and	3,4-DAP	IR,	bridging	of	(non-)	clinical	data	from	3,4-DAP	IR	was	
justified	 for	 Firdapse®.	 The	 equal	 AUCs	 support	 the	 assumption	 that	 efficacy	 between	 those	 two	
medicinal	products	is	identical[25].	
After	 marketing	 authorization	 approval,	 additional	 studies	 were	 required	 by	 the	 EMA.	 For	 non-
clinical	 data,	 a	 carcinogenicity	 and	 a	 reproduction	 toxicity	 study	 still	 had	 to	 be	 performed.	
Furthermore,	a	clinical	pharmacokinetic	study,	concerning	the	effects	of	food	intake[26]	and	genetic	
variation	 in	 aryl	 N-acetyltransferase[24],	 was	 required.	 All	 required	 additional	 studies	 were	
conducted,	except	for	the	non-clinical	carcinogenicity	study[7].	At	last,	more	data	about	the	clinical	
efficacy	and	 safety	had	 to	be	obtained,	which	was	achieved	by	executing	a	phase	 III,	 randomised,	
double-blinded	 clinical	 trial[27],	 on	 the	 company’s	 own	 initiative,	 and	 by	 the	 establishment	 of	 an	
LEMS	 patient	 registry	 in	 Europe[28].	 With	 the	 patient	 registry,	 additional	 long-term	 efficacy	 and	





be	 used	 for	 the	 SR	 formulation,	 since	 both	 pharmaceutical	 formulations	 contain	 the	 same	 active	
ingredient,	as	shown	in	figure	2.	It	 is	also	expected	that	the	exposure	is	the	same	as	3,4-DAP	IR	(in	
case	 the	 active	 ingredient	 is	 completely	 absorbed)[25,29].	 To	 confirm	 these	 assumptions,	 a	
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authorization[7].	 Due	 to	 the	 demonstrated	 bioequivalence	 studies,	 with	 equal	 areas	 under	 the	
curves	(AUC)	for	both	Firdapse®	and	3,4-DAP	IR,	bridging	of	(non-)	clinical	data	from	3,4-DAP	IR	was	
justified	 for	 Firdapse®.	 The	 equal	 AUCs	 support	 the	 assumption	 that	 efficacy	 between	 those	 two	
medicinal	products	is	identical[25].	
After	 marketing	 authorization	 approval,	 additional	 studies	 were	 required	 by	 the	 EMA.	 For	 non-
clinical	 data,	 a	 carcinogenicity	 and	 a	 reproduction	 toxicity	 study	 still	 had	 to	 be	 performed.	
Furthermore,	a	clinical	pharmacokinetic	study,	concerning	the	effects	of	food	intake[26]	and	genetic	
variation	 in	 aryl	 N-acetyltransferase[24],	 was	 required.	 All	 required	 additional	 studies	 were	
conducted,	except	for	the	non-clinical	carcinogenicity	study[7].	At	last,	more	data	about	the	clinical	
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long-term	 experience	 in	 patients.	 Up	 to	 now,	 no	 severe,	 likely	 related	 adverse	 events	 have	 been	
reported	 at	 the	 Dutch	 pharmacovigilance	 database	 (Lareb)	 taking	 into	 account	 that	 no	 official	
pharmacovigilance	has	been	performed	yet.	
Scoring	of	 the	availability	of	 the	aspects,	“yes”	or	“no”,	 in	 the	AR	or	 in	 the	product	dossier	do	not	
reflect	 the	 extensiveness	 of	 the	 available	 data.	 An	 extensive	 amount	 of	 the	 required	 data	 for	
marketing	 authorization	was	 discussed	 in	 the	 AR	 of	 Firdapse®,	 but	 sometimes	 the	 data	were	 only	
briefly	described.	Also	for	3,4-DAP	SR,	not	all	the	data	are	comprehensively	described,	for	example,	
the	quality	part	is	not	as	extensively	described	as	Firdapse®.	Whereas	parts	of	the	guideline	are	very	





Figure	2.	 Chemical	 structures	of	 3,4-diaminopyridine	base	and	3,4-diaminopyridine	phosphate	 (Firdapse®).	
Figure	adapted	 from	Lindquist,	2011[34].	Both	3,4-DAP	base	and	3,4-DAP	phosphate	 (Firdapse®)	 contain	 the	
same	active	ingredient.	3,4-DAP	=	3,4-diaminopyridine;	SR	=	Slow	release.	
Furthermore,	 we	 have	 to	 keep	 in	mind	 that	 the	 Firdapse®	 and	 3,4-DAP	 SR	 is	 a	 specific	 case	 of	 a	
pharmaceutical	 preparation,	 and	 in	 order	 to	 apply	 for	 licensing	 a	 high	 level	 of	 documentation	 is	
needed.	 However,	 we	 think	 that	 this	 example	 clarifies	 the	 possibilities	 of	 pharmaceutical	
preparations	towards	licensing	as	a	possibility	to	keep	treatment	available	at	reasonable	costs.	
Another	possibility	 to	avoid	 tremendous	 increases	 in	pricing	after	 licensing	 former	pharmaceutical	
preparations	 can	 be	 established	 by	 more	 involvement	 from	 the	 government	 in	 protecting	 the	
purpose	of	the	(ultra-)	orphan	drug	designation.	For	example,	 in	case	the		(ultra-)orphan	medicinal	
product	 exceeds	 the	number	of	 50	 000	patients	 using	 it[4],	 the	qualification	of	 an	 (ultra-)	 orphan	
drug	expires	and	 the	exclusivity	period	can	be	decreased[30].	 In	 Japan,	pharmaceutical	 companies	
pay	 a	 1%	 sales	 tax	 on	 orphan	 drugs	 with	 annual	 profits	 exceeding	 100	 million	 Japanese	 yen	













DAP	 IR.	A	pharmacokinetic	 study	 in	 healthy	 volunteers	was	 conducted	 after	 approval	 of	 Firdapse®	
and	published	 in	2014[24],	see	supplementary	3.	At	the	time	of	approval,	 these	data	were	not	yet	
provided,	 thus	 the	 available	 data	 were	 similar	 to	 3,4-DAP	 SR.	 Data	 about	 the	 pharmacokinetic	
interactions	and	pharmacokinetics	using	human	biomaterials	were	not	available	for	both	products.	
The	 presented	 pharmacodynamic	 data	 of	 3,4-DAP	 SR	 were	 the	 same	 as	 Firdapse®	 (see	
supplementary	 3).	 The	 primary	 pharmacology,	 the	 relation	 between	 plasma	 concentration	 and	
effect,	 and	 the	 pharmacodynamic	 interactions	 with	 other	medicinal	 products	 or	 substances	 were	
acquired	from	3,4-DAP	IR	for	both	products.	For	the	clinical	efficacy	and	safety	almost	all	 required	
data	 were	 available	 for	 both	 Firdapse®	 and	 3,4-DAP	 SR,	 with	 the	 exception	 of	 data	 for	 special	
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authorization[7].	 Due	 to	 the	 demonstrated	 bioequivalence	 studies,	 with	 equal	 areas	 under	 the	
curves	(AUC)	for	both	Firdapse®	and	3,4-DAP	IR,	bridging	of	(non-)	clinical	data	from	3,4-DAP	IR	was	
justified	 for	 Firdapse®.	 The	 equal	 AUCs	 support	 the	 assumption	 that	 efficacy	 between	 those	 two	
medicinal	products	is	identical[25].	
After	 marketing	 authorization	 approval,	 additional	 studies	 were	 required	 by	 the	 EMA.	 For	 non-
clinical	 data,	 a	 carcinogenicity	 and	 a	 reproduction	 toxicity	 study	 still	 had	 to	 be	 performed.	
Furthermore,	a	clinical	pharmacokinetic	study,	concerning	the	effects	of	food	intake[26]	and	genetic	
variation	 in	 aryl	 N-acetyltransferase[24],	 was	 required.	 All	 required	 additional	 studies	 were	
conducted,	except	for	the	non-clinical	carcinogenicity	study[7].	At	last,	more	data	about	the	clinical	
efficacy	and	 safety	had	 to	be	obtained,	which	was	achieved	by	executing	a	phase	 III,	 randomised,	
double-blinded	 clinical	 trial[27],	 on	 the	 company’s	 own	 initiative,	 and	 by	 the	 establishment	 of	 an	
LEMS	 patient	 registry	 in	 Europe[28].	 With	 the	 patient	 registry,	 additional	 long-term	 efficacy	 and	





be	 used	 for	 the	 SR	 formulation,	 since	 both	 pharmaceutical	 formulations	 contain	 the	 same	 active	
ingredient,	as	shown	in	figure	2.	It	 is	also	expected	that	the	exposure	is	the	same	as	3,4-DAP	IR	(in	
case	 the	 active	 ingredient	 is	 completely	 absorbed)[25,29].	 To	 confirm	 these	 assumptions,	 a	
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long-term	 experience	 in	 patients.	 Up	 to	 now,	 no	 severe,	 likely	 related	 adverse	 events	 have	 been	
reported	 at	 the	 Dutch	 pharmacovigilance	 database	 (Lareb)	 taking	 into	 account	 that	 no	 official	
pharmacovigilance	has	been	performed	yet.	
Scoring	of	 the	availability	of	 the	aspects,	“yes”	or	“no”,	 in	 the	AR	or	 in	 the	product	dossier	do	not	
reflect	 the	 extensiveness	 of	 the	 available	 data.	 An	 extensive	 amount	 of	 the	 required	 data	 for	
marketing	 authorization	was	 discussed	 in	 the	 AR	 of	 Firdapse®,	 but	 sometimes	 the	 data	were	 only	
briefly	described.	Also	for	3,4-DAP	SR,	not	all	the	data	are	comprehensively	described,	for	example,	
the	quality	part	is	not	as	extensively	described	as	Firdapse®.	Whereas	parts	of	the	guideline	are	very	





Figure	2.	 Chemical	 structures	of	 3,4-diaminopyridine	base	and	3,4-diaminopyridine	phosphate	 (Firdapse®).	
Figure	adapted	 from	Lindquist,	2011[34].	Both	3,4-DAP	base	and	3,4-DAP	phosphate	 (Firdapse®)	 contain	 the	
same	active	ingredient.	3,4-DAP	=	3,4-diaminopyridine;	SR	=	Slow	release.	
Furthermore,	 we	 have	 to	 keep	 in	mind	 that	 the	 Firdapse®	 and	 3,4-DAP	 SR	 is	 a	 specific	 case	 of	 a	
pharmaceutical	 preparation,	 and	 in	 order	 to	 apply	 for	 licensing	 a	 high	 level	 of	 documentation	 is	
needed.	 However,	 we	 think	 that	 this	 example	 clarifies	 the	 possibilities	 of	 pharmaceutical	
preparations	towards	licensing	as	a	possibility	to	keep	treatment	available	at	reasonable	costs.	
Another	possibility	 to	avoid	 tremendous	 increases	 in	pricing	after	 licensing	 former	pharmaceutical	
preparations	 can	 be	 established	 by	 more	 involvement	 from	 the	 government	 in	 protecting	 the	
purpose	of	the	(ultra-)	orphan	drug	designation.	For	example,	 in	case	the		(ultra-)orphan	medicinal	
product	 exceeds	 the	number	of	 50	 000	patients	 using	 it[4],	 the	qualification	of	 an	 (ultra-)	 orphan	
drug	expires	and	 the	exclusivity	period	can	be	decreased[30].	 In	 Japan,	pharmaceutical	 companies	
pay	 a	 1%	 sales	 tax	 on	 orphan	 drugs	 with	 annual	 profits	 exceeding	 100	 million	 Japanese	 yen	
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Furthermore,	 we	 have	 to	 keep	 in	mind	 that	 the	 Firdapse®	 and	 3,4-DAP	 SR	 is	 a	 specific	 case	 of	 a	
pharmaceutical	 preparation,	 and	 in	 order	 to	 apply	 for	 licensing	 a	 high	 level	 of	 documentation	 is	
needed.	 However,	 we	 think	 that	 this	 example	 clarifies	 the	 possibilities	 of	 pharmaceutical	
preparations	towards	licensing	as	a	possibility	to	keep	treatment	available	at	reasonable	costs.	
Another	possibility	 to	avoid	 tremendous	 increases	 in	pricing	after	 licensing	 former	pharmaceutical	
preparations	 can	 be	 established	 by	 more	 involvement	 from	 the	 government	 in	 protecting	 the	
purpose	of	the	(ultra-)	orphan	drug	designation.	For	example,	 in	case	the		(ultra-)orphan	medicinal	
product	 exceeds	 the	number	of	 50	 000	patients	 using	 it[4],	 the	qualification	of	 an	 (ultra-)	 orphan	
drug	expires	and	 the	exclusivity	period	can	be	decreased[30].	 In	 Japan,	pharmaceutical	 companies	
pay	 a	 1%	 sales	 tax	 on	 orphan	 drugs	 with	 annual	 profits	 exceeding	 100	 million	 Japanese	 yen	
	
	
(approximately	€900	000,-)[30].	Moreover,	 the	price	transparency	can	be	 increased.	 In	the	EU,	the	
pricing	of	(ultra-)	orphan	drugs	is	completely	confidential	which	leads	to	unanswered	questions[31].		
Increased	supervision	of	the	Health	Technology	Assessment	(HTA)	might	also	positively	influence	the	
price	 tag[32].	 The	 HTA	 should	 supervise	 the	 data	 on	 which	 a	 product	 received	 marketing	
authorization.	 In	 the	 case	 of	 a	 sudden	 and	 extreme	 price	 increase,	 without	 significant	 research	
performed	by	the	pharmaceutical	company	to	justify	this	increase	in	pricing,	it	is	advisable	that	the	
HTA	can	impose	restrictions	to	stop	the	tremendous	price	increase.	
Since	 the	available	data	 from	3,4-DAP	SR	did	not	differ	 substantially	 from	Firdapse®	at	 the	 time	of	
approval,	 there	 is	 a	 possibility	 that	 academic	 institutions	 can	 retrieve	marketing	 authorization	 for	
pharmaceutical	 preparations	 after	 long-term	 use.	 As	 shown	 in	 the	 case	 of	 Firdapse®,	 a	 medicinal	
product	 can	 receive	 marketing	 authorization	 with	 hardly	 any	 original	 research	 and	 some	 small	
additional	studies.	However,	 in	academic	 institutions,	applying	for	marketing	authorization	 is	not	a	
priority:	 since	 the	 focus	 is	 more	 science	 and	 care-driven	 instead	 of	 product-driven[33].	 A	
commencement	 can	be	made	by	 ensuring	 good	documentation	 and	quality	 controls	 to	 guarantee	
safety	of	the	product	for	the	patients.	Subsequently,	registration	of	all	safety	and	efficacy	data	can	
be	obtained	via	good	documentation,	such	as	an	LEMS	patient	registry,	and	can	be	used	for	applying	




In	 conclusion,	at	 time	Firdapse®	 retrieved	marketing	authorization	approval,	 the	available	data	did	
not	differ	much	from	3,4-DAP	SR,	indicating	that	marketing	authorization	approval	with	3,4-DAP	SR	
would	 have	 been	 possible,	most	 likely	 ‘Under	 Exceptional	 Circumstances’.	 Such	 approval	 requires	
post-marketing	 additional	 studies	 like	 it	 was	 the	 case	 for	 Firdapse®.	 To	 license	 3,4-DAP	 SR,	 a	
pharmacokinetic	study	in	healthy	volunteers	 is	necessary	and	investigation	of	 long-term	safety	and	
efficacy	could	be	established	by	collecting	data	in	a	patient	registry.	To	avoid	the	tremendous	price	
increases	of	pharmaceutical	preparations	 like	3,4-DAP	SR,	 the	 involvement	of	 the	government	and	
HTA	 can	 lead	 to	 more	 control	 over	 the	 data	 used	 for	 marketing	 authorization	 by	 a	 commercial	
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efficacy	could	be	established	by	collecting	data	in	a	patient	registry.	To	avoid	the	tremendous	price	
increases	of	pharmaceutical	preparations	 like	3,4-DAP	SR,	 the	 involvement	of	 the	government	and	
HTA	 can	 lead	 to	 more	 control	 over	 the	 data	 used	 for	 marketing	 authorization	 by	 a	 commercial	





(approximately	€900	000,-)[30].	Moreover,	 the	price	transparency	can	be	 increased.	 In	the	EU,	the	
pricing	of	(ultra-)	orphan	drugs	is	completely	confidential	which	leads	to	unanswered	questions[31].		
Increased	supervision	of	the	Health	Technology	Assessment	(HTA)	might	also	positively	influence	the	
price	 tag[32].	 The	 HTA	 should	 supervise	 the	 data	 on	 which	 a	 product	 received	 marketing	
authorization.	 In	 the	 case	 of	 a	 sudden	 and	 extreme	 price	 increase,	 without	 significant	 research	
performed	by	the	pharmaceutical	company	to	justify	this	increase	in	pricing,	it	is	advisable	that	the	
HTA	can	impose	restrictions	to	stop	the	tremendous	price	increase.	
Since	 the	available	data	 from	3,4-DAP	SR	did	not	differ	 substantially	 from	Firdapse®	at	 the	 time	of	
approval,	 there	 is	 a	 possibility	 that	 academic	 institutions	 can	 retrieve	marketing	 authorization	 for	
pharmaceutical	 preparations	 after	 long-term	 use.	 As	 shown	 in	 the	 case	 of	 Firdapse®,	 a	 medicinal	
product	 can	 receive	 marketing	 authorization	 with	 hardly	 any	 original	 research	 and	 some	 small	
additional	studies.	However,	 in	academic	 institutions,	applying	for	marketing	authorization	 is	not	a	
priority:	 since	 the	 focus	 is	 more	 science	 and	 care-driven	 instead	 of	 product-driven[33].	 A	
commencement	 can	be	made	by	 ensuring	 good	documentation	 and	quality	 controls	 to	 guarantee	
safety	of	the	product	for	the	patients.	Subsequently,	registration	of	all	safety	and	efficacy	data	can	
be	obtained	via	good	documentation,	such	as	an	LEMS	patient	registry,	and	can	be	used	for	applying	




In	 conclusion,	at	 time	Firdapse®	 retrieved	marketing	authorization	approval,	 the	available	data	did	
not	differ	much	from	3,4-DAP	SR,	indicating	that	marketing	authorization	approval	with	3,4-DAP	SR	
would	 have	 been	 possible,	most	 likely	 ‘Under	 Exceptional	 Circumstances’.	 Such	 approval	 requires	
post-marketing	 additional	 studies	 like	 it	 was	 the	 case	 for	 Firdapse®.	 To	 license	 3,4-DAP	 SR,	 a	
pharmacokinetic	study	in	healthy	volunteers	 is	necessary	and	investigation	of	 long-term	safety	and	
efficacy	could	be	established	by	collecting	data	in	a	patient	registry.	To	avoid	the	tremendous	price	
increases	of	pharmaceutical	preparations	 like	3,4-DAP	SR,	 the	 involvement	of	 the	government	and	
HTA	 can	 lead	 to	 more	 control	 over	 the	 data	 used	 for	 marketing	 authorization	 by	 a	 commercial	
company.	 Furthermore,	3,4-DAP	shows	 the	possibility	of	 retrieving	marketing	authorization	with	a	
pharmaceutical	preparation	by	academic	GMP	licensed	institutions.	
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This	 thesis	 focuses	 on	 drug	 development	 and	 drug	 manufacturing	 for	 special	 (small)	 patient	
populations	 in	 academic	 institutions.	 Reaching	 the	 patient	 via	 the	 commercial	 route	 of	marketing	
approval	 (licensing)	does	mostly	not	apply	 to	 these	academic	products.	The	 first	category	of	 these	
drugs,	 the	 advanced	 therapy	 medicinal	 products	 (ATMPs),	 belongs	 to	 a	 new	 complex	 group	 of	











The	mainly	 academic	origin	of	ATMPs[1],	 as	 confirmed	 in	 Chapter	4,	 can	be	explained	by	 the	 fact	
that	academic	institutions	have	many	strengths	in	stimulating	early	development	of	these	products,	
such	as	high	pathophysiological	knowledge	of	diseases	and	availability	of	human	derived	materials	
for	 different	 purposes	 (for	 example	 biobanks,	 disease	 models	 and	 starting	 material;	 Chapter	 2).	
However,	besides	 these	strengths	 in	academia	during	 the	 initial	 stages	of	basic	 research	and	early	
clinical	 development,	 many	 hurdles	 can	 be	 identified	 in	 the	 trajectory	 from	 later	 stage	 clinical	
development	via	marketing	authorization	towards	regular	patient	care.	These	hurdles,	experienced	
in	 later	 stage	 clinical	 development	 and	 marketing	 authorization,	 are	 confirmed	 by	 the	 different	
stakeholders,	 including	 academic	 researchers,	 as	 described	 in	 Chapter	 3.	 In	 the	 last	 decade,	 the	
number	of	 clinical	 trials	 concerning	ATMPs	has	 increased	 in	Europe[1,2]	 (currently,	 estimated	at	≥	
300	 clinical	 trials),	 which	 supports	 the	 promising	 nature	 of	 these	 products.	 In	 Europe,	 the	 main	
countries	that	performed	clinical	trials	(and	adopted	it	in	the	European	clinical	trials	database)	with	









are	 small.	 As	 a	 consequence,	 this	 insufficient	 patient	 recruitment	 can	 affect	 the	 feasibility	 of	
(meeting	 the	 deadline	 for)	 completing	 the	 trial.	 Indeed,	 due	 to	 insufficient	 recruitment,	 some	
chimeric	 antigen	 receptor	 T-cells	 (CAR	 T-cells)	 trials	 failed	 to	 be	 completed	 before	 the	 stated	
deadline,	 as	 shown	 in	Chapter	 5.	 Also	 here,	 academic	 sponsors	 appeared	 to	 have	 problems	with	
recruitment	 more	 frequently	 compared	 to	 commercial	 sponsors.	 A	 solution	 for	 this	 problem	 is	
creating	 public	 databases	 for	 patients,	 showing	 the	 clinical	 trials	 that	 are	 open	 for	 recruitment	 of	
specific	patient	groups,	 as	described	 in	Chapter	3.	 Patient	organisations	 should	help	by	publishing	
such	databases.	
After	phase	I	clinical	trials,	the	majority	of	the	academic	sponsored	trials	were	not	followed	up	by	a	
subsequent	 clinical	 trial.	 An	 explanation	 may	 be	 that	 academic	 sponsors	 are	 not	 product-driven,	
have	less	financial	support	and	lack	in	regulatory	knowledge,	as	described	in	Chapter	2	and	Chapter	
3.	Furthermore,	 the	clinical	 trial	design	 itself	 seems	to	have	an	 impact	on	whether	 trials	are	being	
followed	 up	 by	 subsequent	 trials:	 recruitment	 of	 large	 patient	 numbers	 and	 execution	 of	 a	
multicentre	 clinical	 trial	may	 have	 a	 positive	 influence	 on	 a	 clinical	 trial	 being	 followed	 up	 or	 not	
(Chapter	5).	Proper	clinical	trial	design	forces	investigators	to	consider	the	ultimate	objective	of	their	
product,	 especially	 when	 combined	 with	 a	 target	 product	 profile	 (TPP),	 which	 can	 be	 a	 start	 for	
collaborations	with	commercial	parties.	













for	 the	 ATMPs.	 Here,	 it	 demonstrated	 that	 regulators	 adjusted	 the	 approval	 procedure	 of	 these	
products,	taking	into	account	unmet	medical	needs.	Limited	comprehensive	evidence	on	the	clinical	
outcome	 (efficacy	 and	 safety)	 was	 demonstrated,	 supporting	 the	 experimental	 and	 new	
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outcome	 (efficacy	 and	 safety)	 was	 demonstrated,	 supporting	 the	 experimental	 and	 new	





and/or	 a	 worsened	 safety	 profile	 was	 shown,	 unmet	 medical	 need	 did	 not	 influence	 the	 final	
decision-making.	Remarkably,	 the	quality	profile	of	all	 submitted	ATMPs	raised	major	concerns	 for	
both	 the	approved	and	non-approved	groups	at	 time	of	approval.	This	 confirms	 the	complexity	of	
these	 products	 and	 the	 difference	 in	 quality	 management	 compared	 to	 industrially	 originated	
‘conventional’	medicinal	products.		
Pharmaceutical	preparations		
For	 pharmaceutical	 preparations,	 long-term	 experience	 in	 regular	 patient	 care	 has	 often	 already	
been	achieved,	as	described	in	Chapter	7	and	Chapter	8.	However,	there	is	no	guarantee	that	these	
preparations	 remain	 available	 for	 these	 patients	 at	 an	 affordable	 price,	 since	 there	 is	 the	 risk	 of	
being	 taken	up	by	commercial	 companies.	The	same	hurdles	as	 seen	with	 the	ATMPs	 (such	as	not	
product-driven,	 less	 financial	 support,	 lack	 in	regulatory	 knowledge)	might	 play	 a	 role	 for	 the	




been	 adopted	 and	 licensed	 by	 a	 commercial	 company.	 It	 is	 questionable	 whether	 marketing	
authorization	 is	 necessary	 and	 achievable	 for	 all	 these	 pharmaceutical	 preparations.	 Also,	
pharmaceutical	preparations	without	marketing	authorization	may	provide	an	excellent	opportunity	
to	 treat	 individual	patients	with	 (orphan)	unmet	medical	needs	against	affordable	prices[5].	To	be	
able	to	provide	the	service	of	pharmaceutical	preparations,	without	presenting	unacceptable	risks	to	






are	 not	 reimbursed	 in	 the	 different	 member	 states,	 leading	 to	 inaccessibility	 of	 treatment	 for	




an	 assessment	 of	 cost-effectiveness	 as	 well[10].	 Therefore,	 the	 results	 of	 the	 non-comparability	
	
	
trials	 conducted	 with	 ATMPs	 make	 it	 difficult	 for	 the	 performance	 of	 such	 HTA	 processes[8].	
Globally,	 various	 HTAs	 are	 investigating	 the	 use	 of	 ‘real	 world	 data’	 to	 demonstrate	 efficacy	 for	
products	that	receive	marketing	authorization	without	performance	of	a	randomized	controlled	trial	




example	 ephedrine	 for	 myasthenia	 gravis	 and	 a	 specific	 couch	 technique	 for	 cystic	 fibrosis,	 in	
different	treatment	cycles	[12,13].	Of	course,	due	to	the	small	number	of	patients	 involved,	such	a	





the	 average	 survival	 prolongation	 of	 four	 months.	 For	 Chondrocelect®,	 the	 autologous	
manufacturing	 procedure	 was	 withdrawn	 to	 focus	 on	 the	 allogeneic	 starting	 materials	 as	 it	 was	
commercially	 more	 sustainable[8].	 MACI®	 was	 suspended	 due	 to	 the	 disappointing	 commercial	
performance,	 like	 it	 was	 for	 Provenge®.	 Finally,	 the	 last	 withdrawal	 was	 Glybera®,	 the	 first	 gene	
therapy	medicinal	product	which	was	approved	in	2012	and	which	was	used	only	for	one	patient	in	
Germany.	As	 is	 shown	 in	Chapter	6,	 this	poor	performance	 is	 caused	by	 the	high	price	 tag	on	 the	
product	in	combination	with	the	uncertain	efficacy	and	safety	profile	of	the	product.	Based	on	this	
and	 the	 recent	 withdrawal	 of	 the	 product	 by	 the	 company[15],	 Glybera®	 can	 be	 considered	 as	
another	 commercial	 failure[16].	 To	 increase	 the	 likelihood	 for	 reimbursement	 a	 money	 back	








be	 resolved	 via	 patient	 registry	 risk	 minimisation	 and/or	 post-marketing	 (observational)	 clinical	
trials.	
Finally,	once	approved,	and	in	case	reimbursement	is	arranged,	the	ATMP	has	to	be	prescribed	by	a	
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can	 be	 dependent	 on	 the	 skills	 of	 the	 surgeon	 or	 other	 physician,	 for	 example	 for	 MACI®	 and	
ChrondoCelect®[8].	In	case	of	commercialization	of	products,	the	expertise	of	physicians	in	the	clinic	
plays	 a	 very	 important	 part	 in	 the	 products	 actually	 reaching	 the	 patients	 and	 public-private	
partnership	is	essential[8,18].	Clinicians	need	to	be	familiar	with	the	procedures,	which	is	the	start	of	
prescribing	such	complex	medicinal	product.	Therefore,	the	development	and	use	of	ATMPs	should	







the	 monoclonal	 antibodies	 (MAb)	 resulted	 in	 the	 first	 licensed	 product	 (by	 the	 Food	 and	 Drug	
Administration	 (FDA))	 in	 1986.	 Only	 11	 years	 after	 this	 first	 marketing	 authorized	 MAb,	 an	
exponential	increase	was	shown	in	the	clinical	trials	conducted	with	these	MAbs[19].	Until	now,	this	
has	resulted	in	no	less	than	30	approved	MAbs	by	the	FDA[20].	This	example	clearly	illustrates	that	a	
new	 technology	 or	 medicinal	 product	 group	 needs	 time	 to	 reach	 success	 as	 acquiring	 marketing	




A	way	 to	 reach	 the	patient	with	ATMPs	 in	Europe	without	marketing	authorization	 is	 the	hospital	
exemption,	 stating	 that	 use	 of	 that	 product	 is	 allowed	 solely	 in	 the	 hospital	 that	 developed	 that	
specific	product.	Hospital	exemption	is	only	allowed	when	used	on	a	non-routine	basis,	based	on	a	
prescription,	 with	 specific	 quality	 criteria,	 under	 responsibility	 of	 the	 physician[21].	 In	 The	
Netherlands,	 the	 national	 healthcare	 inspectorate	 judges	 the	 hospital	 exemption	 application.	
Hospital	 exemption	 is	 restricted	 for	 an	 established	 number	 of	 treatments	 with	 that	 ATMP	 after	
which	(or	on	annual	basis)	the	healthcare	 inspectorate	re-examines	the	hospital	exemption	for	the	
following	 year	or	 for	 a	new	number	of	 treatments.	Hospital	 exemption	 is	 a	 solution	especially	 for	
these	ATMPs	that	are	unattractive	for	commercial	companies	to	be	taken	over	and/or	not	intended	








centralized	 patient	 registry.	 Such	 registry	 can	 be	 used	 as	 an	 alternative	 way	 of	 collecting	 data,	
compared	to	the	conventional	RCTs,	to	apply	for	marketing	authorization.	Holoclar®	is	an	example	of	
a	product	that	is	approved	based	on	retrospective	data,	well	collected	and	documented	in	a	registry.	
For	 the	 organisation	 of	 such	 registries,	 the	 main	 responsibility	 of	 data	 collection	 relies	 on	 the	
manufacturers	 of	 the	 academic	 medicinal	 products,	 including	 documentation	 of	 product	 specific	
information,	such	as	batch	numbers,	dose	and	quality	assurance.	Furthermore,	physicians	also	play	a	
very	 important	 role	 in	 supplying	 information	 of	 the	 clinical	 safety	 and	 efficacy	 data	 for	 these	
registries.	 Subsequently,	 these	 registries	 need	 to	 be	 linked	 to	 centralized	 pharmacovigilance	
databases	 on	 a	 national	 level.	 In	 the	 future,	 it	 should	 be	 possible	 to	 automatically	 link	 the	
prescription	 system	 to	 the	 centralized	 pharmacovigilance	 database.	 Thereby,	 also	 the	 patients	
themselves	have	to	be	able	to	put	data	of	usage	experience	in	such	registries.	The	patients	can	be	
reached	 via	 both	 the	 physician	 and	 the	 patient	 organisations.	 However,	 for	 the	 management	 of	
these	registries,	(financial)	stimulation	by	the	government	and	funding	agencies	is	necessary.		
Currently,	 patient	 registries	 are	 often	 required	 for	 orphan	 approved	medicinal	 products	 to	 collect	
post-marketing	comprehensive	clinical	data	on	efficacy	and	safety.	However,	commercial	companies	
experience	difficulties	in	collecting	high	quality	post-marketing	data	and	struggle	in	the	performance	
of	 independent	analyses	of	 the	 clinical	outcome	data[5].	 Such	patient	 registry	 is	more	 feasible	 for	
academic	medicinal	 preparations,	which	 is	 the	 result	 of	 direct	 involvement	 of	 patients,	 physicians	
and	 pharmacists	 in	 treating	 the	 patient[5].	 Such	 close	 collaborations	 and	 interaction	 may	 be	 a	
considerable	contribution	for	collecting	high	quality	data.	
Currently,	the	price	tag	on	academic	medicinal	products	is	based	on	the	production	costs,	including	
starting	 material	 and	 manpower	 used	 for	 the	 production,	 analysis	 and	 for	 the	 facilities.	 Once	 a	
patient	 registry	 is	 required	 for	 such	 preparations	 and	 the	 responsibility	 for	 data	 input	 lies	 at	 the	
producer,	the	price	tag	should	be	able	to	increase.	The	government	should	initiate	a	pilot	for	the	set-
up	 of	 such	 patient	 registry.	 For	 example,	 for	 starting	 a	 patient	 registry	 it	 is	 necessary	 to	 have	 a	
guideline	for	the	set-up	and	maintenance	of	such	registry.	Also,	 linking	of	a	registry	to	the	(Dutch)	




The	 fact	 that	 academic	 institutions	 are	 more	 involved	 in	 the	 early	 stage	 development	 and	 that	
	
	
commercial	 companies	 are	 more	 involved	 in	 the	 process	 of	 late	 stage	 development	 towards	
marketing	authorization,	creates	opportunities	for	collaboration	of	both	stakeholders,	the	so-called	
public-private	 partnerships.	 Combining	 the	 strengths	 of	 both	 partners	 can	 synergize	 the	
development,	 which	 could	 lead	 to	 a	 higher	 likelihood	 of	 bringing	 academic	 medicinal	 products	




and	 commercial	 companies[23].	 Subsequently,	 owning	 intellectual	 property	 on	 a	 product	 or	 on	 a	
product	 specific	 manufacturing	 procedure	 can	 improve	 the	 bargaining	 power	 to	 control	 the	 final	
costs	of	a	product	and	finally,	to	keep	these	products	affordable.		
Due	 to	 the	 insufficient	 financial	 resources	 in	 academia	 for	 late	 stage	 product	 development,	
commercial	companies	play	an	important	role	in	the	existence	of	ATMPs.	The	uncertainty	of	return	
on	investments	 is	an	 important	factor	that	can	limit	the	willingness	from	industry	to	 invest	 in	such	
products.	 The	 fact	 that	 reaching	 the	patient	with	 an	 academic	 product	 in	 development	 is	 difficult	
without	 collaborating	 with	 commercial	 companies	 should	 encourage	 the	 (academic)	 investigators	
even	more	to	think	properly	about	the	future	of	a	product.	A	TPP	can	help	the	investigator	with	the	
design	 of	 a	 feasible	 clinical	 trial,	 which	 can	 be	 even	 further	 improved	 when	 the	 regulatory	
authorities,	who	judge	(ethical)	aspects	of	clinical	trials,	also	take	the	future	perspective	of	a	product	
into	 account	when	 assessing	 the	 clinical	 trial.	 Furthermore,	 the	 better	 the	 TPP	 is	 elaborated,	 the	
more	 realistic	 establishing	 a	 development	 plan	 becomes.	 And	 this,	 in	 turn	may	 influence	 the	 late	
stage	 funding,	 from	 governmental	 resources	 or	 via	 other	 more	 voluntary	 resources,	 such	 as	
philanthropic	 funders	 or	 crowd	 funding.	 Since	 academic	 (early)	 development	 is	 often	 funded	 by	
agencies	and	governmental	 subsidiaries,	 it	 is	 recommended	 that	all	 this	public	 funding	 invested	 in	
developing	products	should	be	taken	in	consideration	when	negotiating	with	interested	commercial	
parties.		
In	 the	 last	decade,	 a	 slight	 increase	of	 involvement	of	 the	 (large)	 commercial	 companies	 in	ATMP	
clinical	development	has	been	observed.	Especially	 in	the	late	stage	phase	III	clinical	trials,	most	of	
the	(large)	commercial	companies	are	now	involved,	as	shown	in	Chapter	4.	However,	when	looking	
at	 the	 CAR	 T-cell	 products	 in	 Chapter	 5,	 large	 companies	 also	 appear	 to	 be	 increasingly	 getting	
involved	 during	 early	 stage	 clinical	 trials.	 The	 fact	 that	 commercial	 companies	 increase	 their	
involvement	at	all	 stage	of	 research	 is	promising:	apparently,	companies	now	come	to	realize	 that	
ATMPs	show	commercial	promise.	
Regulatory	authority	stimulation	and	collaboration	
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and	 commercial	 companies[23].	 Subsequently,	 owning	 intellectual	 property	 on	 a	 product	 or	 on	 a	
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products.	 The	 fact	 that	 reaching	 the	patient	with	 an	 academic	 product	 in	 development	 is	 difficult	
without	 collaborating	 with	 commercial	 companies	 should	 encourage	 the	 (academic)	 investigators	
even	more	to	think	properly	about	the	future	of	a	product.	A	TPP	can	help	the	investigator	with	the	
design	 of	 a	 feasible	 clinical	 trial,	 which	 can	 be	 even	 further	 improved	 when	 the	 regulatory	
authorities,	who	judge	(ethical)	aspects	of	clinical	trials,	also	take	the	future	perspective	of	a	product	
into	 account	when	 assessing	 the	 clinical	 trial.	 Furthermore,	 the	 better	 the	 TPP	 is	 elaborated,	 the	
more	 realistic	 establishing	 a	 development	 plan	 becomes.	 And	 this,	 in	 turn	may	 influence	 the	 late	
stage	 funding,	 from	 governmental	 resources	 or	 via	 other	 more	 voluntary	 resources,	 such	 as	
philanthropic	 funders	 or	 crowd	 funding.	 Since	 academic	 (early)	 development	 is	 often	 funded	 by	
agencies	and	governmental	 subsidiaries,	 it	 is	 recommended	 that	all	 this	public	 funding	 invested	 in	
developing	products	should	be	taken	in	consideration	when	negotiating	with	interested	commercial	
parties.		
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more	 realistic	 establishing	 a	 development	 plan	 becomes.	 And	 this,	 in	 turn	may	 influence	 the	 late	
stage	 funding,	 from	 governmental	 resources	 or	 via	 other	 more	 voluntary	 resources,	 such	 as	
philanthropic	 funders	 or	 crowd	 funding.	 Since	 academic	 (early)	 development	 is	 often	 funded	 by	
agencies	and	governmental	 subsidiaries,	 it	 is	 recommended	 that	all	 this	public	 funding	 invested	 in	
developing	products	should	be	taken	in	consideration	when	negotiating	with	interested	commercial	
parties.		
In	 the	 last	decade,	 a	 slight	 increase	of	 involvement	of	 the	 (large)	 commercial	 companies	 in	ATMP	
clinical	development	has	been	observed.	Especially	 in	the	late	stage	phase	III	clinical	trials,	most	of	
the	(large)	commercial	companies	are	now	involved,	as	shown	in	Chapter	4.	However,	when	looking	
at	 the	 CAR	 T-cell	 products	 in	 Chapter	 5,	 large	 companies	 also	 appear	 to	 be	 increasingly	 getting	
involved	 during	 early	 stage	 clinical	 trials.	 The	 fact	 that	 commercial	 companies	 increase	 their	






different	 authorities	 foresee	 a	 sanguine	 prospective	 for	 these	 ATMPs.	 To	 be	more	 precise,	 some	
legal	 instruments	 exist	 to	 facilitate	 ATMP	 development	 in	 an	 academic	 setting,	 such	 as	 the	
certification	procedure	 for	 small	 and	medium	sized	enterprises	 (SMEs),	which	 is	 a	 label	on	quality	
and	non-clinical	 data	 that	 judges	whether	 the	development	and/or	 the	manufacturing	procedures	
are	 corresponding	 with	 the	 regulations[4,24,25].	 This	 was	 initiated	 by	 the	 European	 Commission,	
due	 to	 the	 hurdles	 experienced	with	 quality	 and	 preclinical	 data	with	ATMPs	 for	 SMEs.	However,	






regulatory	 authority,	 for	 instance	 in	 order	 to	 obtain	 scientific	 advice.	 In	 such	 a	 dialogue,	 the	
developer	 has	 the	 opportunity	 to	 discuss	 the	 development	 of	 a	 product,	 such	 as	 quality	 and	
(pre)clinical	aspects,	with	 the	CAT.	 In	 case	of	a	 large	enterprise	 status,	 the	costs	are	high	 for	 such	
scientific	advice,	which	is	often	not	available	in	academic	institutions.	
The	 different	 milestones	 in	 a	 development	 trajectory	 are	 focused	 on	 diverse	 aspects.	 And	 each	





evaluation	 for	 marketing	 authorization,	 since	 early	 discussions	 on	 e.g.	 quality	 already	 have	 been	
performed.	On	the	contrary,	 this	collaboration	delays	 the	early	clinical	development.	The	 fact	 that	
stakeholders	have	different	aims	and	perspectives	contributes	to	the	difficulties	often	experienced	





regulatory	 authorities,	 including	 the	 HTA,	 for	 academic	 institutions.	 Such	 an	 initiative	 can	 help	
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Also	 on	 a	 centralized	 level,	 a	 special	 scheme	 was	 launched	 by	 the	 EMA	 in	 2016,	 entitled	 PRIME	
(priority	medicine).	This	scheme	is	used	to	support	the	development	of	medicinal	products	that	are	
considered	 promising,	 often	 for	 unmet	 medical	 needs	 and	 to	 do	 so	 by	 opening	 possibilities	 for	
having	early	dialogues	for	all	authorities	involved[27].	Scientific	advice	on	(preliminary)	early	clinical	
outcomes	is	made	available	for	all	companies.	Subsequently,	for	the	academic	institutions	and	SMEs	
earlier	 dialogues,	 concerning	 non-clinical	 data,	 are	 also	 possible.[27]	 In	 these	 (early)	 dialogues,	 all	
authoritative	bodies	can	be	involved,	including	the	HTA,	in	order	to	improve	the	development	plans,	
including	 high	 quality	 of	 the	 applications	 for	 marketing	 authorization[27].	 Therefore,	 it	 would	 be	
interesting	 to	 see	 whether	 having	 the	 PRIME	 scheme	 in	 place	 actually	 does	 improve	 the	
development	of	(academic)	ATMPs	towards	marketing	authorization	and	whether	this	does	 indeed	
increase	the	chance	of	ATMPs	eventually	being	used	in	regular	patient	care.		
Another	 new	 and	 promising	 initiative	 has	 been	 introduced	 in	 The	 Netherlands:	 “the	 Dutch	
conditionally	approval	trajectory”,	which	supports	further	collaboration	between	all	parties	involved,	
such	as	investigators,	regulators,	HTAs	and	health	care	insurances.	Currently,	two	ATMPs,	which	are	
still	 in	 the	 investigational	 phase,	 are	 used	 in	 this	 Dutch	 conditional	 approval	 trajectory.	 In	 this	
trajectory,	 the	 use	 of	 developmental	 ATMPs	 in	 phase	 III	 clinical	 trials	 is	 reimbursed	 by	 the	 health	
care	 insurances	 for	 maximum	 duration	 of	 3,5	 years	 to	 investigate	 whether	 that	 product	 can	
demonstrate	 efficacy	 with	 regards	 to	 “state	 of	 the	 science	 and	 practice”[28].	 In	 case	 of	
demonstrated	 efficacy	 and	 safety,	 this	may	 lead	 to	 granting	marketing	 approval.	 Further	 study	 in	
order	 to	 follow	up	on	 these	 two	ATMPs	currently	 in	 the	Dutch	conditionally	approval	 trajectory	 is	
recommended.	
The	initiatives	mentioned	above	are	more	focused	on	the	development	pathway	of	ATMPs	than	on	
the	 unlicensed	 pharmaceutical	 preparations.	 Since	 these	 pharmaceutical	 preparations	 are	 already	
used	 in	 clinical	 care,	 good	 documentation	 including	 initiatives	 for	 patient	 registries	 is	 most	
important.	For	 these	patient	 registries,	which	also	applies	 for	ATMPs	used	via	hospital	exemption,	
awareness	 from	 the	different	authorities	and	 stimulation	 from	 these	bodies	are	 important	 for	 the	





all	 different	 stakeholders:	 (academic)	 developers,	 commercial	 companies,	 ethical	 committees,	
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design	 of	 a	 feasible	 clinical	 trial,	 which	 can	 be	 even	 further	 improved	 when	 the	 regulatory	
authorities,	who	judge	(ethical)	aspects	of	clinical	trials,	also	take	the	future	perspective	of	a	product	
into	 account	when	 assessing	 the	 clinical	 trial.	 Furthermore,	 the	 better	 the	 TPP	 is	 elaborated,	 the	
more	 realistic	 establishing	 a	 development	 plan	 becomes.	 And	 this,	 in	 turn	may	 influence	 the	 late	
stage	 funding,	 from	 governmental	 resources	 or	 via	 other	 more	 voluntary	 resources,	 such	 as	
philanthropic	 funders	 or	 crowd	 funding.	 Since	 academic	 (early)	 development	 is	 often	 funded	 by	
agencies	and	governmental	 subsidiaries,	 it	 is	 recommended	 that	all	 this	public	 funding	 invested	 in	
developing	products	should	be	taken	in	consideration	when	negotiating	with	interested	commercial	
parties.		
In	 the	 last	decade,	 a	 slight	 increase	of	 involvement	of	 the	 (large)	 commercial	 companies	 in	ATMP	
clinical	development	has	been	observed.	Especially	 in	the	late	stage	phase	III	clinical	trials,	most	of	
the	(large)	commercial	companies	are	now	involved,	as	shown	in	Chapter	4.	However,	when	looking	
at	 the	 CAR	 T-cell	 products	 in	 Chapter	 5,	 large	 companies	 also	 appear	 to	 be	 increasingly	 getting	
involved	 during	 early	 stage	 clinical	 trials.	 The	 fact	 that	 commercial	 companies	 increase	 their	






different	 authorities	 foresee	 a	 sanguine	 prospective	 for	 these	 ATMPs.	 To	 be	more	 precise,	 some	
legal	 instruments	 exist	 to	 facilitate	 ATMP	 development	 in	 an	 academic	 setting,	 such	 as	 the	
certification	procedure	 for	 small	 and	medium	sized	enterprises	 (SMEs),	which	 is	 a	 label	on	quality	
and	non-clinical	 data	 that	 judges	whether	 the	development	and/or	 the	manufacturing	procedures	
are	 corresponding	 with	 the	 regulations[4,24,25].	 This	 was	 initiated	 by	 the	 European	 Commission,	
due	 to	 the	 hurdles	 experienced	with	 quality	 and	 preclinical	 data	with	ATMPs	 for	 SMEs.	However,	






regulatory	 authority,	 for	 instance	 in	 order	 to	 obtain	 scientific	 advice.	 In	 such	 a	 dialogue,	 the	
developer	 has	 the	 opportunity	 to	 discuss	 the	 development	 of	 a	 product,	 such	 as	 quality	 and	
(pre)clinical	aspects,	with	 the	CAT.	 In	 case	of	a	 large	enterprise	 status,	 the	costs	are	high	 for	 such	
scientific	advice,	which	is	often	not	available	in	academic	institutions.	
The	 different	 milestones	 in	 a	 development	 trajectory	 are	 focused	 on	 diverse	 aspects.	 And	 each	





evaluation	 for	 marketing	 authorization,	 since	 early	 discussions	 on	 e.g.	 quality	 already	 have	 been	
performed.	On	the	contrary,	 this	collaboration	delays	 the	early	clinical	development.	The	 fact	 that	
stakeholders	have	different	aims	and	perspectives	contributes	to	the	difficulties	often	experienced	





regulatory	 authorities,	 including	 the	 HTA,	 for	 academic	 institutions.	 Such	 an	 initiative	 can	 help	
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Also	 on	 a	 centralized	 level,	 a	 special	 scheme	 was	 launched	 by	 the	 EMA	 in	 2016,	 entitled	 PRIME	
(priority	medicine).	This	scheme	is	used	to	support	the	development	of	medicinal	products	that	are	
considered	 promising,	 often	 for	 unmet	 medical	 needs	 and	 to	 do	 so	 by	 opening	 possibilities	 for	
having	early	dialogues	for	all	authorities	involved[27].	Scientific	advice	on	(preliminary)	early	clinical	
outcomes	is	made	available	for	all	companies.	Subsequently,	for	the	academic	institutions	and	SMEs	
earlier	 dialogues,	 concerning	 non-clinical	 data,	 are	 also	 possible.[27]	 In	 these	 (early)	 dialogues,	 all	
authoritative	bodies	can	be	involved,	including	the	HTA,	in	order	to	improve	the	development	plans,	
including	 high	 quality	 of	 the	 applications	 for	 marketing	 authorization[27].	 Therefore,	 it	 would	 be	
interesting	 to	 see	 whether	 having	 the	 PRIME	 scheme	 in	 place	 actually	 does	 improve	 the	
development	of	(academic)	ATMPs	towards	marketing	authorization	and	whether	this	does	 indeed	
increase	the	chance	of	ATMPs	eventually	being	used	in	regular	patient	care.		
Another	 new	 and	 promising	 initiative	 has	 been	 introduced	 in	 The	 Netherlands:	 “the	 Dutch	
conditionally	approval	trajectory”,	which	supports	further	collaboration	between	all	parties	involved,	
such	as	investigators,	regulators,	HTAs	and	health	care	insurances.	Currently,	two	ATMPs,	which	are	
still	 in	 the	 investigational	 phase,	 are	 used	 in	 this	 Dutch	 conditional	 approval	 trajectory.	 In	 this	
trajectory,	 the	 use	 of	 developmental	 ATMPs	 in	 phase	 III	 clinical	 trials	 is	 reimbursed	 by	 the	 health	
care	 insurances	 for	 maximum	 duration	 of	 3,5	 years	 to	 investigate	 whether	 that	 product	 can	
demonstrate	 efficacy	 with	 regards	 to	 “state	 of	 the	 science	 and	 practice”[28].	 In	 case	 of	
demonstrated	 efficacy	 and	 safety,	 this	may	 lead	 to	 granting	marketing	 approval.	 Further	 study	 in	
order	 to	 follow	up	on	 these	 two	ATMPs	currently	 in	 the	Dutch	conditionally	approval	 trajectory	 is	
recommended.	
The	initiatives	mentioned	above	are	more	focused	on	the	development	pathway	of	ATMPs	than	on	
the	 unlicensed	 pharmaceutical	 preparations.	 Since	 these	 pharmaceutical	 preparations	 are	 already	
used	 in	 clinical	 care,	 good	 documentation	 including	 initiatives	 for	 patient	 registries	 is	 most	
important.	For	 these	patient	 registries,	which	also	applies	 for	ATMPs	used	via	hospital	exemption,	
awareness	 from	 the	different	authorities	and	 stimulation	 from	 these	bodies	are	 important	 for	 the	
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all	 different	 stakeholders:	 (academic)	 developers,	 commercial	 companies,	 ethical	 committees,	
	
	
regulatory	 authority	 and	HTA	bodies.	New	programs	 to	 stimulate	 the	development	 are	 starting	 in	
Europe.	Therefore,	 it	would	be	interesting	to	investigate	the	status	of	the	developed	ATMPs	in	the	




Furthermore,	 hospital	 exemption	 can	 impact	 the	 approved	 products,	 since	 in	 case	 of	 good	
documentation	 and	 in	 case	 a	 format	 of	 a	 patient	 registry	 is	 set	 up,	 these	 data	 can	 be	 used	more	
frequently	 in	 applying	 for	marketing	 authorization.	 The	main	 focus	 of	 this	 thesis	 is	 on	 the	 ATMP	





This	 thesis	 demonstrates	 that	 academic	 institutions	 play	 an	 important	 role	 in	 the	 discovery	 and	
development	 of	 specific	medicinal	 products,	 such	 as	 ATMPs	 and	 pharmaceutical	 preparations	 for	
special	 patient	 populations.	 In	 this	 regard,	 academic	 institutions	 are	 essential	 drug	manufacturers	
providing	specialized	and	orphan	drugs	for	treatment	of	patients.	In	our	studies,	we	have	shown	that	
–	 until	 now	 –	mostly	 these	 academic	medicinal	 product	 do	 not	 hold	marketing	 authorization	 and	
commercialization	of	 these	products	does	not	 take	place	and	 is	perhaps	 in	 several	 cases	not	even	
preferred.	 Especially,	 for	 products	 related	 to	 ultra-orphan	 diseases,	 in	 which	 case	 conventional	
phase	III	clinical	trials	are	not	feasible,	(late	stage)	data	collection	on	efficacy	should	be	collected	for	
example	via	hospital	exemption.	For	the	pharmaceutical	preparations	it	was	explored	that	acquiring	
approval	 is	 possible,	 however,	 the	 cost-effectiveness	of	 such	preparations	 is	 uncertain.	 This	 raises	
the	question	how	feasible	it	is	for	preparations,	used	for	ultra-orphan	patient	cohorts	combined	with	
relatively	easy	manufacturing	procedures,	to	be	commercialized.		
For	both	 types	of	 academic	medicinal	products	 it	 is	 important	 to	guarantee	 safety	and	have	good	
documentation.	 Via	 databases,	 such	 as	 patient	 registries,	 good	 documentation	 is	 provided	 in	 a	
structural	 manner.	 Furthermore	 it	 is	 important	 to	 take	 pharmacovigilance	 to	 a	 next	 (more	
professional)	 level,	 which	 can	 be	 achieved	 by	 linking	 patient	 registries	 with	 centralized	
pharmacovigilance	databases.	 It	 is	 considered	 the	 responsibility	of	 the	academic	 institutions	as	an	
‘academic	pharma’	to	set	up	and	maintain	good	drug	product	files	and	safe	use	of	these	academic	
medicinal	 products	 in	 regular	 patient	 care.	 The	 government	 and	 regulatory	 authorities	 should	
stimulate	 and	 embrace	 the	 ‘academic	 pharma’	 to	 keep	 developing	 and	 manufacturing	 academic	
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interesting	 to	 see	 whether	 having	 the	 PRIME	 scheme	 in	 place	 actually	 does	 improve	 the	
development	of	(academic)	ATMPs	towards	marketing	authorization	and	whether	this	does	 indeed	
increase	the	chance	of	ATMPs	eventually	being	used	in	regular	patient	care.		
Another	 new	 and	 promising	 initiative	 has	 been	 introduced	 in	 The	 Netherlands:	 “the	 Dutch	
conditionally	approval	trajectory”,	which	supports	further	collaboration	between	all	parties	involved,	
such	as	investigators,	regulators,	HTAs	and	health	care	insurances.	Currently,	two	ATMPs,	which	are	
still	 in	 the	 investigational	 phase,	 are	 used	 in	 this	 Dutch	 conditional	 approval	 trajectory.	 In	 this	
trajectory,	 the	 use	 of	 developmental	 ATMPs	 in	 phase	 III	 clinical	 trials	 is	 reimbursed	 by	 the	 health	
care	 insurances	 for	 maximum	 duration	 of	 3,5	 years	 to	 investigate	 whether	 that	 product	 can	
demonstrate	 efficacy	 with	 regards	 to	 “state	 of	 the	 science	 and	 practice”[28].	 In	 case	 of	
demonstrated	 efficacy	 and	 safety,	 this	may	 lead	 to	 granting	marketing	 approval.	 Further	 study	 in	
order	 to	 follow	up	on	 these	 two	ATMPs	currently	 in	 the	Dutch	conditionally	approval	 trajectory	 is	
recommended.	
The	initiatives	mentioned	above	are	more	focused	on	the	development	pathway	of	ATMPs	than	on	
the	 unlicensed	 pharmaceutical	 preparations.	 Since	 these	 pharmaceutical	 preparations	 are	 already	
used	 in	 clinical	 care,	 good	 documentation	 including	 initiatives	 for	 patient	 registries	 is	 most	
important.	For	 these	patient	 registries,	which	also	applies	 for	ATMPs	used	via	hospital	exemption,	
awareness	 from	 the	different	authorities	and	 stimulation	 from	 these	bodies	are	 important	 for	 the	





all	 different	 stakeholders:	 (academic)	 developers,	 commercial	 companies,	 ethical	 committees,	
	
	
regulatory	 authority	 and	HTA	bodies.	New	programs	 to	 stimulate	 the	development	 are	 starting	 in	
Europe.	Therefore,	 it	would	be	interesting	to	investigate	the	status	of	the	developed	ATMPs	in	the	




Furthermore,	 hospital	 exemption	 can	 impact	 the	 approved	 products,	 since	 in	 case	 of	 good	
documentation	 and	 in	 case	 a	 format	 of	 a	 patient	 registry	 is	 set	 up,	 these	 data	 can	 be	 used	more	
frequently	 in	 applying	 for	marketing	 authorization.	 The	main	 focus	 of	 this	 thesis	 is	 on	 the	 ATMP	





This	 thesis	 demonstrates	 that	 academic	 institutions	 play	 an	 important	 role	 in	 the	 discovery	 and	
development	 of	 specific	medicinal	 products,	 such	 as	 ATMPs	 and	 pharmaceutical	 preparations	 for	
special	 patient	 populations.	 In	 this	 regard,	 academic	 institutions	 are	 essential	 drug	manufacturers	
providing	specialized	and	orphan	drugs	for	treatment	of	patients.	In	our	studies,	we	have	shown	that	
–	 until	 now	 –	mostly	 these	 academic	medicinal	 product	 do	 not	 hold	marketing	 authorization	 and	
commercialization	of	 these	products	does	not	 take	place	and	 is	perhaps	 in	 several	 cases	not	even	
preferred.	 Especially,	 for	 products	 related	 to	 ultra-orphan	 diseases,	 in	 which	 case	 conventional	
phase	III	clinical	trials	are	not	feasible,	(late	stage)	data	collection	on	efficacy	should	be	collected	for	
example	via	hospital	exemption.	For	the	pharmaceutical	preparations	it	was	explored	that	acquiring	
approval	 is	 possible,	 however,	 the	 cost-effectiveness	of	 such	preparations	 is	 uncertain.	 This	 raises	
the	question	how	feasible	it	is	for	preparations,	used	for	ultra-orphan	patient	cohorts	combined	with	
relatively	easy	manufacturing	procedures,	to	be	commercialized.		
For	both	 types	of	 academic	medicinal	products	 it	 is	 important	 to	guarantee	 safety	and	have	good	
documentation.	 Via	 databases,	 such	 as	 patient	 registries,	 good	 documentation	 is	 provided	 in	 a	
structural	 manner.	 Furthermore	 it	 is	 important	 to	 take	 pharmacovigilance	 to	 a	 next	 (more	
professional)	 level,	 which	 can	 be	 achieved	 by	 linking	 patient	 registries	 with	 centralized	
pharmacovigilance	databases.	 It	 is	 considered	 the	 responsibility	of	 the	academic	 institutions	as	an	
‘academic	pharma’	to	set	up	and	maintain	good	drug	product	files	and	safe	use	of	these	academic	
medicinal	 products	 in	 regular	 patient	 care.	 The	 government	 and	 regulatory	 authorities	 should	
stimulate	 and	 embrace	 the	 ‘academic	 pharma’	 to	 keep	 developing	 and	 manufacturing	 academic	
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170  | Part III - Chapter 10
	
	
The	wide	variety	of	 licensed	medicinal	products,	mainly	produced	by	 the	pharmaceutical	 industry,	
offers	 many	 patients	 a	 treatment	 for	 their	 disease.	 However,	 not	 everyone	 benefits	 from	
conventional	licensed	medicinal	products.	For	these	patients,	so-called	academic	medicinal	products	
developed	 in	 academic	 setting	 or	 manufactured	 by	 (hospital)	 pharmacies	 often	 offer	 a	 better	




products	 in	 their	 characteristics	 and	manufacturing.	 These	 ATMPs	 are	 medicinal	 products	 mostly	
derived	 from	 human	 cells	 obtained	 from	 either	 the	 patient	 (autologous)	 or	 a	 donor	 (allogeneic).	
These	 cells	 are	 hence	 substantially	 manipulated	 or	 the	 cells	 received	 a	 different	 function	 in	 the	
recipient	 compared	 to	 the	original	 function	 (non-homologous	use).	 In	 case	 these	 cells	 are	used	 in	
diagnosis,	 prevention	or	 treatment	 they	are	 classified	as	 cell	 therapy	medicinal	products	 (CTMPs).	
On	the	other	hand	when	the	purpose	of	these	cells	is	to	regenerate,	repair	or	replace	tissue	(such	as	
skin)	they	are	classified	as	tissue	engineered	products	(TEPs).	Finally,	the	third	category	of	ATMPs	is	
the	gene	 therapy	medicinal	products	 (GTMPs),	which	 include	genes	 for	diagnostic,	prophylactic	or	
therapeutic	purposes.		
Since	 the	 European	 special	 Regulation	 (EC)	 No.	 1394/2007	 was	 imposed	 in	 2009,	 a	 centralized	
regulatory	framework	for	these	products	was	established.	 In	general,	the	Committee	for	Medicinal	
Products	for	Human	Use	(CHMP)	is	responsible	for	the	evaluation	of	quality,	safety	and	efficacy	of	all	
medicinal	 products	 in	 the	 centralized	 procedures.	 However,	 due	 to	 this	 new	 complex	 group	 of	
medicinal	products,	a	group	of	experts	was	established	by	the	European	Medicines	Agency	(EMA)	to	




















Mostly,	 these	 preparations	 are	 manufactured	 for	 orphan	 indications	 (<5	 patients	 per	 10,000	
humans).	 Although	 unlicensed,	 they	 should	 guarantee	 safety	 similar	 to	 the	 licensed	 medicinal	
products.	Since	these	products	are	unlicensed,	there	is	a	risk	that	pharmaceutical	preparations	from	
an	 active	 pharmaceutical	 ingredient	 are	 detected	 by	 the	 industry	 which	 hence	 can	 apply	 for	
marketing	 authorization	 and	 imply	 a	 tremendously	 higher	price	 tag	on	 the	 licensed	product.	 Such	
increase	 in	 price	 can	 lead	 to	 inaccessible	 treatment	 for	 patients.	 It	would	 be	 unethical	 that	 price	
increases	would	lead	to	non-refunded	treatment	for	patients	with	a	long	history	of	treatment	with	
specific	 unlicensed	 pharmaceutical	 preparations.	 Understanding	 pharmaceutical	 preparations	
including	 the	 safety	 requirements	 and	 proper	 documentation	 can	 facilitate	 these	 pharmaceutical	
preparations	to	patients	in	need.	
The	 general	 aim	 of	 this	 thesis	 is	 to	 investigate	 how	 academic	 medicinal	 products	 reach	 clinical	
patient	 care.	 This	 was	 explored	 by	 investigating	 the	 ATMP	 development	 field	 from	 hurdles	
experienced	 in	 early	 clinical	 development	 towards	 the	 decision-making	 by	 authorities	 of	 these	




In	 Chapter	 2	 we	 outlined	 the	 strengths	 and	 hurdles	 that	 apply	 to	 the	 development	 of	 ATMPs	





direct	 access	 to	 human	 starting	material	 for	 these	 CTMPs	 and	 TEPs,	 including	 a	 rapid	 and	 direct	
organized	logistic	process	from	manufacturing	until	treatment	within	an	institution.	Finally,	patient	
enrolment	 and	 follow	 up	 is	 facilitated	 in	 the	 academic	 setting	 by	 the	 fact	 that	 patients	 already	
undergo	 their	 medical	 treatment	 at	 academic	 institutions.	 In	 contrast,	 limitations	 have	 a	 higher	
impact	towards	 late	phase	clinical	development,	such	as	 lack	of	regulatory	knowledge.	This	can	be	
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recipient	 compared	 to	 the	original	 function	 (non-homologous	use).	 In	 case	 these	 cells	 are	used	 in	
diagnosis,	 prevention	or	 treatment	 they	are	 classified	as	 cell	 therapy	medicinal	products	 (CTMPs).	
On	the	other	hand	when	the	purpose	of	these	cells	is	to	regenerate,	repair	or	replace	tissue	(such	as	
skin)	they	are	classified	as	tissue	engineered	products	(TEPs).	Finally,	the	third	category	of	ATMPs	is	
the	gene	 therapy	medicinal	products	 (GTMPs),	which	 include	genes	 for	diagnostic,	prophylactic	or	
therapeutic	purposes.		
Since	 the	 European	 special	 Regulation	 (EC)	 No.	 1394/2007	 was	 imposed	 in	 2009,	 a	 centralized	
regulatory	framework	for	these	products	was	established.	 In	general,	the	Committee	for	Medicinal	
Products	for	Human	Use	(CHMP)	is	responsible	for	the	evaluation	of	quality,	safety	and	efficacy	of	all	
medicinal	 products	 in	 the	 centralized	 procedures.	 However,	 due	 to	 this	 new	 complex	 group	 of	
medicinal	products,	a	group	of	experts	was	established	by	the	European	Medicines	Agency	(EMA)	to	




















Mostly,	 these	 preparations	 are	 manufactured	 for	 orphan	 indications	 (<5	 patients	 per	 10,000	
humans).	 Although	 unlicensed,	 they	 should	 guarantee	 safety	 similar	 to	 the	 licensed	 medicinal	
products.	Since	these	products	are	unlicensed,	there	is	a	risk	that	pharmaceutical	preparations	from	
an	 active	 pharmaceutical	 ingredient	 are	 detected	 by	 the	 industry	 which	 hence	 can	 apply	 for	
marketing	 authorization	 and	 imply	 a	 tremendously	 higher	price	 tag	on	 the	 licensed	product.	 Such	
increase	 in	 price	 can	 lead	 to	 inaccessible	 treatment	 for	 patients.	 It	would	 be	 unethical	 that	 price	
increases	would	lead	to	non-refunded	treatment	for	patients	with	a	long	history	of	treatment	with	
specific	 unlicensed	 pharmaceutical	 preparations.	 Understanding	 pharmaceutical	 preparations	
including	 the	 safety	 requirements	 and	 proper	 documentation	 can	 facilitate	 these	 pharmaceutical	
preparations	to	patients	in	need.	
The	 general	 aim	 of	 this	 thesis	 is	 to	 investigate	 how	 academic	 medicinal	 products	 reach	 clinical	
patient	 care.	 This	 was	 explored	 by	 investigating	 the	 ATMP	 development	 field	 from	 hurdles	
experienced	 in	 early	 clinical	 development	 towards	 the	 decision-making	 by	 authorities	 of	 these	




In	 Chapter	 2	 we	 outlined	 the	 strengths	 and	 hurdles	 that	 apply	 to	 the	 development	 of	 ATMPs	





direct	 access	 to	 human	 starting	material	 for	 these	 CTMPs	 and	 TEPs,	 including	 a	 rapid	 and	 direct	
organized	logistic	process	from	manufacturing	until	treatment	within	an	institution.	Finally,	patient	
enrolment	 and	 follow	 up	 is	 facilitated	 in	 the	 academic	 setting	 by	 the	 fact	 that	 patients	 already	
undergo	 their	 medical	 treatment	 at	 academic	 institutions.	 In	 contrast,	 limitations	 have	 a	 higher	
impact	towards	 late	phase	clinical	development,	such	as	 lack	of	regulatory	knowledge.	This	can	be	
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explained	 as	 most	 academic	 institutions	 are	 science-driven	 rather	 than	 product-driven	 which	
includes	the	output	system	of	academic	institutions	mainly	being	driven	by	peer-reviewed	scientific	
publications.	 Also,	 the	 lack	 of	 long-term	 goals	 on	 product	 development	 shows	 that	 academic	
institutions	are	mostly	not	product-driven.	In	addition,	the	lack	of	sufficient	funding	also	negatively	
influences	performance	of	phase	III	clinical	trials	and	the	ability	to	apply	for	marketing	authorization.		
Hurdles	 experienced	 by	 different	 stakeholders	 in	 The	 Netherlands	 during	 clinical	 development	 of	
ATMPs	were	investigated	in	Chapter	3.	More	than	half	(56%	of	45)	of	the	principal	investigators	from	
academic	 institutions	 planned	 to	 reach	 patients	 in	 clinical	 care	 after	 successful	 clinical	 trials	 via	
marketing	 authorization	 and/or	 via	 hospital	 exemption.	 The	 other	 part	 of	 principal	 investigators	
were	planning	on	reaching	clinical	care	with	ATMPs	via	other	routes,	such	as	the	Tissues	and	Cells	
Directive	 (n=12)	and	a	 fifth	did	not	have	a	 future	plan	 for	 implementation	 in	clinical	care	yet.	One	
year	after	 the	 interviews,	an	 increased	number	of	principal	 investigators	 intended	to	reach	clinical	
care	 after	 successful	 clinical	 development	 via	 either	 marketing	 authorization	 and/or	 hospital	
exemption.	 All	 other	 stakeholders	 perceived	 that	 only	 hospital	 exemption	 and	 marketing	
authorization	were	the	possibilities	of	reaching	clinical	care.	The	main	hurdles	in	ATMP	development	







public	data	of	phase	 I	clinical	 trials.	Half	of	 the	trials	were	phase	 II	 trials,	a	quarter	were	phase	 I/II	
combined	trials	and	the	rest	were	phase	III	trials.	More	than	half	of	the	trials	(56%)	were	sponsored	
by	 academic	 institutions.	 However,	 the	 part	 of	 clinical	 trials	 with	 commercial	 sponsors	 involved,	
increased	 slightly	 in	 2014	 compared	 to	 2010,	 including	 an	 increase	 of	 involvement	 of	 large	
commercial	companies	 (8%	 in	2014	versus	4%	 in	2010	).	The	main	characteristics	of	academic	and	
commercial	 sponsored	 trials	 differ	 as	 academic	 sponsors	mostly	 used	 autologous	 derived	 starting	
material	(78%),	of	which	most	from	bone	marrow	(29%),	while	commercial	sponsors’	main	focus	has	
been	the	GTMPs	–	 in	vivo	 (46%)	and	almost	all	were	part	of	 the	 later	stage	phase	 III	 clinical	 trials.	
From	all	included	clinical	trials	approximately	one	in	ten	proceeded	towards	a	clinical	trial	in	the	next	
clinical	trial	phase.		
Chapter	 5	 describes	 the	 field	 of	 a	 specific	 subtype	 of	 the	 ATMPs,	 the	 Chimeric	 Antigen	 Receptor	
(CAR)	 T-cells.	 The	 goal	 was	 to	 investigate	 whether	 characteristics	 of	 clinical	 trials	 show	 trends	 in	
	
	





trials	 had	 an	 academic	 sponsor,	 and	 more	 than	 half	 were	 in	 phase	 I.	 Furthermore,	 autologous	
starting	material	was	used	most	frequently.	Clinical	trials	with	CAR-T	cells	were	more	likely	to	have	a	
subsequent	 clinical	 trial	 when	 commercially	 sponsored,	 recruiting	 a	 large	 number	 of	 patients	 (n=	
>33)	or	when	it’s	design	was	multicentre.	
The	 regulatory	 decision-making	 on	 marketing	 authorization	 of	 all	 ATMP	 assessment	 reports	 for	
marketing	authorization	 in	Europe	was	 investigated	 in	Chapter	6.	Of	 the	14	 investigated	ATMPs,	5	
were	 approved	 according	 to	 standard	 procedure,	 3	were	 approved	 via	 the	 expedited	 pathway	 (2	
conditional	 approval	 and	 1	 approval	 under	 exceptional	 circumstances)	 and	 6	were	 not	 approved.	
Major	 issues	 in	quality,	 for	example	vector-related	and	release	tests,	were	raised	 in	all	assessment	
procedures,	demonstrating	that	this	domain	is	an	important	issue	in	the	ATMP	field.	Whereas	for	the	
approved	 products	most	 of	 these	 quality	 issues	 were	 considered	 to	 be	 resolved	 (for	 example	 by	
post-marketing	 requirements)	 the	 objections	 for	 the	 non-approved	 products	 were	 considered	
unresolved	 at	 time	 of	 final	 decision	 by	 the	 regulators.	 The	 most	 robust	 clinical	 trial	 design	 and	
clinical	outcomes	were	evident	for	the	standard	approved	ATMPs,	compared	to	expedited	approvals.	
All	expedited	approvals	were	granted	for	orphan	ATMPs,	for	which	considerations	of	unmet	medical	








the	 level	 of	 risk	 linked	 to	 the	 pharmaceutical	 preparation,	 that	 has	 consequences	 for	 the	 level	 of	
documentation.	 In	 case	 of	 low	 risk,	 quality	 assurance	 has	 to	 be	 performed	 according	 to	 the	
Pharmaceutical	 Inspection	Co-operation	 Scheme	Good	Preparation	 Practices	 (PIC/S	GPP),	whereas	
for	 high	 risk	 preparations,	 quality	 is	 guaranteed	 by	 meeting	 with	 Good	 Manufacturing	 Practices	
(GMP).	Furthermore,	pharmacovigilance	of	these	pharmaceutical	preparations	are	the	responsibility	
of	 the	 (hospital)pharmacy	 and	 should	 be	well-documented,	 including	 documentation	 provided	 by	
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the	 level	 of	 risk	 linked	 to	 the	 pharmaceutical	 preparation,	 that	 has	 consequences	 for	 the	 level	 of	
documentation.	 In	 case	 of	 low	 risk,	 quality	 assurance	 has	 to	 be	 performed	 according	 to	 the	
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(GMP).	Furthermore,	pharmacovigilance	of	these	pharmaceutical	preparations	are	the	responsibility	
of	 the	 (hospital)pharmacy	 and	 should	 be	well-documented,	 including	 documentation	 provided	 by	
174  | Part III - Chapter 10
	
	
the	 prescribing	 physician,	 information	 about	 the	 patients	 and	 specific	 attention	 to	 any	 adverse	
events	that	may	occur	of	have	occurred.	Especially	for	the	active	pharmaceutical	 ingredient	(API)	a	
concise	product	dossier	with	data	on	efficacy	and	safety	is	important	since	no	available	information	
on	 these	 aspects	 exists.	 The	 product	 dossiers	 of	 preparations	 adapted	 from	 licensed	 medicinal	
products	 need	 to	 contain	 a	 substantiated	 rationale	 besides	 safety	 and	 efficacy	 data	 from	 these	
preparations.	 The	 reconstituted	 preparations	 are	 executed	 with	 licensed	 medicinal	 products,	
allowing	pharmacovigilance	conform	the	licensed	individual	reconstitution.	
In	Chapter	 8,	 the	 unlicensed	 pharmaceutical	 preparation	 3,4-diaminopyridine	was	 used	 as	 a	 case	




compared	 to	 the	 price	 of	 the	 pharmaceutical	 preparations.	 Furthermore,	 it	 showed	 that	




Finally,	 in	 Chapter	 9,	 all	 study	 results	 are	 discussed	 and	 concluding	 remarks	 on	 the	 role	 of	 the	




is	 important	 to	 guarantee	 safety	 and	 have	 good	 documentation.	 Via	 databases,	 such	 as	 patient	
registries,	 good	 documentation	 is	 provided	 in	 a	 structural	 manner.	 Furthermore,	 increased	
(professional)	 pharmacovigilance	 should	 be	 achieved	 by	 linking	 patient	 registries	 with	 centralized	
pharmacovigilance	databases.	 It	 is	 considered	 the	 responsibility	of	 the	academic	 institutions	as	an	
‘academic	pharma’	 to	 set	up	and	maintain	proper	drug	product	 files	and	ensure	safe	use	of	 these	
academic	 medicinal	 products	 in	 regular	 patient	 care.	 The	 government	 and	 regulatory	 authorities	
should	 stimulate	 and	 embrace	 the	 ‘academic	 pharma’	 to	 keep	 developing	 and	 manufacturing	
academic	medicinal	products	in	order	to	enable	treatment	of	the	special	(ultra-)	orphan	patients	for	
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Vandaag	 de	 dag	 bestaat	 er	 een	 grote	 variëteit	 van	 geregistreerde	 geneesmiddelen,	 meestal	
geproduceerd	 door	 de	 farmaceutische	 industrie.	 Helaas	 kunnen	 niet	 alle	 patiënten	 worden	
behandeld	 met	 deze	 beschikbare,	 geregistreerde,	 conventionele	 producten.	 Academische	





(autoloog)	 of	 van	 een	 donor	 (allogeen),	 die	 ofwel	 ‘substantieel’	 gemanipuleerd	 zijn,	 ofwel	 een	
andere	 functie	 hebben	 dan	 de	 originele	 functie	 van	 de	 cellen	 (niet-homoloog,	 bijvoorbeeld	 stam	
cellen	uit	beenmerg	die	dienen	voor	reparatie	van	het	hart).	Als	deze	cellen	worden	toegepast	voor	
diagnose,	preventie	of	behandeling	behoren	ze	tot	de	celtherapieën.	Echter	wanneer	de	toepassing	
van	 deze	 cellen	 is	 om	 te	 regenereren,	 repareren	 of	 om	weefsel	 te	 vervangen	 (bijvoorbeeld	 huid)	
worden	 deze	 cellen	 weefselproducten	 genoemd.	 De	 laatste	 subcategorie	 zijn	 de	 gentherapie	
producten,	 deze	 producten	 bevatten	 een	 gen	 dat	 een	 diagnosticerende,	 profylactische,	 of	
therapeutische	functie	heeft.		
De	geavanceerde	 therapieën	worden	gezien	als	 innovatieve,	complexe	geneesmiddelen	die	anders	
zijn	 dan	 de	 conventionele	 geneesmiddelen,	 zoals	 de	 productkarakteristieken	 en	 de	
bereidingsprocessen.	 Sinds	 2009	 is	 er	 een	 speciale	 Europese	 regelgeving	 van	 kracht,	 (EC)	 No.	
1394/2007,	 	 voor	 de	 geavanceerde	 therapieën.	Ondanks	 het	 toenemende	 aantal	 klinische	 studies	
dat	 wordt	 uitgevoerd	 met	 deze	 geneesmiddelen,	 zijn	 er	 tot	 nu	 toe	 slechts	 9	 geavanceerde	
therapieën	op	de	markt	gekomen	in	Europa.	Dat	het	aantal	goedgekeurde	producten	zo	laag	is,	kan	
liggen	aan	het	feit	dat	het	om	relatief	nieuwe	geneesmiddelen	gaat,	waardoor	meer	tijd	nodig	is	om	
te	 zien	of	 de	ontwikkeling	daadwerkelijk	 succesvol	 is	 of	 niet.	 Een	 andere	oorzaak	 kan	 zijn	 dat	 het	
huidige	 systeem	 nog	 niet	 goed	 is	 ingericht	 op	 deze	 groep	 geneesmiddelen,	 wat	 kan	 leiden	 tot	
obstakels	tijdens	het	ontwikkelingsproces.		
Daar	 waar	 de	 geavanceerde	 therapieën	 nog	 in	 ontwikkeling	 zijn,	 worden	 de	 niet-geregistreerde	
farmaceutische	 bereidingen	 vaak	 al	 jaren	 gebruikt	 in	 de	 patiëntenzorg.	 Deze	 farmaceutische	
bereidingen	zijn	geneesmiddelen	die	vaak	ontstaan	als	een	bereiding	voor	de	individuele	patiënt	(ad	
hoc).	 Als	 deze	 bereiding	 uiteindelijk	 vaker	 moeten	 worden	 gemaakt,	 kan	 worden	 overwogen	 om	
over	te	gaan	op	(kleine)	voorraadbereidingen.	Vaak	worden	ze	gemaakt	door	(ziekenhuis)apotheken	
voor	 zeldzame	 ziektes	 (<5	 patiënten	 per	 10.000	 mensen	 in	 Europa).	 Ondanks	 het	 feit	 dat	 deze	
geneesmiddelen	 niet	 geregistreerd	 zijn,	 moet	 de	 kwaliteit	 en	 veiligheid	 van	 het	 product	 en	 de	





geneesmiddelen	 de	 patiënt	 bereiken.	 Dit	 is	 gedaan	 door	 allereerst	 het	 ontwikkelingsveld	 van	 de	







geavanceerde	 (cel)therapieën	 die	 plaatsvindt	 in	 de	 academische	 centra.	 Met	 name	 in	 de	 vroege	




voor	 de	 celtherapieën	 en	 weefselproducten.	 Naast	 de	 toegang	 tot	 menselijk	 materiaal,	 is	 het	
logistieke	proces	 in	de	academische	centra	snel	en	direct	aangezien	het	plaatsvindt	op	één	locatie.	
Ook	 zal	 de	 inclusie	 en	 opvolging	 van	 patiënten	 in	 klinische	 studies	 goed	 te	 organiseren	 zijn	 in	 de	
academie,	 vanwege	de	 directe	 patiëntenzorg	 die	 plaatsvindt	 in	 dat	 centrum.	Hier	 staat	 tegenover	
dat	 hoe	 verder	 het	 ontwikkeltraject	 voortschrijdt,	 op	 weg	 naar	 registratie,	 er	 meer	 obstakels	
ontstaan	waar	de	academische	centra	tegenaanlopen.	Bovendien	krijgen	academische	onderzoekers	
vaak	te	maken	met	het	 feit	dat	de	regulatoire	kennis,	wat	nodig	 is	voor	registratie,	ontbreekt.	 	De	




echte	 ontwikkeling	 van	 een	 product.	 Tot	 slot	 kan	 nog	worden	 toegevoegd	 dat	 het	 ontbreken	 van	
voldoende	financiële	ondersteuning	negatieve	invloed	heeft	op	de	mogelijkheid	om	een	(goede)	fase	
III	klinische	studie	uit	te	kunnen	voeren,	of	om	het	product	te	registreren.	
Diverse	 stakeholders	 (hoofdonderzoekers	 van	 geavanceerde	 therapieën	 in	 academische	 centra,	
patiënt	 organisaties,	 de	 Centrale	 Commissie	 Mensgebonden	 Onderzoek	 (CCMO),	 het	 College	 ter	
Beoordeling	van	Geneesmiddelen	(CBG),	Zorginstituut	Nederland,	een	zorgverzekeraar	en	drie	kleine	
farmaceutische	bedrijven)	 in	Nederland	zijn	 in	Hoofdstuk	3	 geïnterviewd	over	hun	ervaringen	met	
de	 productontwikkeling	 van	 de	 geavanceerde	 therapieën.	 Meer	 dan	 de	 helft	 van	 de	
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geneesmiddelen	 de	 patiënt	 bereiken.	 Dit	 is	 gedaan	 door	 allereerst	 het	 ontwikkelingsveld	 van	 de	







geavanceerde	 (cel)therapieën	 die	 plaatsvindt	 in	 de	 academische	 centra.	 Met	 name	 in	 de	 vroege	
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echte	 ontwikkeling	 van	 een	 product.	 Tot	 slot	 kan	 nog	worden	 toegevoegd	 dat	 het	 ontbreken	 van	
voldoende	financiële	ondersteuning	negatieve	invloed	heeft	op	de	mogelijkheid	om	een	(goede)	fase	
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Diverse	 stakeholders	 (hoofdonderzoekers	 van	 geavanceerde	 therapieën	 in	 academische	 centra,	
patiënt	 organisaties,	 de	 Centrale	 Commissie	 Mensgebonden	 Onderzoek	 (CCMO),	 het	 College	 ter	
Beoordeling	van	Geneesmiddelen	(CBG),	Zorginstituut	Nederland,	een	zorgverzekeraar	en	drie	kleine	
farmaceutische	bedrijven)	 in	Nederland	zijn	 in	Hoofdstuk	3	 geïnterviewd	over	hun	ervaringen	met	
de	 productontwikkeling	 van	 de	 geavanceerde	 therapieën.	 Meer	 dan	 de	 helft	 van	 de	






niet	 geregistreerd	 en	 buiten	 studieverband	 onder	 restricties,	 welke	 gecontroleerd	 worden	 op	
nationaal	 niveau,	 bij	 de	 patiënt	 toe	 te	 passen.	 De	 overige	 hoofdonderzoekers	 wilden	 het	
geneesmiddel	toepassen	middels	andere	routes,	zoals	via	de	zogenaamde	‘tissues	and	cells	directive’	
(n=12),	die	 is	opgesteld	voor	stamceltransplantaties.	Een	vijfde	van	de	onderzoekers	had	nog	geen	
toekomstplannen	 bedacht	 voor	 het	 geneesmiddel	waarmee	 een	 klinische	 studie	werd	 uitgevoerd.	
De	belangrijkste	knelpunten	die	werden	ervaren	door	de	stakeholders	waren:	financiële	steun,	het	
ontbreken	 van	 regulatoire	 kennis,	 het	 snelle	 ontwikkelingsveld,	 studie-gerelateerde	 problemen	
(zoals	recruitment)	en	problemen	in	samenwerkingen	met	daarbij	de	verantwoordelijkheden	van	de	
verschillende	betrokken	partijen.		
Om	 een	 beeld	 te	 krijgen	 van	 het	 ontwikkelingsveld	met	 geavanceerde	 therapieën	 in	 Europa	 is	 in	
Hoofdstuk	4	een	overzicht	gemaakt	 van	de	klinische	 studies	die	met	deze	geneesmiddelen	 tussen	
2004	 en	 2014	 zijn	 gedaan.	 In	 die	 tijd	 zijn	 278	 klinische	 studies	 uitgevoerd	 met	 198	 unieke	
geavanceerde	therapie	producten,	waarvan	de	helft	fase	II	studies	waren.	Meer	dan	de	helft	van	de	




(78%)	 autoloog	 startmateriaal,	 vaak	 afkomstig	 uit	 beenmerg	 (29%).	 De	 commerciële	 bedrijven	








uitgevoerd	voor	bijv.	 een	andere	 indicatie’.	Van	de	106	klinische	 studies	met	CAR	T-cel	producten	
gedaan	 in	 Amerika,	 Canada	 en	 Europa,	 waren	 de	 meeste	 studies	 (91%)	 uitgevoerd	 door	 een	
academische	 sponsor,	was	68%	een	 fase	 I	 studie	en	werd	er	 voornamelijk	autoloog	 startmateriaal	
gebruikt	 (89%).	 Bijna	 de	 helft	 van	 de	 studies	 (46%)	 werd	 opgevolgd	 door	 een	 volgende	 klinische	








product	 onder	 uitzonderlijke	 voorwaarden)	 en	 6	 producten	 niet	 goedgekeurd	 voor	 registratie.	
Kwaliteitsissues	kwamen	voor	bij	alle	ingediende	dossiers	voor	registratie,	wat	laat	zien	dat	dit	een	
belangrijk	 knelpunt	 is	 in	 het	 veld	 van	 de	 geavanceerde	 therapieën.	 Waar	 voor	 de	 goedgekeurde	
producten	deze	bezwaren	opgelost	waren	bij	besluitvorming,	bijv.	door	post-marketing	eisen,	waren	
echter	de	meeste	van	de	kwaliteitsissues	voor	de	afgewezen	producten	niet	opgelost	ten	tijde	van	
de	 uiteindelijke	 beslissing	 over	 registratie.	 Robuust	 ontworpen	 klinische	 studies	 en	 uitkomsten	
waren	aangetoond	voor	de	standaard	goedgekeurde	producten,	wat	echter	niet	het	geval	was	voor	
de	 conditioneel	 goedgekeurde	 producten.	 Alle	 conditioneel	 goedgekeurde	 producten	 hadden	 het	
label	 van	 ‘zeldzaam	 geneesmiddel’.	 Zodoende	 speelden	 argumenten	 omtrent	 hoge	 medische	
noodzaak		een	belangrijke	rol	in	de	afweging	tot	de	uiteindelijke	besluitvorming,	met	name	wanneer	
er	 sprake	 was	 van	 onzekerheid	 in	 de	 effectiviteit	 en	 veiligheidsrisico’s	 bij	 een	 product.	 Voor	 de	




In	 Hoofdstuk	 7	 is	 een	 overzicht	 gemaakt	 van	 de	 verschillende	 soorten	 niet-geregistreerde	
farmaceutische	 bereidingen	 die	worden	 geproduceerd	 voor	 kleine	 patiëntgroepen	met	 daarbij	 de	





Om	 de	 kwaliteit	 te	 garanderen	 van	 deze	 niet-geregistreerde	 geneesmiddelen	 moet	 een	 risico	
bepaling	 worden	 gedaan	 aan	 de	 hand	 van	 een	 benefit/risk	 matrix,	 zoals	 beschreven	 wordt	 in	 de	
resolutie	 (CM/RES(2016)).	 Deze	 matrix	 kan	 bepalen	 welk	 niveau	 van	 risico	 is	 verbonden	 aan	 het	
product,	wat	op	zijn	beurt	invloed	heeft	op	de	mate	van	documentatie.	Een	kanttekening	van	deze	
matrix	 is	 dat	 het	 slechts	 betrekking	 heeft	 op	 de	 kwaliteit	 van	 het	 product	 en	 dat	 het	 niet	 het	
therapeutisch	 belang	 meeneemt.	 In	 het	 geval	 dat	 er	 laag	 risico	 is	 kan	 de	 kwaliteit	 worden	
gegarandeerd	conform	de	Pharmaceutical	Inspection	Co-operation	Scheme	(PIC/S)	richtlijnen.	Echter	
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(geneesmiddelbewaking)	 uit	 te	 voeren	 met	 deze	 niet-geregistreerde	 producten.	 Door	 alle	
veiligheidsaspecten	 te	documenteren,	 inclusief	gegevens	over	de	arts,	de	patiënt	en	bijwerkingen.	
Met	name	voor	de	geneesmiddelen	die	gemaakt	worden	uit	een	actief	farmaceutische	grondstof	is	
een	 productdossier	 met	 een	 rationale	 en	 data	 over	 de	 effectiviteit	 en	 veiligheid	 van	 belang	
aangezien	er	 geen	beschikbare	data	hiervan	 zijn.	De	 verantwoordelijkheid	 van	deze	documentatie	
ligt	 bij	 de	 maker	 van	 deze	 producten,	 in	 dit	 geval	 dus	 bij	 de	 (ziekenhuis)apotheek.	 De	mate	 van	
documentatie	 is	ook	afhankelijk	van	de	risicobepaling	 in	de	kwaliteit	van	het	product,	bijvoorbeeld	
bij	schaalvergroting	zullen	meer	kwaliteitscontroles	nodig	zijn	dan	voor	de	ad	hoc	producten.		
Niet-geregistreerde	 producten	met	 een	 actief	 farmaceutische	 grondstof	 lopen	 het	 risico	 om	 door	
een	firma	te	worden	geregistreerd	zonder	dat	oorspronkelijk	onderzoek	met	die	grondstof	is	gedaan	
door	de	 firma,	wat	kan	 leiden	 tot	extreme	prijsverhogingen.	Hoofdstuk	8	 beschrijft	een	casus	van	
een	farmaceutische	bereiding	(3,4-DAP)	voor	Lambert-Eaton	myasteen	syndroom	(LEMS)	die	in	2009	
werd	 geregistreerd,	 zonder	 oorspronkelijk	 onderzoek	 te	 hebben	 gedaan,	 door	 een	 commercieel	
bedrijf	 (Firdapse®)	 tegen	een	50x	hogere	prijs.	Na	 vergelijking	 van	de	data	die	 zijn	 gebruikt	 in	het	
registratiedossier	 van	 Firdapse®	 en	 de	 data	 die	 aanwezig	 zijn	 in	 het	 productdossier	 van	 de	
farmaceutische	 bereiding,	 bleek	 dat	 de	 meeste	 data	 die	 voor	 registratie	 zijn	 gebruikt	 niet	 zijn	
gebaseerd	 op	 onderzoeksresultaten	 van	 de	 firma	 zelf	 met	 die	 formulering.	 Slechts	 twee	 bio-

















In	 Hoofdstuk	 9	 zijn	 alle	 resultaten	 uit	 de	 verschillende	 hoofdstukken	 bediscussieerd	 en	
concluderende	 opmerkingen	 over	 de	 toekomst	 van	 de	 academische	 geneesmiddelen	 besproken.	
Academische	 centra	 zijn	 essentiële	 bereiders	 van	 geneesmiddelen	 voor	 het	 genereren	 van	
therapieën	voor	specifieke	patiëntgroepen.	De	meeste	van	de	academische	geneesmiddelen	zijn,	tot	
nu	 toe,	 niet	 geregistreerd	 en	 commercialisatie	 gebeurt	 zelden,	 al	 is	 dit	wellicht	 ook	niet	 gewenst.	
Voor	beide	 type	academische	geneesmiddelen,	beschreven	 in	dit	proefschrift,	 is	het	belangrijk	om	
veiligheid	 te	 garanderen	 en	 uitgebreide	 documentatie	 bij	 te	 houden.	 Via	 databases,	 zoals	 patiënt	
registers,	 kan	 documentatie	 op	 gestructureerde	 wijze	 plaatsvinden.	 Tevens	 zal	 een	 toename	 in	
(professionele)	 geneesmiddelbewaking	 bereikt	 kunnen	 worden	 door	 deze	 patiënt	 registers	 te	
koppelen	 aan	 centrale	 geneesmiddelbewaking	 databases.	 De	 academische	 instellingen	 zijn	 als	
‘academische	 farma’	 verantwoordelijk	 voor	 het	 opzetten	 en	 het	 handhaven	 van	 geneesmiddel	
product	 dossiers	 en	 voor	 het	 veilig	 gebruiken	 van	 deze	 academische	 geneesmiddelen	 in	 klinische	
patiënten	zorg.	De	overheid	en	regulatoire	autoriteiten	moeten	de	‘academische	farma’	stimuleren	
in	het	blijven	ontwikkelen	en	produceren	van	academische	geneesmiddelen	voor	behandeling	van	
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